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The biopharmaceutical industry has been growing at a tremendous rate, with sales of $63.6 
billion 2012 in the US [1]. Nevertheless, the successful development of many protein drugs 
has been impeded by physical and chemical instabilities arising from their inherent 
chemical complexity and often leading to protein aggregation. The formation of non-native 
disulfide bonds is a common route to covalent aggregation of therapeutic proteins and other 
biologics [2, 3]. Disulfide bonds participate in hydrolytic and oxidative degradation 
reactions that form non-native disulfide bonds and other reactive species. The mechanisms 
responsible for protein aggregation are poorly understood and formulations are currently 
optimized on a trial and error basis. This approach contributes to high development costs 
and increases the time to market. The main goal of our research is to elucidate the 
mechanisms of thiol-disulfide exchange and disulfide scrambling in therapeutic proteins. 
To accomplish this goal, model peptides derived from human growth hormone (hGH) and 
intact hGH were used to investigate reaction mechanisms and kinetics in solution and solid-
state environments. The results will be useful in the rational development of stable, safe 
and efficacious protein formulations that contain free cysteines and disulfides. 
xxii 
 
Chapter 1 of this dissertation focuses on background information and explains the 
role of disulfide bonds in proteins, their advantages and limitations and different 
degradation pathways.  Research objective and specific aims are also outlined in Chapter 
1. Model hGH-derived tryptic peptides were used to investigate reaction mechanism and 
kinetics in aqueous solution (Chapter 2). RP-HPLC was used as a quantitative tool and 
product identity was further confirmed on the LC-MS. The effects of pH, temperature, 
oxidation suppressants and peptide secondary structure on thiol-disulfide exchange were 
also explored.  
Protein drugs are also manufactured as lyophilized powders to improve stability 
and retain potency during storage. In Chapter 3 of this dissertation, thiol-disulfide exchange 
during lyophilization and storage in the solid state using model peptides are discussed. 
Comparisons are drawn to the aqueous solution studies in Chapter 2. We also investigated 
the effect of factors that may contribute to thiol-disulfide exchange during lyophilization 
and these include; initial peptide concentration, temperature, buffer type and concentration, 
length of primary drying time and peptide adsorption to ice.  
In Chapter 4, thiol-disulfide exchange in intact hGH was investigated to understand 
the effects of higher-order structure on reaction kinetics. Free thiol containing peptides of 
different length and sequence and GSH were used to facilitate thiol-disulfide exchange in 
intact hGH and hGH-derived peptides with a disulfide bond. Finally, concluding remarks, 
future perspectives and implications for protein formulations are discussed in Chapter 5. 
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CHAPTER 1. OVERVIEW OF THERAPEUTIC PROTEINS 
1.1 Introduction 
 
Many low molecular weight drugs are chemically manufactured and processed into 
tablets and capsules that are easily ingestible. In contrast, protein drugs are macromolecules 
that contain many labile groups and have fragile, dynamic three-dimensional structures. 
Protein pharmaceuticals have been gaining widespread importance as new treatments for 
serious diseases such as cancer, cardiovascular and autoimmune diseases. The growth of 
protein therapeutics has been facilitated by the rapid development of recombinant DNA 
(rDNA) technology since the approval of recombinant insulin. The different categories of 
biologic drugs and their 2012 U.S. sales are shown in Figure 1.1.  
Figure 1.1: Categories of biologic drugs in terms of US sales in 2012. Adapted 
with permission from [1]. 
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Protein drugs and other biologics are the fastest growing sector of the U.S. 
pharmaceutical industry, with sales expected to increase to $144 billion by 2016 [1]. Nine 
new biopharmaceutical entities (NBE) were approved by the FDA in 2012 [4] and industry 
pipelines suggest the potential for many more protein drugs in the future. Protein instability 
presents many challenges to the development of new protein drug products which 
ultimately increase the time and cost required.  Recent data suggest that approximately 
$400 million is associated with pre-clinical development of new biopharmaceuticals, a cost 
ultimately borne by the public [5].  
Protein drug development is further complicated by the fact that formulations often 
contain an ensemble of protein conformations, which include the native state, partially 
unfolded states and even completely denatured states. This heterogeneity stems from the 
dynamics and thermodynamics of protein folding, the source of the protein (usually a 
complex biological mixture of proteins from cells), and the effects of upstream and 
downstream processing conditions. An ideal protein formulation would contain the pure 
protein in its native state; however, structural complexity and the presence of numerous 
reactive centers in proteins make it almost impossible to identify optimum conditions to 
maintain this ideal. In addition, the mechanisms of most aggregation pathways have not 
yet been investigated in detail and aggregates of protein drugs are typically classified as 
covalent and non-covalent [6]. This broad classification of protein aggregates precludes the 
mechanistic details of aggregation pathways like thiol-disulfide exchange and is a 
limitation in designing rational approaches to improve protein stability during manufacture, 
processing and storage.  
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1.2 Recombinant DNA technology 
 
Therapeutic proteins are now produced using recombinant DNA (rDNA) 
technology, where a vector containing the gene of interest is transformed into a host cell 
for protein expression. The protein of interest is then purified from the cell lysate; this 
process varies depending on the type of protein, the way it is expressed (secreted vs. 
inclusion bodies) and the host cell in which it is expressed. Insulin was the first recombinant 
product to be licensed for therapeutic use in 1982. FDA approved recombinant proteins for 
therapeutic use includes hormones, growth factors, coagulation factors, interferons, 
interleukins and enzymes [7]. Theoretically any protein can be produced using rDNA 
technology. However, the protein may undergo changes during 
manufacture/purification/processing (Figure 1.2) that make it unstable and unsuitable for 
therapeutic use. During a typical protein manufacturing process, nearly 20-30 unit 
operations are performed and these steps increase the chances of variability in the final 
protein product [8]. Protein properties are also affected by post-translational modifications 
such as glycosylation, amidation, carboxylation, sulfation and hydroxylation [9]. Overall, 
the process of expressing and purifying proteins is a rate-limiting process in research, 
demanding expertise and making protein therapeutics very expensive. 
Different factors associated with the host cell and manufacturing process can affect 
protein drug quality [8]. Some of these undesirable modifications are: i) undesirable host 
cell and process modifications: truncation, glycation, methylation and isomerization, ii) 
undesirable process modifications: aggregation, oxidation, deamidation and misfolded 
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forms of protein and impurities from host cell and process related impurities: host cell 
proteins and endotoxins. 
 
 
Figure 1.2: a) Monoclonal antibody structure showing regions that are prone to undergo 
chemical modifications, resulting in product heterogeneity. b) Schematic showing a typical 
protein manufacturing process. Adapted with permission from [8]. 
 
 
1.3 Stability of protein drugs 
 
Challenges associated with the development of protein pharmaceuticals arise from 
the unique flexible structure of proteins that enable them to interact with other biological 
molecules and also adapt to changes in their microenvironment. Structural flexibility 
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promotes conformational changes, chemical modifications (via exposure to reactive 
species like ROS), aggregation and precipitation. Such modifications have been associated 
with loss of biological activity and immunogenicity [10-12]. Aggregation is known to occur 
both in solution [13] and the solid state [14-16] and can be induced by chemical and/or 
physical changes. Chemical instabilities that involve bond formation or cleavage include 
deamidation, thiol-disulfide exchange, proteolysis and oxidation. Physical instabilities 
result in changes to higher order structure without covalent modification; these include 
denaturation, aggregation, adsorption to surfaces and precipitation [6]. The onset of 
aggregation is protein specific and the effect of stabilizers on therapeutic proteins must be 
studied on a case-by-case basis, which further retards drug development and increases 
manufacturing costs. Different chemical and physical degradation pathways in proteins and 
peptides are discussed below.  
 
1.3.1 Physical degradation 
Denaturation: protein denaturation is the loss of tertiary or secondary structure or 
both, which can then lead to any of the other degradation pathways listed below. Protein 
denaturation is further classified as thermal, cold, chemical or pressure-induced [6]. 
Thermal denaturation occurs at elevated temperatures and is irreversible, these thermally 
unfolded proteins have a tendency to associate and form aggregates. There are few reports 
on cold denaturation of proteins; nevertheless it is an important phenomenon as even at -
20 oC and in the presence of stabilizers, they have mobility. Chaotropes like guanidine 
hydrochloride and urea are used to chemically denature proteins. These reagents are used 
in studies to determine the free energy associated with unfolding events. For pressure-
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induced denaturation to occur, proteins must be exposed to pressures in the range of 2000-
4000 bar. A lower pressure range (1000-1500 bar) is typically employed to dissociate 
aggregates. Pressure-induced denaturation is usually reversible, unlike the other types of 
protein denaturation described above [17].  
Aggregation: involves the formation of non-native bonds following disruption of 
native bonds. Loss of native protein conformation during purification, formulation, freeze-
thawing and freeze-drying often leads to the exposure of hydrophobic residues in unfolded 
and partially unfolded states that can then promote aggregation [6]. Both non-covalent and 
covalent interactions can result in protein aggregation, which ultimately affects biological 
activity and can result in a severe immunogenic response after administration. Proteins do 
not aggregate via a single pathway and this adds to the challenges associated with 
investigating the mechanism of aggregation. There are five general mechanisms of protein 
aggregation: 1) association of native monomers, 2) aggregation of conformationally altered 
monomers, 3) aggregation of chemically-modified monomers, 4) nucleation-controlled 
aggregation and 5) surface-induced aggregation [18].  Typically, protein conformational 
stability is considered to be a significant factor in regulating aggregation; a partially 
unfolded state is the aggregation initiator (also the rate-limiting factor) [6, 19]. Stabilizing 
agents like sucrose and Tween have been used to effectively suppress aggregation in human 
interferon- γ13 and human growth hormone respectively [20].  
Surface adsorption: proteins are exposed to a multitude of surfaces to which they 
can adsorb during manufacture, processing and storage. The physical state of a protein can 
be altered when it adsorbs to a surface or is exposed to interfacial stress [6]. Though both 
the native and partially unfolded states can adsorb to surfaces, adsorption of a partially 
  7 
 
 
unfolded protein may be energetically favored due to the exposure of more hydrophobic 
residues when compared to the native state, in which they are buried within the core. A 
combination of interfacial structure perturbation and desorption of partially unfolded 
proteins can set off nucleation and result in aggregation [21-24]. The effects of surface 
adsorption on protein function and conformation have been reported previously [25, 26]. 
Precipitation: there are two different mechanisms by which proteins can precipitate. 
First, salting out of proteins in the presence of an excluded solvent can result in 
precipitation, a process that is usually reversible upon dilution [27]. Further, salted-out 
proteins retain activity similar to that of the native protein. Second, aggregates can grow 
so large in size that they are no longer soluble and manifest as haziness or cloudiness. The 
observed haziness is termed particulate formation and is typically irreversible. Particulate 
identification and detection is a major concern to the pharmaceutical industry and 
regulatory agencies as the particles may have immunogenic implications [28].  It is 
important to distinguish particulates formed from protein aggregates and foreign materials.  
 
1.3.2 Chemical degradation 
Oxidation: amino acids His, Trp, Met, Cys and Tyr can undergo oxidation in the 
presence of a reactive oxygen species (ROS) [29]. Oxidation reactions in proteins are 
classified as sit-specific (metal catalyzed) and non-site specific (photooxidation and free 
radical cascades). Methionine (Met) is oxidized easily to its sulfoxide and sulfone in the 
presence of ROS and molecular oxygen. Met oxidation has been reported in mAbs, 
particularly in the Fc region [30]. Oxidation of Trp generates kynurenine derivatives and 
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can occur both in the presence and absence of light. Yang et al. determined Trp oxidation 
in mAbs using RP-HPLC as an analytical tool [31].  
Deamidation: is one of the most common pathways for chemical degradation in 
peptides and proteins. Asn and Gln can undergo deamidation to form Asp and Glu 
respectively at neutral to alkaline pH. Gln deamidation is less common due to the formation 
of a less stable six-membered ring intermediate. Primary structure effects on deamidation 
have been explored, and faster deamidation is observed when smaller amino acids are 
present after (e.g., N+1) residues due to minimal steric effects [6]. Deamidation is also 
favored in polypeptide regions that are known to be flexible and when amino acid side 
chains that can act as hydrogen bond donors are present in the N+1 position. Asn-Gly is 
frequently the most reactive sequence for deamidation to occur in peptides and proteins. 
Preceding (e.g., N-1) amino acids typically have little effect on deamidation in solution, 
however, in the solid-state deamidation is accelerated with a Gln or Glu residue. 
Deamidation has been observed in therapeutic proteins like rhGH [32], glucagon [33] and 
mAbs [34]. Asp residues can also participate in isomerization and racemization reactions, 
which follow mechanisms similar to that for deamidation.  
Proteolysis/hydrolysis/clipping: hinge region hydrolysis can occur in mAbs and 
peptide backbone hydrolysis can occur near Asp residues. Asp hydrolysis in the solid state 
has been observed for recombinant bovine growth hormone [35]. Hinge region hydrolysis 
facilitated by hinge region flexibility and Fab region conformational instability has been 
reported in mAbs.  
Dityrosine formation and formaldehyde mediated cross-linking: Formaldehyde 
can form covalent bonds with a nitrogen atom of Lys or His to produce a hydroxylmethyl 
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derivative, which is then transformed into a Schiff base imine upon condensation. The 
imine is reactive and facilitates a cross-linking reaction with Tyr [36]. Dityrosine can be 
formed by photoactivation or enzyme catalysis. Dityrosine formation between two tyrosyl 
residues has been identified in calmodulin [37].  
Thiol-disulfide exchange and disulfide scrambling: Thiols and disulfides in 
proteins have functional roles and can participate in oxidative and hydrolytic pathways. 
Disulfide scrambling has been observed in therapeutic proteins like mAbs [38], insulin [39] 
and hGH [40]. However, very little is known about the effect of higher order structure on 
the mechanism and kinetics of thiol-disulfide exchange and disulfide scrambling. As the 
number of antibodies and antibody- or albumin-fusion drug products increases, the need to 
control thiol/disulfide reactivity becomes more acute. This reaction is the focus of the work 
presented in this dissertation and is discussed in detail in below.  
  
1.4 Thiols and disulfide bonds 
 
There are three types of Cys: i) free SH groups, ii) ligand SH groups and iii) 
disulfides (cystines) [41]. Cysteine is similar to Serine but is a poorer hydrogen bond donor. 
In vivo, free Cys are present only in reducing environments that make them less harmful, 
for example in bacterial and viral proteins [41]. A common location for free Cys is on a β 
strand, pointing inward and buried. They are rarely found on the surface of proteins due to 
their reactive nature. Wolfenden et al. have shown Cys to be neutral or mildly hydrophobic 
and this could also explain their tendency to be the most buried amino acid [42]. Ligand 
Cys can bind to different metals and prosthetic groups like Fe, Cu, Zn, Fe-S clusters and 
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hemes. Typically, ligand Cys are found in coil regions and in helices, they are quite rare in 
β-sheets. Mettalothionien is an example of a protein that contains ligand Cys with 20 Cys 
that can bind to seven metals [41]. Disulfide bonds stabilize native protein structures by 
crosslinking distant regions into a compact three- dimensional structure and reducing 
conformational entropy of the unfolded state.  However, in their reduced forms (as free 
thiol groups) they may have very little role in the early folding process. The Cα-Cβ vectors 
are either antiparallel or perpendicular in the most common disulfide conformations, the 
left-handed spiral and right-handed hook respectively. In addition to the vector orientation, 
the distance between the α-carbons of the cysteines must be 4-7.5 Å.  
 
1.5 Disulfide bond formation in proteins 
 
In eukaryotes, protein disulfide bonds are formed in the endoplasmic reticulum (ER) 
where the redox state is more favorable when compared to the cytosol. Oxidation of 
cysteines is initiated when proteins are translocated into the ER lumen. The rate of disulfide 
bond formation in living cells is faster than the rate of formation in vitro (in air), this has 
been attributed to the role of enzymes in the catalysis of protein oxidative folding in 
addition to the role of small-molecule redox buffers (GSH/GSSG) [43]. GSH provides 
reducing equivalents that are necessary to optimize folding conditions and counterbalance 
conditions of oxidative stress [43]. Protein disulfide isomerase (PDI) is an enzymatic 
catalyst that facilitates disulfide bond formation, reduction and isomerization. At the active 
site of PDI is a Cys-x-x-Cys motif similar to thioredoxin. When the cysteines are oxidized, 
  11 
 
 
PDI transfers disulfide bonds to proteins in the ER (Figure 1.3). Disulfide scrambling is 
catalyzed when the cysteines in PDI are in the reduced state.  
Similarly, in prokaryotes, DsbA (thioredoxin-like oxidoreductase, disulfide bond 
A enzyme) and DsbB (a membrane protein) initiate disulfide bond formation in periplasmic 
proteins. DsbA oxidizes cysteines in periplasmic proteins with the reduction of its own 
disulfide bond, DsbA is then reoxidized by DsbB. Components of the electron transport 
system help maintain DsbB in its oxidized state. DsbC reduces non-native disulfides in 
protein substrates, this is followed by re-oxidation of the Cys residues in the substrate by 
DsbA or DsbC. The role of DsbD is to maintain DsbC in its oxidized state, and cytoplasmic 
thioredoxin then reduces DsbD.  
 
Figure 1.3: A pathway for protein disulfide bond formation in the endoplasmic reticulum 
(ER). Oxidizing equivalents flow from Ero1p to Pdi1p, and then from Pdi1p to secretory 
proteins through a series of thiol-disulfide exchange reactions. Adapted with permission 
from [43]. 
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Disulfide bond formation in proteins is typically favored at neutral to alkaline pH 
and the rate of oxidative folding is increased in the presence of an oxidizing agent. A 
common oxidizing agent that is used to facilitate oxidative folding of proteins is oxidized 
glutathione (GSSG). Denaturing agents like guanidine hydrochloride and urea disrupt the 
folding process [3].  One exception to this general rule is murine prion protein (mPrP), 
which has only one intramolecular disulfide bond. At alkaline pH and in the absence of a 
denaturing agent, disulfide bond formation in mPrP is very slow [44]. However, at pH 8.0 
in the presence of both a denaturing agent and glutathione, mPrP folds correctly. The 
optimum pH for oxidative refolding of mPrP is 4.0-5.0. In the absence of a denaturant, 
mPrP is in a stable conformation at pH 8.0, where the Cys residues are isolated from one 
another and cannot form a disulfide bond. In the denaturant-mediated unfolded state, the 
Cys residues are in close enough proximity to form a stable disulfide bond. This is a good 
example of both intrinsic and extrinsic factors (discussed below in section 1.6) contributing 
to disulfide bond formation. 
Many therapeutic proteins like antibodies, enzymes and hormones contain disulfide 
bonds that crosslink distant regions to help maintain the native fold and stabilize the three-
dimensional structure of proteins [45, 46]. Other roles of disulfide bonds include enzyme 
catalysis [47], regulation of biological activity [46], structural stabilization of extracellular 
proteins [47] and protection against oxidative damage [45]. It is not always easy to predict 
the effect a disulfide bond can have on a protein. In some cases, engineered disulfide bonds 
can have destabilizing effects, if the entropy of the folded state is decreased by reduced 
flexibility [3]. In the same way, mutating Cys to other amino acid residues may not 
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necessarily impede degradation via other pathways and in addition may be accompanied 
by a loss of biological activity.  
Figure 1.4 shows how disulfide bond stability and stability provided to the folded 
protein by a disulfide bond are thermodynamically linked; ΔG of this cycle is zero [45]. In 
one pathway, formation of disulfide bonds occurs first by organizing the unfolded protein 
in such a way that the entropy loss accompanying protein folding is less than that of the 
unfolded state [45]. In an alternative pathway, the protein folds first bringing together 
distant Cys residues that can then be oxidized to form stable disulfide bonds.  
 
 
Figure 1.4: Thermodynamic cycle linking disulfide bond stability in the reduced and 
oxidized folded structure with the stability of the folded and unfolded states [45]. 
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1.5.1 Disulfide bond disruption and rearrangement 
Disulfide bonds are prone to undergo cleavage because they have 0.4-fold lower 
dissociation energy than C-C and C-H bonds [49]. Some of the mechanisms by which 
disulfide bonds may be disrupted include thiol-disulfide exchange, alkaline hydrolysis, 
photodegradation, thioether formation and trisulfide variants.  
Thiol-disulfide exchange: This reaction typically occurs at alkaline pH [50], as the 
reactive species is the thiolate anion with pKa 8-9. Reactivity of the thiol group can 
however be increased by a decrease in pKa, influenced by surrounding amino acid residues. 
This means that thiol-disulfide exchange reactions cannot be ruled out even under 
physiological conditions or lower pH. Thiol-disulfide exchange involves the nucleophilic 
attack (SN2) of a thiolate anion (RSH-) on a disulfide bond (S-S) to form a transition state 
(TS), expelling a thiol group (with lower pKa) and forming a new disulfide bond [45]. In 
the TS, negative charge is delocalized over the three sulfur atoms, with more negative 
charge on the terminal sulfurs than the central sulfur atom [51]. The energy barrier between 
the reactants and TS is the activation energy (Ea) of the reaction and the potential energy 
difference between reactants and products in ∆E (Figure 1.5). Thiol-disulfide exchange is 
reversible at room temperature and at physiological pH. In the presence of oxygen, metal 
and reactive oxygen species (ROS) other products of thiol oxidation like sulfenic, sulfinic, 
sulfonic acids and thiosulfonate (Figure 1.6) may be generated [52, 53]. Both intra- and 
intermolecular disulfide bonds can undergo scrambling reactions (Figure 1.7).  
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          Figure 1.5: Energy diagram for thiol-disulfide exchange reactions.  
 
        
     Figure 1.6: Oxidative pathways for thiols, adapted with permission from [52]. 
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Direct hydrolysis: The direct attack of a hydroxyl ion on a sulfur atom generates 
sulfenic acid (RSOH) and thiolate anion (RS-). RS- is a reactive nucleophile which can 
react with another disulfide bond (R′SSR″) to form RSSR″ and release R′S- (Figure 1.8B).  
β-elimination: involves proton abstraction from the α-carbon on Cys to form 
dehydroalanine and thiocysteine. Removal of a sulfur atom from the thiocysteine generates 
a thiolate anion and hydrosulfide ion. Thiolate anion can then participate in the formation 
of non-native disulfide bonds via thiol-disulfide exchange or oxidative pathways. The 
hydrosulfide ion can initiate disulfide scrambling via thiol-catalyzed exchange. 
Dehydroalanine can react further with lysine to form lysinoalanine cross-links.  
α-elimination: involves proton abstraction from the β-carbon of the Cys residue to 
form thiolate and thioaldehyde. Thioaldehyde can react further to form an aldehyde or 
imine group.  Thiolate anion can also react further with disulfides, reactive oxygen species 
to form the products shown in Figure 1.6.  
 
Figure 1.7: Different thiol-disulfide exchange reactions: A) intramolecular, B) 
intermolecular and C) intermolecular disulfide bond disrupted by thiol-disulfide exchange. 
Adapted with permission from reference [54]. 
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At low pH: Protons can cleave disulfide bonds to give sulfenium ions (RS+) under 
strong acidic conditions (Figure 1.8D). Sulfenium ions can then react with a sulfur atom in 
another disulfide bond via an electrophilic displacement to form a scrambled disulfide, 
expelling another sulfenium ion (R′S+ + RSSR ↔ R′SSR + RS+).  
Photodegradation: Photoionization of tyrosine/tryptophan generates a solvated 
electron which can then reduce a disulfide bond to thiyl radical (RS●) and thiolate anion 
(RS-) 1. Thiyl radicals are reactive and can form disulfide bonds (RSSR) with other thiyl 
radicals or a reductive disulfide radical anion (RSSR●-) with a thiolate.  
Thioether formation: Tous et al. identified thioether (-C-S-C) linkages (also called 
lanthionine) that are formed by the removal of a sulfur atom from a disulfide bond (-C-S-
S-C-) in monoclonal antibodies (mAbs) during production and storage [55]. Thioether-
linked antibodies have been detected even in endogenous antibodies [56]. The effect of 
thioether formation on the safety and efficacy of mAbs has not been reported; nevertheless 
it may affect protein conformation and biological activity and should be characterized in 
recombinant therapeutic proteins.  
Trisulfide variants: Formation of trisulfides in proteins is not a common post-
translational modification. Proteins that are known to form trisulfide variants include 
superoxide dismutase [57], mutein of interleukin [58], monoclonal antibodies [59] and hGH. 
A trisulfide variant (-C-S-S-S-C-) of hGH was identified only in recombinant protein 
expressed in E.coli and not in hGH preparations from human pituitaries [60]. Although the 
trisulfide variant did not affect the biological activity of hGH and converted completely 
into disulfides in IgG1 upon intraperitoneal injection in rats, the identification and 
characterization of such variants is still critical in determining protein drug quality.  





Figure 1.8: Different pathways that lead to disulfide bond disruption. A) Thiol-disulfide 
exchange (nuc: nucleophile, c: central sulfur and lvg: leaving group). B) Direct attack of 
hydroxyl ion on disulfide bond generates sulfenic acid and thiolate anion. C) Acid-base 
assisted hydrolysis of disulfide bond. D) Disulfide bond disruption under acidic conditions.  
 
1.6  Factors that influence disulfide bond reactivity 
 
Both intrinsic (physicochemical properties of the protein) and extrinsic factors 
(environmental factors like pH, temperature, mechanical force and in the presence of low 
molecular weight thiols in serum) can affect disulfide bond stability.  
 
1.6.1 Intrinsic factors 
These are factors that are innate to the protein itself. Primary sequence and higher 
order structure have been shown to affect thiol-disulfide exchange [61, 62]. Introduction of 
a positively charged amino acid neighboring a Cys residue in a model redox-sensitive 
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yellow fluorescent protein promoted electrostatic interactions with glutathione disulfide 
(GSSG) and decreased thiol pKa such that the rate of thiol-disulfide exchange increased 
13-fold [62]. In another study with cyanogen bromide fragments of hen egg white lysozyme, 
for a Cys with two positively charged neighbors, the rate of thiol-disulfide exchange 
increased 6.5-fold in a 20 mM ionic strength medium relative to a lower ionic strength 
medium [63]. In a high ionic strength medium (≥ 20 mM), the rate of thiol-disulfide 
exchange was reported to decrease by 700-fold. Ionic influences from distant residues are 
minimized at a high ionic strength (≥ 20 mM), thus reducing the rate of thiol disulfide 
exchange.  
In a thioredoxin from E.coli, disulfide reactivity is 102-103 times greater than that 
of normal disulfides due to the presence of a lysyl residue nearby with a positively charged 
group [47]. Similarly, in seminal ribonuclease, the presence of positively charged groups 
nearby (from Lys) was found to influence reactivity of the Cys31-Cys32 disulfide in 
addition to contributions from adjacency of the thiols and protein tertiary structure [64].  In 
peptides with the sequence Cys-X-Cys (where X is any amino acid), Zhang et al. have 
shown that disulfide bonds can be reduced rather easily. In contrast, in peptides with 4-5 
residues between terminal Cys residues, the disulfide bonds were more resistant to 
reduction and formed stable loops [65].  The equilibrium constant for ring closure in 
dipeptide (-Cys-Cys-) and tripeptide (-Cys-Val-Cys-) models was not affected by the 
addition of an Ala residue C-terminal to Cys [65].  
Disulfide reactivity can also be influenced by geometric strain that the protein 
native state imposes on a disulfide bond. For example, α-lactalbumin has four native 
disulfides of which Cys6-Cysl20 was reported to be 140 times more reactive in the fully 
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unfolded state; observed super reactivity of this disulfide bond was attributed to the 
geometric strain imposed on it in the native folded state [66].  Zavialov et al. elucidated the 
relationship between protein structure and the formation of a disulfide bond between small 
heat shock protein 25 (Hsp25) and GSH [67]. Hsp25 has a free Cys residue at position 41, 
in a redox environment; Hsp25 in its reduced form (PSH) is in equilibrium with a mixed 
disulfide (PSSG) and its oxidized dimer (PSSP). Tertiary and/or quaternary structural 
changes induced by protein denaturation prevent Hsp25 from forming the dimer (PSSP) 
due to changes in proximity of the 2 subunits. This study shows the importance of the 
proximity of a disulfide bond to a Cys residue to undergo thiol-disulfide exchange. The 
authors also demonstrated the effect of steric and electrostatic hindrances on thiol-disulfide 
exchange. Figure 1.9 below shows the formation of a mixed disulfide between heat shock 
protein and GSH; steric and electrostatic hindrances appear after the formation of this 
mixed disulfide, entry of another GSH molecule is inhibited thus resulting in an 
intersubunit disulfide [67].  
 
1.6.2 Extrinsic factors 
Extrinsic factors like pH (neutral to alkaline) will influence the rate of disulfide 
interchange by affecting the formation of the reactive species. Thiol-disulfide exchange in 
general is accelerated under neutral to alkaline pH [45], however it can also occur in strong 
acidic media facilitated by a sulfenium ion (Figure 1.8D). Benesch and Benesch have 
reported that disulfide exchange is rapid in concentrated HCl and the rate drops below a 
concentration of 9 N. At lower acid concentrations, the amount of RS+ generated also 
decreases thus affecting the overall rate of interchange [68]. Similar observations favoring 
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sulfenium ion mediated exchange in strong acidic media (7-12 N HCl) were reported by 
Ryle and Sanger [69]. In moderately acidic solutions disulfide interchange is not observed. 
The effects of temperature on thiol-disulfide exchange reactions have been studied 
in small organic molecules and proteins [70, 71]. Thiol-disulfide exchange follows 
Arrhenius behavior with activation energies in the range of 30-70kJ/mol [70]. The effects 
of urea and temperature on the formation of the disulfide-linked dimer of Hsp25 are shown 
in Figure 1.10; the fraction of subunits forming the dimer decreases with increasing urea 
concentration and temperature [67]. In addition to pH and temperature, recent studies have 
shown the effects of an external mechanical force on thiol-disulfide exchange. Using 
cardiac titin domain as a model protein, Wiita et al. have shown that an applied mechanical 
force > 100 pN promotes thiol-disulfide exchange [70].   
       
Figure 1.9: Scheme showing assumed effects of the appearance of steric and electrostatic 
hindrances after the formation of a mixed disulfide on thiol-disulfide exchange in Hsp25. 
The two subunits that form the subunit are shown in black. Adapted with permission from 
reference [67].  
 
Disulfide exchange can also occur in the presence of low molecular weight thiols 
both in vitro and in vivo. Thiols in serum like GSH, cysteine and cystine are known to 
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mediate thiol-disulfide exchange [72]. The formation of correct disulfides inside cells is 
regulated by a redox environment, typically consisting of GSH and GSSG, and where the 
ratio of GSH/GSSG varies from 30: 1 to 100:1 [39]. Once the protein is secreted from the 
cell, it is no longer exposed to a reducing environment. Instead, exposure to small amounts 
of thiols can initiate disulfide interchange that results in altered conformations and thus 
reduced protein activity [39, 49].  Disulfide-linked dimers have been reported in IgG2 both 
in cell culture and in human serum [73]. Disulfide isoforms have also been observed in 
IgG4, a phenomenon known as Fab-arm exchange. Fab-arm exchange occurs in the 
presence of GSH concentrations as low as 0.5 mM in vitro and results in the formation of 
bispecific antibodies that can bind only monovalently even to repeating antigens [74]. Thus, 
disulfide exchange may be favored in the reducing environment in cell culture during 
recombinant protein expression and in blood after administration of protein therapeutics.  
 
Figure 1.10: Dependence of fraction of subunits forming the inter-subunit disulfide bond 
(PSSP) on urea concentration (left) and on temperature (right). Adapted with permission 
from reference [67].  
 
  23 
 
 
1.7 Impact on protein physical stability and biological activity 
 
The effect of disulfide bonds on protein stability can be advantageous or 
disadvantageous; some of these effects are discussed in this section. In general, the native 
state of a protein (N) and its unfolded state (U) are in equilibrium such that N↔U. The 
introduction of a disulfide bond in a protein increases the free energy of U, with the 
assumption is that there is no difference in the enthalpies of the disulfide-linked protein 
and the reduced form of the protein. The contribution of an intramolecular disulfide bond 
to the decrease in entropy of U can be calculated using the equation: ΔS = -2.1-(3/2)R ln n, 
where R is the gas constant and n is the number of residues between the two Cys residues 
that form the intramolecular disulfide bond. An engineered intramolecular disulfide bond 
(Cys61-S-S-Cys98) in subtilisin E improved protein stability with a 4.5 oC increase in the 
melting temperature and a longer half time while there was no significant effect on 
enzymatic activity [75].   
There have been numerous reports of how disulfide scrambling can lead to 
aggregation [76-79]. Aggregates can affect therapeutic efficacy, biological activity and 
safety of protein drugs. Atypical disulfide bond formation can lead to misfolded forms of 
proteins that are dysfunctional [55].  Proteins like bovine pancreatic trypsin inhibitor [80], 
bovine pancreatic ribonuclease A [81] and human proinsulin [82] fold into their native 
conformations only after most of their native disulfide bonds have been formed. This has 
provided a useful approach to studying the folding pathways of these proteins in detail by 
trapping the different disulfide intermediates. In natriuretic peptide receptor-A, an 
intermolecular disulfide bond functions as an allosteric bond where the formation of a 
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disulfide-linked dimer (undesirable in protein therapeutics) is essential for its activation 
[83]. Dillon et al. measured in vitro binding ability and biological activity of different IgG2 
disulfide isoforms. The authors reported significant differences in biological activity of the 
isoforms and attributed these differences to changes in conformational angles and 
flexibility of the Fab region of IgG2 [38]. In another study, Qiao et al. reported that human 
insulin requires the correct formation of both intra- and interchain disulfide bonds to 
function properly [82]. Thus non-native disulfide bonding patterns can introduce 
conformational changes in proteins that may be detrimental to their therapeutic activity. 
Disulfide bonds can also have a positive impact on biological activity. For example, 
recombinant immunotoxins (RITs) are anti-cancer agents that contain the Fv region of an 
antibody and a protein toxin from bacteria or plants. Liu et al. observed that engineering a 
disulfide bond into an RIT significantly lowered immunogenicity in mice while retaining 
cytotoxicity and anti-tumor activity [84].  HA22-LR-DB, formed by anti-CD22 Fv fused 
to domain III of pseudomonas exotoxin A, with a disulfide bond in domain III improved 
thermal stability and altered the kinetics of antibody formation in mice. In another study, 
the aggregation propensity in IgG1 antibodies was found to be significantly lower when 
compared to IgG2 antibodies, though they share 95% sequence identity [85]. This was 
attributed to the presence of an interchain disulfide bond in IgG1. Thus it is important to 
understand the roles of disulfide bonds in therapeutic proteins before suitable formulation 
strategies can be employed.  
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1.8 Formulation strategies for Cys-containing proteins 
 
As described in the section above, disulfide bonds can be advantageous or 
disadvantageous to protein function/activity. Different strategies have been employed to 
minimize disulfide exchange and disulfide-mediated aggregation in proteins that contain 
free thiols and/or disulfide bonds [3]. Some of these approaches are discussed below.  
 
1.8.1 Formulating proteins with a reducing agent 
There have been reports of covalent dimer formation in E-Cadherin via a disulfide 
bond which ultimately leads to protein degradation [86]. Dithiothreitol (DTT), a reducing 
agent, and thiol group derivatizing agents like iodoacetamide and polyethylene-glycol 
malemide were used in formulations to improve protein stability [86]. Addition of DTT 
prevented dimer formation and further inhibited protein precipitation. This strategy may 
not be suitable for all proteins, especially if the protein also contains a functional disulfide 
bond. Addition of a reducing agent could reduce the native disulfide bond and change 
protein conformation, exposing reactive centers to a myriad of degradation pathways.  
 
1.8.2 Chemical modification of thiol groups 
Another strategy to formulate proteins that contain unpaired cysteine residues is to 
derivatize the thiol group in order to prevent thiol mediated aggregation. The thiol group 
on Cys residues is a reactive species that can participate in oxidation reactions in addition 
to thiol-disulfide exchange. Some of the derivatizing agents that have been used are 
iodoacetate, iodoacetamide, 1,3-propane sultone, methyl methanethiosulfonate, 
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methoxycarbonylmethyl disulfide, maleimide, tetrathionates, and dinitrophenyl alkyl 
disulfides. Ruegg et al. have used 1,3 propane sultone to derivatize thiol groups on [Lys8] 
vasopressin, human serum albumin, bovine insulin and bovine pancreatic ribonuclease, 
increasing their stability to acid hydrolysis [87]. Some commonly used Cys-derivatizing 
agents are shown in Figure 1.11. Cys residues can also be PEGylated with PEG-maleimide, 
PEG-iodoacetamide and PEG-epoxide [3]. Proteins generally have fewer Cys than Lys 
residues thus making Cys-PEGylation more selective. PEGylated proteins have improved 
physicochemical stability, pharmacokinetic and pharmacodynamic properties.  
PEG can also react with disulfide bonds; PEG-monosulfone forms a three carbon 
bridge with the native disulfide bond-sulfurs. For example, the native disulfide bond in 
interferon α-2b was conjugated with PEG and retained its biological activity and tertiary 
structure [88]. Although thiol derivatization is an attractive option, it is not a feasible one 
for proteins where free Cys and/or the native disulfide bond are important in biological 
activity and protein stability.  




Figure 1.11: Thiol derivatizing agents that are commonly used to derivatize thiols in 
proteins to prevent reaction with other groups [3].  
 
1.8.3 Protein engineering  
Disulfide bond heterogeneity in therapeutic proteins can be reduced by mutating 
Cys residues with other non-reactive amino acids like Ser. Antibodies have a large number 
of disulfide bonds and they are classified by the number and type (inter/intra) of bonds. 
Allen et al. have shown that Cys→Ser mutations in IgG2 reduce disulfide bond 
heterogeneity while maintaining in vitro activity [89]. Browning et al. observed disulfide 
scrambling in interleukin-2 (IL-2) with one disulfide bond and a free Cys residue, under 
denaturing and alkaline conditions (Figure 1.12). The scrambled forms were less active 
than the native form [90]. A Cys125Ser mutant of IL-2 was found to be more stable to 
disulfide scrambling at alkaline pH.  
 




Figure 1.12: Thiol-disulfide exchange in interleukin-2. Adapted with permission from 
reference [90]. 
 
Junnila et al. determined the role of the C-terminal solvent exposed disulfide bond 
(Cys182-Cys189) in hGH by mutating the Cys residues with Ala. The hGH analogs were 
found to have reduced receptor binding affinity and stability compared to the wild type 
[91]. Although biological activity did not change drastically with this mutation, decreased 
stability of the mutants could lead to other degradation pathways, including aggregation. 
In other proteins, disulfide bonds have been introduced to improve overall stability [92]. 
Introducing an intermolecular disulfide bond is usually associated with increased protein 
stability. However, the effect of an intramolecular disulfide bond or the presence of an 
unpaired Cys can be unpredictable [93]. For example, Hsu et al. observed that deletion of 
a free Cys residue in recombinant keratinocyte growth factor affected protein stability [94]. 
This Cys (residue 40) was found to play an important role in maintaining protein stability 
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and structural integrity. Protein engineering may not always be a practical option, 
especially if the role of the Cys/disulfide bond is unknown. In addition to the strategies 
mentioned above (that cannot be applied to all therapeutic proteins), targeting specific 
mechanisms that contribute to and processing conditions that facilitate disulfide-mediated 
aggregation is instrumental in designing rational approaches to stabilize protein 
formulations. 
 
1.9 Lyophilization of peptide and protein drugs 
 
Therapeutic proteins are often lyophilized to improve storage stability. However, 
aggregation is known to occur even in the solid state [14, 79, 95, 96]. Proteins can undergo 
conformational changes during lyophilization, particularly during dehydration. Different 
effects of dehydration on protein conformation have been reported. Desai et al. observed 
freeze-drying induced partial denaturation in bovine pancreatic trypsin inhibitor [97]. In 
another study by Rupley et al., no difference in protein conformation was observed for 
lyophilized lysozyme when compared to the protein in aqueous solution [98]. Costantino 
et al. observed that the process of lyophilization itself induced structural changes in 
recombinant human albumin (rHA) [95]. During lyophilization of rHA, there was an 
increase in both β-sheet content and unordered structural elements resulting in partial 
protein unfolding. Such conformational changes can expose hydrophobic regions and 
reactive groups, facilitating aggregation via hydrophobic interactions and other covalent 
and non-covalent pathways. 
  30 
 
 
Cryoprotectants and lyoprotectants such as sugars, polyols, polymers and 
surfactants are typically used to protect peptides and proteins from process induced 
degradation [99]. Solid properties of the excipients themselves must be investigated before 
they can be used with a protein or peptide. Mannitol, for example can crystallize into three 
different polymorphic forms (α, β and δ) as well as a hemi-hydrate. The type of polymorph 
that is generated will depend on lyophilization conditions and the presence of other 
excipients. The mannitol hemi-hydrate may release its crystal water during storage. Unlike 
mannitol, sucrose is amorphous after lyophilization. For some therapeutic proteins a 
combination of both amorphous and crystalline excipients may be advantageous. Prior 
knowledge of protein aggregation mechanisms may be beneficial to the process of 
excipients screening and selection to add further stability during freeze- and spray drying. 
This highlights the importance of understanding the effect of processing conditions and the 
use of excipients/stabilizers on chemical modifications in addition to determining storage 
stability under accelerated conditions. 
 
1.9.1 Thiol-disulfide exchange in the solid-state 
Lyophilized protein powders in the ‘dry state’ or ‘anhydrous state’ are thought to 
exhibit behavior and ionization states similar to pH conditions in aqueous solution before 
lyophilization, thus demonstrating a “pH memory” [100]. Alkaline hydrolysis of disulfide 
bonds and thiol-disulfide exchange are favored at neutral to alkaline pH, with the thiolate 
anion being the reactive species. Thus, formulating proteins with free thiols and/or 
disulfides in neutral to alkaline buffers prior to lyophilization would be expected to 
facilitate disulfide-mediated aggregation during lyophilization and storage in the solid state. 
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In addition, the three dimensional structure of proteins can influence disulfide-mediated 
degradation. Any structural rearrangement of proteins (perturbation during lyophilization) 
can have a profound effect on the pKa of reactive residues. Structural changes induced by 
process stresses can be probed using Fourier transform infrared spectroscopy (FTIR) [101]. 
FTIR spectra of human growth hormone lyophilized with and without excipients are shown 
in Figure 1.13. In addition, the presence of moisture and high storage temperatures can 
further influence reaction rates.  
Thiol-disulfide exchange has been reported in lyophilized proteins like bovine 
serum albumin (BSA) when exposed to moisture at 37 oC [96].  Similarly, Constantino et 
al. investigated the mechanism of aggregation in recombinant human albumin (rHA) 
during storage in the solid state at 37 oC and 96% RH [95]. They attributed the formation 
of insoluble aggregates to disulfide exchange in the absence of any stabilizing excipients. 



















Disulfide mediated aggregation can also occur in proteins with no free thiols but 
with disulfide bonds. One such example is insulin, in which β-elimination followed by 
thiol-catalyzed disulfide exchange results in the formation of insoluble aggregates during 
storage at 50 oC and 96% RH. These studies show how structural perturbations during 
lyophilization can have a profound effect on the storage stability of therapeutic proteins 
and disulfide bond reactivity, especially when exposed to high relative humidity and 
temperature.  
 
1.10 Disulfide bond mapping 
 
Recombinant proteins that are expressed in different systems like E.coli and CHO 
cells can have incorrectly folded, scrambled forms. Thus, it is important to identify the 
 Figure 1.13: FTIR spectra of human growth hormone. 1- hGH in solution, 2- hGH 
lyophilized with sucrose, 3- hGH lyophilized with trehalose and 4- hGH lyophilized alone. 
Adapted with permission from reference [101].  
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presence and extent of scrambling in protein therapeutics to assess the quality of the final 
drug product, particularly for biosimilars. Conventional methods for disulfide bond 
determination such as NMR and Edman sequencing typically require large amounts of 
protein samples. Mass spectrometry coupled with ionization methods for ionizing large 
molecules has emerged as a novel analytical tool for characterizing protein structure and 
disulfide bond analysis/mapping.  
The first step in disulfide bond mapping is to determine the number of disulfide 
bonds, by comparing MS spectra before and after protein reduction and the mass shift 
between the two samples. In recombinant human granulocyte-macrophage colony-
stimulating factor (GM-CSF), ESI MS analysis before and after protein reduction revealed 
a 4Da shift in reduced protein spectra [102], suggesting that GM-CSF has two native 
disulfide bonds. Using an alkylating agent in addition to a reducing agent will confirm the 
presence of any free Cys residues when compared to the MS spectra of the native and non-
reduced protein. The next step in disulfide bond mapping is to identify the location of these 
disulfide bonds and free Cys. This can be achieved with proteolytic and alkylating agents, 
comparing HPLC-UV chromatograms followed by tandem MS [103]. A combination of 
two or more proteolytic agents may be required for proteins where disulfide bonds are 
found to hinder proteolysis to form simple disulfide-linked peptides. Different ionization 
methods such as FAB/liquid secondary ion, plasma desorption (PD) and MALDI have been 
used to map disulfide bonds recombinant human interferon α-2b, human growth hormone 
and IL-4 [103].  
Disulfide scrambling can occur even during analysis of disulfide bonding patterns 
in proteins and peptides. Suitable quench conditions (low pH) and thiol derivatizing agents 
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(described under formulation strategies for cysteine-containing proteins) can be employed 
to minimize these effects. Tang and Speicher describe four steps for disulfide bond 
mapping in proteins: i) cleaving proteins using proteases or other chemical reagents (shown 
in Table 1.1) under acidic and non-reducing conditions, ii) chromatographic separation of 
cleaved fragments, iii) use of disulfide reducing agents to confirm disulfide containing 
complexes and iv) characterizing disulfide-linked peptides using mass spectrometry (MS) 
and N-terminal Edman sequencing [104]. For large proteins (> 50 kDa) or proteins with 
multiple disulfide bonds and large domains that are typically resistant to denaturation and 
proteolysis, cyanogen bromide (CNBr) cleavage can be used. In this method, fragmentation 
occurs C-terminal to Met residues and large fragments are usually generated. Further, the 
low pH employed for CNBr cleavage prevents disulfide bond scrambling.  
More recently, MS-based approaches (tandem-MS) for disulfide bond 
identification in proteins are becoming popular. Collision-induced dissociation (CID) in 
MS results in amide bond cleavage to yield b- and y- ions and is the most common tandem 
MS approach that is used to obtain protein structural information [105]. Disulfide bonds 
can either be broken or remain intact during CID. In addition to b/y ions, disulfide bonds 
can fragment (S-S or S-C bonds) to form free Cys residues, thioaldehydes, dehydroalanines 
and persulfides. Using CID as the fragmentation mode eliminates the need for sample 
reduction prior to MS analysis and high- end MS instruments. However, the formation of 
different cysteinyl peptide combinations can complicate analysis of the spectra and 
disulfide bond assignment, particularly for proteins for which the native disulfide linkage 
is unknown. 
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Haitao et al. have described a method for direct disulfide bond cleavage in the gas 
phase using electron transfer dissociation (ETD) [106]. Disulfide bond cleavage is 
preferred to peptide bond cleavage in ETD due to the fact that sulfur atoms capture 
electrons easily during the electron transfer process. This approach eliminates the need for 
two separate experiments, i.e., enzymatic digestion with and without reducing agents to 
determine the exact location of disulfide bonds. ETD and ECD are more suitable for 
disulfide bond identification, particularly for proteins in which the disulfide-bonding 
pattern is unknown. 16 disulfide bonds in an anti-HER2 mAb (Herceptin®) were mapped 
using ETD fragmentation followed by CID-MS3 on the dissociated peptides to further 
verify the disulfide arrangement. However, the authors report that a disadvantage of using 
ETD for disulfide bond identification is that for precursor ions with m/z > 900, in this case, 
the charge-reduced species is the dominant form and not the disulfide-dissociated peptide. 
Nevertheless, this analytical technique has been used to effectively map disulfide bonds in 
recombinant proteins such as human growth hormone and tissue plasminogen activator 
[106].  
Zhang et al. used an electrolytic reduction approach coupled with desorption 
electrospray ionization mass spectrometry (EC/DESI-MS) to analyze disulfide linkages in 
insulin and somatostatin [107]. The EC/DESI-MS method could effectively map disulfide 
bonding patterns and determine the role of disulfide bonds in maintaining protein 
conformation based on charge state distributions. Use of a selenamide derivatizing agent 
with EC/DESI-MS facilitated the analysis of intra- and interpeptide disulfide bonds.  
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Table 1.1: Chemical cleavage reagents and proteases commonly used for disulfide 




1.11 Research objectives and specific aims 
 
The main objective of this research is to elucidate the mechanisms of thiol-disulfide 
exchange and identify factors that determine reaction rate in solution, during lyophilization 
and storage in the solid-state using model peptides derived from human growth hormone 
(hGH) and the intact protein. The studies test the central hypothesis that the rate of thiol-
disulfide exchange differs in solution and amorphous solids and is affected by higher order 
structure. To test the hypothesis, the following specific aims were proposed: 
Specific Aim 1:  To elucidate the mechanism of thiol-disulfide exchange in aqueous 
solution and to determine the effect of pH, temperature, oxidation suppressants and peptide 
secondary structure on reaction kinetics. Thiol-disulfide exchange can result in protein 
aggregation via the formation of scrambled inter- and intramolecular disulfide bonds. 
Previous studies of thiol-disulfide exchange have been based on reactions between 
Protease Cleavage site Buffer conditions Temperature Reference
Chymotrypsin Trp, Tyr, Phe 50 mM sodium phosphate, pH 5.5 37 
oC
 Schnaible et al (2002a) 
[108] 
Endoproteinase Glu-C Glu, Asp 100 mM sodium acetate, pH 4.0 24 
oC
Lippincott and apostol 
(2002) [109]
Endoproteinase Lys-C Lys 25 mM Tric-HCl, pH 6.8 37 oC Lead et al (1999) [110]
Pepsin non-specific 0.02N HCl, pH 2.0 37 oC Bures et al (1998) [111]
Subtilisin non-specific 50 mM sodium phosphate, pH 6.5 37 
oC Chong et al (2002) [112]
Thermolysin non-specific 0.1 M triethylamine-HCl, pH 6.0 37 
oC Bures et al (1998) [111]
Trypsin Lys, Arg 50 mM sodium phosphate, pH 6.0 37 
oC
Schnaible et al (2002a) 
[108]
Trypsin (immobilized) Lys, Arg 50 mM sodium phosphate, pH 6.5 23 
oC
Chong and Speicher 
(2001) [113]
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proteins/peptides and low molecular weight thiols such as glutathione and DTT. However, 
these species are not representative of free thiol groups in larger proteins, and very little is 
known about the reaction mechanisms in these materials. Our hypothesis was that the 
reaction in solution will proceed primarily through the thiolate anion when oxidative 
pathways are inhibited and will be affected by secondary structure.  To test this hypothesis, 
the effects of pH, temperature, oxidation suppressants and peptide secondary structure were 
explored in detail using model tryptic peptides derived from human growth hormone 
(hGH). The results provide mechanistic detail for thiol-disulfide exchange in aqueous 
solution, and are reported in Chapter 2.  
Specific Aim 2: To elucidate the mechanism of thiol-disulfide exchange during 
lyophilization and storage in the solid state. To improve storage stability and shelf-life, 
many protein drugs are marketed as lyophilized powders. However, protein aggregation is 
known to occur even in the solid-state. Tryptic peptides derived from hGH and containing 
disulfide bonds were co-lyophilized with peptides containing free thiols to determine the 
effect of processing conditions on the thiol-disulfide exchange reaction and comparisons 
were drawn to aqueous solution studies. The results provide insights into the effects of 
lyophilization on thiol-disulfide exchange and peptide secondary structure contribution to 
reaction kinetics.  
Specific Aim 3: To determine the effects of higher order structure on the kinetics 
of thiol-disulfide exchange using intact hGH. To test the applicability of studies with model 
peptides to a therapeutic protein, the studies of Aims 1 and 2 were extended to intact hGH. 
The studies in Aim 3 test the null hypothesis that the rates and mechanisms of thiol-
disulfide exchange are unaffected by higher order structure and are identical in hGH and 
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in the model peptides. hGH has two disulfide bonds and no free cysteine residues. The 
results are expected to provide a qualitative measure of the effects of structure on the thiol-
disulfide exchange reaction and an indication of the degradation propensity of disulfide 
bonds in hGH in comparison to model peptides.  
 
1.12 Research Significance 
 
The rate of failure of candidate drug molecules to successfully obtain regulatory 
approval to treat patients is significant, with only one in ten biopharmaceuticals reaching 
the market between 2003 and 2010 [114]. Selecting a promising molecule rather than one 
with inadequate developability characteristics can reduce the total cost of drug 
development and deliver greater value to a larger number of patients. Reducing the attrition 
rate of candidate drug molecules is dependent upon the selection of quality leads. 
Candidate drug molecules are evaluated for stability and shelf-life by assessing their 
potential to degrade by various physical and chemical pathways, including aggregation. 
Different aggregation pathways are often grouped together because of the lack of 
information on the mechanism of individual pathways. This can result in overlooking a 
relevant aggregation pathway, such as disulfide exchange, during candidate evaluation.  
The aggregation of therapeutic proteins has been a major concern for the 
biopharmaceutical industry and regulatory agencies alike, since aggregates have been 
associated with adverse immune responses in patients. To make matters worse, aggregates 
are often difficult to detect and control. Strategies to determine aggregation propensity and 
to inhibit protein aggregation include molecular dynamics simulations [115], protein 
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engineering and process optimization [116] and formulation design [117, 118]. In addition, 
new analytical techniques are being developed to detect protein aggregates formed during 
manufacturing and storage. While these strategies are effective for some proteins, the 
inherent structural complexity of these large molecule drugs makes it challenging to devise 
a general approach that can be adapted to all classes of therapeutic proteins.   
The development of protein therapeutics currently involves a trial and error 
paradigm, which is often the rate-limiting step in getting a drug approved and to the market. 
In order to effectively control aggregation in therapeutic proteins, the mechanisms of 
relevant degradation pathways must be understood in detail. Detailed mechanistic studies 
of protein aggregation pathways like thiol-disulfide exchange, in combination with 
computational methods will facilitate successful development of protein pharmaceuticals 
and minimize associated costs.  
Thiol-disulfide exchange and disulfide scrambling are widely recognized as 
common routes to covalent aggregation in protein drugs. While there are reports of thiol-
disulfide exchange reactions between low molecular weight thiols like GSH [67, 119] and 
CySH [120] and proteins, they are not entirely applicable to disulfide-mediated aggregation 
in proteins since steric effects may influence reaction rates and these low molecular weight 
thiols may not always be present in protein formulations. Thus, understanding the 
mechanisms of thiol-disulfide exchange in aqueous solution and in the solid-state will 
improve our ability to control aggregation in therapeutic proteins. Understanding the 
mechanism of chemical reactivity of a protein is strategic in that it will steer protein 
formulation development away from a trial and error paradigm. The results obtained will 
facilitate the design of rational approaches to control disulfide-mediated aggregation in 
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solution and lyophilized formulations and decrease the likelihood of immunogenic effects 
after administration.  
Finally, biosimilars are proteins that are intended to be similar to the innovator drug 
with respect to quality, safety and efficacy. Variations in biosimilars production include 
manufacturing, cell culture and purification processes and the type of formulation used. 
These differences can have significant effects on the quality of a protein drug. There are 
many analytical tools that are currently being used to characterize follow-on protein 
products [121, 122]. A combination of these analytical methods and the knowledge of 
disulfide rearrangement mechanisms and kinetics are expected to provide improved 
screening.   




CHAPTER 2. ELUCIDATING THE MECHANISM AND KINETICS OF 
THIOL-DISULFIDE EXCHANGE IN PEPTIDES DERIVED FROM 
HUMAN GROWTH HORMONE IN AQUEOUS SOLUTION 
This work was published in the Journal of Pharmaceutical Sciences DOI 





Disulfide bonds stabilize proteins by crosslinking distant regions into a compact 
three-dimensional structure. However, disulfide bonds can participate in degradation 
pathways that can contribute to protein aggregation. In this chapter, experimental data for 
the mechanism of thiol-disulfide exchange in tryptic peptides derived from human growth 
hormone in aqueous solution is presented. Reaction kinetics were monitored to investigate 
the effect of pH (6.0-10.0), buffer concentration (10, 20 and 40 mM), temperature (4-50 
oC), oxidation suppressants (EDTA and N2 sparging) and peptide secondary structure 
(linear vs. cyclic). The concentrations of free thiol containing peptides, scrambled 
disulfides and native disulfide-linked peptides generated via thiol-disulfide exchange and 
oxidation reactions were determined using RP-HPLC and LC-MS Concentration  vs. time 
data  were fitted to a mathematical model using non-linear least squares regression analysis. 
Excluding oxidation suppressants (EDTA and N2 sparging) did not influence the intrinsic 
  42 
 
 
rate of thiol-disulfide exchange. In addition, peptide secondary structure was found to 









In therapeutic proteins, correct disulfide linkages are critical to the biological 
activity and stability of this growing class of drugs [54]. For example, non-native disulfide 
bonding patterns in IgG antibodies have been associated with changes in receptor binding 
affinity, stability, and circulating half-life [123]. A disulfide-linked homodimer of human 
growth hormone (hGH) showed reduced receptor binding affinity and attenuated cell 
proliferative activity [124]. Human albumin or albumin fusion proteins, which contain 17 
disulfides and may contain a free-thiol, also may be prone to deleterious disulfide-mediated 
events [125]. The fundamental mechanism of thiol-disulfide exchange has been defined in 
previous reports using low molecular weight thiols and proteins [45, 61, 119, 120]; 
however, controlling these reactions in therapeutic proteins still remains challenging. It is 
often difficult to predict the most labile disulfide bonds based on structure alone [126], 
suggesting that the structural determinants of thiol-disulfide exchange may be weaker than 
for other reactions such as deamidation [127, 128]. An intact IgG antibody can have more 
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than 20 disulfide bonds, with the potential to form more than 200 species with a single 
scrambled intra- or intermolecular disulfide. While “reducible” aggregates are common in 
protein drug formulations, the disulfide bonds involved are not often identified. There have 
been reports from our group [129] and others [70] that thiol-disulfide exchange is sensitive 
to process-induced stresses such as freezing and fluid shear, but the mechanisms of these 
effects and their interplay with protein structure and fluid composition have not been fully 
elucidated.  
Different factors were critical in designing experiments relevant to achieving the 
overall goals of this project. First, human growth hormone (hGH) is a 4-helix bundle 
protein that belongs to the cytokine family with 191 amino acids and two disulfide bonds 
(no free cysteine residues). The C-terminal disulfide bond is known to have a functional 
role [91]; hence the common formulation strategies for Cys-containing proteins (discussed 
in Chapter 1) are not applicable for hGH. Further, hGH is known to aggregate in solution 
[130,131] and the solid state [132-134], facilitated by the formation of scrambled disulfides 
[91, 135] and/or protein unfolding [130, 136]. Thus, hGH is a tractable model system for 
detailed mechanistic studies. Trypsin digestion map for hGH is shown in Figure 2.1 with 
the disulfide linked peptides; i) T6 and T16 and ii) T20 and T21. Tryptic peptides derived 
from the solvent exposed disulfide bond (T20, T20-T21 and cT20-T21, Table 2.1) in hGH 
were used as model compounds to elucidate the mechanism of thiol-disulfide exchange 
(Scheme 2.1). The T20 peptide contains Cys182, which has been identified as the most 
reactive thiol in hGH [137].   
Second, physical and chemical instabilities are interrelated, for example a chemical 
modification can lead to an unfolding event and vice versa, both modifications contribute 
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to the overall drug decomposition rate. In a review by Waterman and Adami, the authors 
state that drug shelf-life is determined by the rate of formation of individual products and 
rarely by the overall drug decomposition rate [138]. The use of peptide model compounds 
allows determination of mechanisms and rate constants for a specific chemical 
modification in the absence of higher order structure and other degradation pathways, thus 
facilitating better molecular and formulation design approaches.  
Finally, elucidating the reaction mechanism in solution will provide a basis for 
better understanding reactions in solid state systems and determining the influence of other 
external factors like processing and storage conditions. T20 was used in its reduced form 
to react with linear (T20-T21) and cyclic (cT20-T21) peptide models of the native disulfide 
bond. The results show that for these hGH tryptic peptides, the mechanism of thiol-
disulfide exchange is pH independent and the reactions follow Arrhenius behavior. 
However, the observed rate constant (kobs) depends on the concentration of thiolate anion 
and hence the solution pH. Intrinsic rates of thiol-disulfide exchange are not affected by 
oxidation of free thiol-containing peptides even in the absence of oxidation suppressants. 
Additionally, cyclization of the peptide is shown to influence the kinetics of thiol-disulfide 
exchange, with the cyclic peptide having 10-fold lower reactivity when compared to the 
linear peptide.  
 
 














Figure 2.1: hGH-trypsin digestion map, tryptic fragments are labeled T1 to T21 starting
from the N-terminus. Disulfide bonds are represented by the two solid lines between T6-
T16 and T20-T21. Adapted with permission from [139]. 
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Table 2.1: Abbreviations and amino acid sequences of hGH-derived peptides used in 
studies of thiol-disulfide exchange. 
 
 
                            
2.4 Materials 
 
Model peptides T20, T21, T20-T21 and cT20-T21 (see Table 2.1 for structures) 
were purchased from GenScript (Piscataway, NJ) with > 95% purity and supplied as a 
lyophilized powder. HPLC grade acetonitrile (ACN), NaCl and KCl were purchased from 
Fisher Scientific Co. (Pittsburgh, PA). H2O2 and Na2CO3 (anhydrous granules) were 
obtained from Mallinckrodt Baker Inc. (Phillipsburg, NJ). K2HPO4 and 
ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma Chemical Co. (St. 
Louis, MO). Trifluoroacetic acid (TFA) and formic acid were obtained from Thermo 
Abbreviation Description Amino acid sequence Theoretical mass Observed mass
T20
Monomeric peptide, free 
SH group
NH2- IVQCR-OH 617.3319 617.3290
T21
Monomeric peptide, free 
SH group




















Cyclic peptide, disulfide 
linked
NH2-IVQCRSVEGSCGF -OH 1381.6118 1381.6201
rT20-T21
Linear peptide, free SH 
groups
NH2-IVQCRSVEGSCGF -OH 1383.6275 1383.6344
  47 
 
 
Scientific (Rockford, IL). Double-distilled water (DDI) used for buffer preparation and as 
HPLC mobile phase was deionized and purified using a Milli-Q water system, Millipore 




2.5.1 Preparation of peptide stock solutions and disulfide linked peptides for kinetic 
studies 
All peptides were used as provided by the manufacturer. Stock solutions were 
prepared in a 0.1% formic acid solution in DDI. T20, T21, T20-T21 and cT20-T21 stock 
solutions were stable at 4 oC for up to 2 weeks and T20-T20, T21-T21 solutions (pH <3.0 
after quenching with a 0.5% formic acid solution) were stable for 4 days at 4 oC. Far-UV 
(190-260 nm) CD analysis with a J-815 CD spectrometer (JASCO, Easton, MD) was used 
to assess peptide secondary structure. 
2.5.2 Homodimer formation 
T20-T20 and T21-T21 homodimers (Table 2.1) were synthesized in-house using 
H2O2 as an oxidizing agent according to a method described by Luo et al. [140]. H2O2 in 
phosphate buffer (pH 8.0, 2 mM) was added to solutions of T20 or T21 (4 mM) monomers 
in a 1:2 molar ratio (total reaction volume < 1 mL) and allowed to react for 1 day. The 
reaction was then quenched with a 0.5% formic acid solution (2x reaction volume). 
Conversion of monomer to homodimer was > 98% for both monomers, as determined by 
both RP-HPLC (Figure 2.2) and LC-MS. These homodimers were then used to construct 
calibration plots and synthetic standards were not purchased from GenScript.  Attempts to 
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produce the T20-T21 heterodimer using a similar method resulted in very low yields, so 
synthetic T20-T21 was purchased from GenScript (Piscataway, NJ). 
 
 
Figure 2.2: HPLC chromatograms showing T20-T20 formation over time at pH 6.0 in 50 
mM phosphate buffer with H2O2 as the oxidizing agent.  
 
2.5.3 Buffer preparation 
Phosphate buffers (PB) for pH 6.0-8.0 and carbonate buffers (CB) for pH 9.0-10.0 
were prepared at different concentrations (10, 20 and 40 mM) to enable extrapolation of 
rate constants to zero buffer concentration. The ionic strength of all buffers was adjusted 
to 0.08 M using KCl for PB and NaCl for CB. To minimize oxidation of free thiols, 0.5 
mM EDTA and N2 were used. Buffers were sparged with N2 for 30 min and then degassed 
and filtered with a 0.2 µm (Millipore, MA) filter before use. For reactions without 
suppression of oxidation, PB (pH 7.0, 10 mM) was used without EDTA and N2.  
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2.5.4 Quantification of reactants and products by HPLC 
RP-HPLC assays were developed to detect and quantify each of the seven species 
(T20, T20-T20, T20-T21, T21, T21-T21, cT20-T21, rT20-T21) with baseline resolution 
(Figure 2.3). Samples were analyzed using reverse-phase high-performance liquid 
chromatography (RP-HPLC, Agilent 1200 series). The system was equipped with a UV 
detector operating at 215 nm for all studies. Agilent Chemstation software was used for 
data acquisition and analysis. A ZORBAX Eclipse plus C18, 5 µm (4.6 X 250 mm) 
analytical column (Agilent Technologies, Santa Clara, CA) was used with gradient elution 
(column temperature was maintained at 25 oC). Solvent A was 0.1% TFA (pH~2.5) in 
water and Solvent B was 0.1 % TFA in acetonitrile. Elution was performed at 1 mL/min 
starting with 14% Solvent B, which was increased to 47% in 5.2 min, then held at 47% for 
3 min and finally returned to 14% at 8.3 min. Total run time for each sample was 12 min. 
The retention times for T20, T20-T20, T20-T21, T21 and T21-T21 were 4.7 min, 5.2 min, 
6.5 min, 7.2 min and 7.9 min respectively (Figure 2.3), as confirmed by mass spectrometry 
(ESI-QTOF-MS, Agilent). For studies with the cyclic peptide, a similar gradient elution 
was used with a total run time of 13 min. The retention times for T20, T20-T20, cT20-T21 
and rT20-T21 were 4.8 min, 5.3 min, 7.3 min and 7.7 min, respectively, as confirmed by 
MS. Calibration curves were linear in the following concentration ranges: 20 µM -1 mM 
(T20), 10-500 µM (T20-T20), 5-500 µM (T20-T21), 20-180 µM (T21), 10-200 µM (T21-
T21), 5-500 µM (cT20-T21), and 5-500 µM (rT20-T21). Limits of detection (S/N = 2) 
were 15 µM (T20), 2.5 µM (T20-T20), 1 µM (T20-T21), 5 µM (T21), 5 µM (T21-T21) 
and 5 µM (cT20-T21 and rT20-T21). No cleavage of disulfide bonds was observed at pH 
levels above the Cys thiol pKa, as has been previously reported [141].  
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At the end of each experiment, the total mass of the identified products was >98% 
for pH 6.0-9.0 and >95% for pH 10.0 of the total initial mass of the reactants. Based on the 
limits of detection and linear ranges of the calibration curves, initial reactant concentrations 
of 350 µM (T20) and 250 µM (T20-T21) were used. The amount of T20-T20 and T20-T21 
formed via oxidative pathways was determined by mass balance. For example, in the 
absence of oxidation, the amount of T20-T20 generated will equal the amount of T20-T21 
consumed.  Any additional T20-T20 formed is assumed to occur via oxidation. 
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Figure 2.3: HPLC chromatograms (215nm) at various times during the reaction of T20 
with T20-T21 at pH 7.0, 10 mM phosphate buffer with 0.5 mM EDTA. A) 0 mins. B) 180 
mins and C) 1440 mins.  
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2.5.5 Determination of reaction order 
The initial reaction rates were monitored at room temperature (22 oC) and pH 7.0 
(10 mM PB, 0.5 mM EDTA, 0.08 M ionic strength, N2 sparged) in a 2 mL microcentrifuge 
tube with a total reaction volume of 1250 µL. Initial volumes of T20 were 500 µL, 500 µL 
and 250 µL, respectively and initial concentrations were calculated based on final 
concentrations listed below. To determine the reaction order with respect to T20, a final 
concentration of T20-T21 of 250 µM was used and kinetics monitored at different initial 
concentrations of T20 (80, 250, 370 and 630 µM). In the same way, the reaction order with 
respect to T20-T21 was determined using a fixed initial concentration of T20 (350 µM) 
and different initial concentrations of T20-T21 (130, 270, 410 and 600 µM).  
 
2.5.6 Thiol-disulfide exchange reactions 
Reaction kinetics were monitored at five different pH values (6.0, 7.0, 8.0, 9.0, and 
10.0). For the reaction, 500 µL of T20 (875 µM), 500 µL of T20-T21 (625 µM) and 250 
µL of buffer (50, 100 and 200 mM) were added to a 2 mL microcentrifuge tube and mixed 
by pipetting. The final pH of the reaction mixture was adjusted using NaOH or HCl (exact 
volume to be added was determined from pilot studies at each pH) after a 100 µL aliquot 
was removed and quenched to verify initial concentrations (t = 0 min). Samples were 
withdrawn in triplicate at all time points and quenched with 10 µL of 20% formic acid 
solution in DDI to prevent further scrambling. 30 µL of this quenched solution was then 
used for RP-HPLC analysis. Dilution factors from total reaction volume, addition of 
NaOH/HCl for pH adjustment and quench solution were accounted for in determining final 
peptide concentrations. No measurable changes in concentration were observed in 
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quenched samples within the time scale of the experiment. The cyclic peptide cT20-T21 
(see Table 2.1) was reacted with T20 in 10 mM PB and CB (0.08 M ionic strength, 0.5 mM 
EDTA and N2 sparged). The reaction was monitored kinetically at 22 oC and at 40 oC at 
pH 7.0 and 9.0 for 6 hours. Initial reactant concentrations were [T20] = 450 µM and [cT20-
T21] = 45 µM. Quench conditions were the same as in studies with T20-T21 and aliquots 
were withdrawn in triplicate and analyzed using RP-HPLC.  
 
2.5.7 Determining activation parameters for the reaction of T20 with T20-T21 
Reaction kinetics were also monitored at five different temperatures (in triplicate): 
4, 15, 25, 40 and 50 oC at pH 7.0 (PB, 10 mM with 0.5 mM EDTA). Initial reactant 
concentrations, quench conditions and sample analysis were identical to those in the pH 
studies. Arrhenius parameters obtained from accelerated storage conditions are generally 
used to predict protein stability at low temperatures [142]. However, for proteins, non-
Arrhenius behavior is not uncommon due to the complexity of the aggregation process 
itself. In simpler model compounds like peptides, we expect the reaction to follow 
Arrhenius behavior in a narrow temperature window. Use of high temperatures (≥ 60 oC) 
can lead to degradation of the peptides. Thus, for the hGH-derived peptides used in studies 
here, Arrhenius behavior was investigated from 4 to 50 oC using Equation 2.1 below.  
 
                                    k = A exp [-(Ea/RT)]                                      Eq. 2.1 
 
Where, k- rate constant, A- preexponential factor, R- gas constant, T-temperature and Ea 
is the activation energy.  
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The Eyring equation (Eq 2.2) provides molecular insight into how a reaction 
progresses with changing temperature. Activation energy, Ea and enthalpy of activation 
(ΔH‡) only have small differences in their values and are often used interchangeably.  
 
             ln (k/T) = (-ΔH‡/T)(1/T) + ln (kB/h) + (ΔS‡/R)                           Eq. 2.2    
 
Where, k- rate constant, T-temperature, ΔH‡ - enthalpy of activation, ΔS‡ - entropy of 
activation, kB – Boltzmann constant, h – Planck’s constant and R – gas constant.  
                            
2.6 Data analysis 
 
For the reaction of T20 with linear T20-T21, the data were consistent with a 
reaction scheme involving: (i) equilibrium ionization of T20 and T21, (ii) reversible thiol-
disulfide exchange reactions of the ionized thiolate forms of T20 and T21 (i.e., T20-S-, 
T21-S-) with T20-T21 and (iii) oxidation of the ionized thiolate forms of T20 and T21 
(Scheme 2.1). A system of equations corresponding to this scheme was used to describe 
the time-varying concentrations of each species and to estimate values of the microscopic 
rate constants.  
 
T20S- = T20 / {1 + (10-7)/ (10-pKa)}                  Eq. 2.3  
T21S- = T21 / {1 + (10-7)/ (10-pKa)}                                        Eq. 2.4 
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d [T20-T21]/dt = -k1 [T20S-][T20-T21] + k2 [T20-T20] – k3 [T21S-][T20-T21] + k4 [T21- 
T21][T20S-] +   k5 [T20S-]3 [T21S-]                                                              Eq. 2.5      
 
d [T20-T20]/dt = k1 [T20S-][T20-T21] – k2 [T20-T20][T21S-] + k5 [T20S-]3 [T21S-]     
Eq. 2.6 
 
d [T21-T21]/dt = k3 [T21S-][T20-T21] – k4 [T21-T21][T20S-] + k6 [T21S-]2 Eq. 2.7 
 
d [T20S-]/dt = –k1 [T20S-][T20-T21] + k2 [T20-T20][T21S-] + k3 [T21S-][T20-T21] – k4 
[T21-T21][T20S-] – k5 [T20S-]3 [T21S-]     Eq. 2.8 
 
d [T21S-]/dt = k1 [T20S-][T20-T21] – k2 [T20-T20][T21S-] – k3 [T21S-][T20-T21] + 
k4[T21-T21][T20S-]    – k5 [T20S-]3[T21S-] - k6 [T21S-]2                         Eq. 2.9                         
           
In the kinetic model, time is the independent variable, reactant and product 
concentrations are dependent variables, and the rate constants (k1, k2, k3, k4, k5 and k6) are 
treated as parameters to be determined by non-linear regression. The model returned a 
value of 8.3 for thiol pKa when it was defined as a parameter to be determined by regression 
of pH 7.0 data. Thus, the pKa values for the ionization of the T20 and T21 thiol groups 
(Ka20, Ka21) were fixed at 8.3 for all reaction conditions, consistent with previous reports 
for cysteine [143, 144]. Rate constants k1, k2, k3, and k4 are second-order rate constants for 
thiol-disulfide exchange; k5 is a composite rate constant for the production of T20-T21 and 
T20-T20 by the oxidation of T20S- and T21S-. A composite oxidation rate constant (k5) 
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was used to minimize model parameters. This composite reaction (R5, Scheme 2.1) was 
sufficient to describe the minor oxidation observed when oxidation was suppressed (i.e., 
with EDTA and N2 sparging). Kinetic data were fitted to the model (Equations 2.3-2.9) 
using non-linear regression (SCIENTIST®, Micromath Research, St. Louis, MO). 
SCIENTIST® reports Model Selection Criterion (MSC) values to determine the most 
appropriate models; a greater MSC value represents a better model. MSC is independent 
of the scaling of data points and is similar to the Akaike Information Criterion (AIC), which 
is considered to be a better measure of model validity than R2 values for non-linear models 
[145]. MSC value for the model with composite k5 was greater than the MSC value for a 
model with two separate oxidation rate constants. When oxidation was not suppressed, the 
additional parameter k6 for the oxidation of ionized T21 to T21-T21 (R6, Scheme 2.1) was 
included to compare data to oxidation suppressed studies and to obtain better model fits 
based on MSC values. 
Average values of the measured concentrations of each of the five species (i.e., T20, 
T21, T20-T20, T21-T21 and T20-T21), as measured by RP-HPLC in triplicate at each time 
point, defined the data set. In studies of the effect of pH, kinetic studies were repeated at 
several buffer concentrations and the values of the rate constants extrapolated to zero buffer 
concentration. An Arrhenius plot was constructed from reactions at various temperatures 
to estimate the activation energy (Ea) of the reactions. All calculated Ea values were 
evaluated by one-way ANOVA using SAS, a statistical analysis software (SAS Institute, 
Cary, NC) at 95% confidence to determine significant differences in Ea among the four 
thiol-disulfide exchange reactions (R3 and R4, Scheme 2.1).For the reaction of T20 with 
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cT20-T21, the data were fitted to the equation (Eq. 2.10) for first order irreversible reaction 
to give kobs.  
                                    
                                   A/A0 = exp (-kobs t)                                Eq. 2.10 
 
Here, A = [T20-T21] or [cT20-T21] and A0 is the initial concentration of the respective 




2.7.1 Addition of oxidation suppressants to favor the thiol-disulfide exchange reaction 
Peptides derived from hGH were used to investigate thiol-disulfide exchange in 
aqueous solution. Initial studies of the reaction of T20 with T20-T21 in buffer without 
EDTA or N2 sparging (pH 7.0) showed that the reactants and products did not appear to 
reach equilibrium (Figure 2.4), suggesting another reaction pathway in addition to thiol-
disulfide exchange. In reactions of T20 and T20-T21, only five species (i.e., T20, T21, 
T20-T20, T20-T21, and T21-T21) were detected at all reaction conditions studied (Figure 
2.3). Similarly, in reactions of T20 and cT20-T21, only four species were detected (i.e., 
T20, T20-T20, cT20-T21, rT20-T21). No additional oxidation products (e.g., sulfenic, 
sulfinic, or sulfonic acids) were detected with either RP-HPLC or LC-MS both in the 
presence and absence of oxidation suppressants, strongly suggesting that the additional 
reaction pathway is the formation of T20-T20, T20-T21 and T21-T21 from their respective 
monomers via oxidation. In order to isolate the thiol-disulfide exchange reaction for further 
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investigation, PB buffers (pH 7.0) were sparged with N2 for 30 minutes, degassed, and 
different concentrations of EDTA (0.5 mM, 1 mM and 2 mM) were evaluated for their 
ability inhibit the oxidation reactions. Because the reactions were unaffected by higher 
EDTA concentrations (data not shown), 0.5 mM was chosen for all subsequent studies in 
which oxidation was suppressed. Although the rates of the oxidation reactions were 
significantly attenuated (see below), oxidation could not be eliminated completely using 
EDTA and N2 sparging. Other methods to inhibit oxidation like using a nitrogen controlled 
atmosphere were not investigated as <10% of T20 and T21 participate in the oxidation 
pathways in the presence of EDTA and N2 (based on mass balance from RP-HPLC data). 
Oxidation of rT20-T21 to cT20-T21 is the major reaction (Figure 2.5, concentration 
of cT20-T21 increases while rT20-T21 decreases beyond 500 min), even in oxidation 
suppressed conditions, after 6 hours. As the main aim was to study thiol-disulfide exchange, 
we monitored the reaction for up to 6 hours, a time period within which oxidation of T20 
to T20-T20 or rT20-T21 to cT20-T21 does not occur to an appreciable extent (determined 
from pilot studies that were monitored at later time points, Figure 2.5). Also, mass balance 
showed that the amount of T20-T20 formed was equivalent to the amount of cT20-T21 
consumed, further supporting thiol-disulfide exchange as the major pathway for disulfide 
scrambling for t < 6 h. For studies with cT20-T21 at pH 7.0 and T20 and T20-T21 at pH 
7.0 and 9.0, a similar sampling schedule was used 
 




Figure 2.4: The concentration of reactants and products for a kinetic study with T20 and 
T20-T21 at pH 7.0, 10 mM PB and 0.08 M ionic strength (without EDTA or N2 sparging). 
Initial concentrations of peptides were: [T20] = 350 µM; [T20-T21] = 250 µM. The 
symbols represent actual data points obtained from samples at different times (n=3, +/-SD). 




Figure 2.5: Concentrations of cT20-T21 (▲) and rT20-T21 (●) for the reaction of cT20-T21 with 
T20 in 10 mM carbonate buffer, pH 9.0, and 0.08 M ionic strength (with EDTA and N2 sparged) at 
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2.7.2 Apparent order of reaction; reaction of T20 and T20-T21 
To estimate the order of the disulfide exchange reaction and guide the development 
of a proposed reaction scheme (Scheme 2.1), reactant and product concentrations were 
monitored in the early stages of the reaction (pH 7.0, 10 mM PB, 0.5 mM EDTA and N2 
sparging) where <5% change in both reactants was observed. The apparent first-order 
reaction rates were estimated for a range of initial concentrations. Slopes of log-log plots 
of the rate of reactant disappearance versus reactant concentration were 0.99±0.01 for T20 
and 0.93±0.03 for T20-T21 (Figure 2.6), indicating that the reaction is first-order with 
respect to the thiol and disulfide reactants and second-order overall. Kuwajima et al. 
investigated disulfide bond reduction in α-lactalbumin with DTT [66]. The authors 
reported that the kinetics of disulfide bond reduction is rate-limited by inter-molecular 
disulfide exchange between α-lactalbumin and DTT and that such a reaction is second-
order [66], consistent with our findings using hGH-derived peptides. This report and our 
observation that thiol-disulfide exchange is a second-order reaction are also consistent with 
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Reaction schemes for thiol-disulfide exchange in hGH-derived peptides 
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Figure 2.6: Thiol-disulfide exchange initial rate studies in which the concentration of one 
reactant (either T20 or T20-T21) was fixed while the concentration of the second reactant 
(either T20 or T20-T21) was varied (see text). Reaction kinetics was monitored at pH 7.0, 
10mM PB, 0.08M ionic strength with EDTA and N2 sparging at 22 oC. Log-log plots of 
rate of loss of T20 versus T20 concentration (■) and rate of loss of T20-T21 versus T20-
T21 concentration (♦). 
 
2.7.3 Effect of oxidation suppressants on thiol-disulfide exchange 
To determine the effect of oxidation on the rate and mechanism of thiol-disulfide 
exchange at pH 7.0, the rate constants for the exchange and oxidation reactions were 
estimated by fitting the experimental data from reactions with and without EDTA and N2 
sparging to the model described in Scheme 2.1 (Figures 2.4 and 2.7). The oxidation 
suppressed thiol-disulfide exchange data of T20 with T20-T21 were well described by the 
model in Scheme 2.1 without R6 (R2 ≥0.95, see below), as T21-T21 was formed only via 
thiol-disulfide exchange in the presence of oxidation suppressants at all pH 6.0-10.0. In the 
absence of oxidation suppressants, including a separate reaction (Scheme 2.1, R6), 
described the data better than combining all oxidation reactions into a composite reaction 
y = 0.9938x - 3.5876
R² = 0.9947
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for all three oxidation reactions in Scheme 2.1 (R5 and R6). For the oxidation of T21 to 
form T21-T21 in the absence of oxidation suppressants (R6, Scheme 2.1), the estimated 
value of rate constant k6 was 8.9±2.6 M-1s-1. In the presence of oxidation suppressants, 
oxidation of T21 was not observed (k6 = 0). Rate constants for thiol-disulfide exchange 
were similar with and without oxidation suppressants, while k5 increased 3.6-fold and k6 
increased from 0 to 8.9±2.6 M-1s-1 (Figure 2.8). Statistical analysis showed no significant 
difference in rate constants for thiol-disulfide exchange (p>0.05) and a significant 
difference for the oxidation reaction rate constant (p<0.05) in the presence and absence of 
EDTA and N2, indicating that the intrinsic rate of the disulfide exchange reactions are not 
affected by the presence of oxidation side-reactions.  
 
Figure 2.7: The concentration of reactants and products for a kinetic study with T20 and 
T20-T21 at pH 7.0, 10mM phosphate buffer with 0.5 mM EDTA and N2 sparging. Initial 
concentrations of peptides were: [T20] = 350 µM; [T20-T21] = 250 µM. The symbols 
represent actual data points obtained from samples at different times (n=3, +/- SD. Solid 




























Figure 2.8: Comparison of rate constants for reactions with and without oxidation 
suppressants (0.5 mM EDTA and N2 sparging) at pH 7.0, 10 mM PB and 0.08 M ionic 
strength at 22 oC. Initial concentrations of peptides were: [T20] = 350 µM and [T20-T21] 
= 250 µM (n=3, +/- SD). Unit for k5 is M-3s-1.   
 
2.7.4 Effect of pH on the reaction of T20 with T20-T21 
Thiol-disulfide exchange reactions were monitored as a function of buffer 
concentration to determine the effect of buffer catalysis. At pH 6.0, 8.0, 9.0 and 10.0, a 
high buffer concentration (40 mM) appears to have had a moderate stabilizing effect 
(Figure 2.9; A, C, D and E). Statistical analysis showed no significant difference between 
extrapolated rate constants and the rate constants at 10 mM buffer (p>0.05). Nevertheless, 
at all pH values, we report rate constants extrapolated to zero buffer concentration. An 
example of the fit of the data to the model (Scheme 2.1) at pH 7.0 is shown in Figure 2.7; 
similar fits were obtained at the other pH values (Figure 2.10; A, B, C and D). At pH 7.0, 
the extrapolated rate constants of the reactions shown in Scheme 2.1 were: k1 = 5.0±0.2 M-
1s-1, k2 = 10.6±0.3 M-1s-1, k3 = 3.4±0.1 M-1s-1, k4 = 6.9±0.1 M-1s-1. Rate constants at other 



























  65 
 
 
shown in Figure 2.11 for the extrapolated rate constants. Statistical analysis showed no 
significant difference (p>0.05) in the rate constants for this pH range. This suggests that 
the mechanism of thiol-disulfide exchange is independent of pH as reported by others [146, 
147]. Although a change in solution pH did not affect the rate of thiol-disulfide exchange 
in tryptic peptides, it can influence reaction kinetics in proteins, which can undergo pH-
induced conformational changes that can alter the exposure of disulfides and/or free thiols. 
The pseudo-first order rate constant (kobs) for the loss of T20-T21 was determined by 
monitoring the change in concentration over time. Data at different pH values (6.0-10.0) 
are shown as a pH-rate profile in Figure 2.12. The slope of the pH-rate profile in the 
pharmaceutically relevant range of pH 6.0 to 8.0, below the thiol pKa (8.3), is ~ 1. The 
change in kobs with increasing pH (i.e., the slope of the pH rate profile) decreases above pH 
8.0. However, there is a slight increase in kobs above pH 8.0 as the population of thiolate 
anion still changes, albeit at decreasing proportions at pH > thiol pKa. The observed pH 
dependence of kobs and the pH independence of k1-k4 indicate that thiol-disulfide exchange 
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Figure 2.9: Rate constants vs. buffer concentration. Rate constants were obtained from 
model fits to reaction scheme 2.1 (n=3, +/-SD): A) pH 6.0, B) pH 7.0, C) pH 8.0, D) pH 
9.0, and E) pH 10.0 at 0.08 M ionic strength,  different buffer concentrations of 10, 20 and 
40 mM (with EDTA and N2 sparging) and at 22 oC. Initial concentrations of peptides were: 
[T20] = 350 µM; [T20-T21] = 250 µM. Dotted lines are trendlines.  
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Figure 2.10: Kinetic plots at different pH for the reaction of T20 with T20-T21 at 22 oC. 
Symbols represent actual data points (n=3, +/- SD) and solid lines represent model fits.[T20] 
= 350 µM; [T20-T21] = 250 µM. Buffer conditions: pH 6.0-8.0 is with 10 mM phosphate 
buffer and pH 9.0-10.0 is with 10 mM carbonate buffer. Ionic strength (0.08 M) and EDTA 
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Table 2.2: Measured rate constants for all buffer concentrations for the reaction of T20 





Figure 2.11: pH-rate profile for second order microscopic rate constants (see Scheme 2.1 
and text for details) obtained for kinetic studies with T20 and T20-T21 at 22 oC. All rate 


























Figure 2.12: Pseudo-first order rate constant for the loss of T20-T21 () at different pH 
(10 mM buffer, 0.08 M ionic strength with oxidation suppressants) and at 22 oC. Rate 
constants were determined by non-linear regression. Uncertainties are within the size of 
the symbol (n=3, +/-SD). 
 
2.7.5 Activation parameters for the reaction of T20 with T20-T21 
Microscopic rate constants for thiol-disulfide exchange (k1, k2, k3, and k4) obtained 
from model fits to data at 4, 15, 35, 40 and 50 oC were used to construct an Arrhenius plot 
(Figure 2.13, see Figure 2.14 for Arrhenius plot of k5). The resulting Arrhenius parameters 
can be used to predict the extent to which temperature changes during storage and 
processing conditions can affect thiol-disulfide exchange. The thiol-disulfide exchange 
reaction was found to follow linear Arrhenius behavior in the temperature range 4-50 oC. 
Linear Arrhenius plots suggest that a change in temperature within this range does not 
result in a change in the proposed reaction mechanism or the rate-limiting step (Scheme 
2.1). There is no significant difference (p>0.05) in the activation energy values for the any 
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ANOVA. R3 and R4 represent two mechanistically equivalent reversible reactions and thus 
would be expected to have similar activation energies. We estimated Arrhenius activation 
energies for the reaction of T20 and T20-T21 to be in the range of 41-53 kJ/mol (Table 
2.3). An Eyring plot (Figure 2.15) was used to estimate values for enthalpy (∆H‡), entropy 
(∆S‡) and free energy of activation (∆G‡) at 25 oC (Table 2.3).  
 
 
Figure 2.13: Arrhenius plots for microscopic rate constants for the reaction of T20 and 
T20-T21 (Scheme 2.1) at pH 7.0, 10 mM phosphate buffer and 0.08 M ionic strength with 























Figure 2.14: Arrhenius plot for microscopic rate constant k5 (●) for the reaction of T20 
and T20-T21 (see 2.1). The reaction was monitored at pH 7.0, 10 mM buffer and 0.08 M 
ionic strength (with EDTA and N2 sparging) (n=3, +/- SD). Solid lines represent trendlines. 
 
 
Figure 2.15: Eyring plot for microscopic rate constants for the reaction of T20 with T20-
T21 at pH 7.0, 10 mM buffer and 0.08 M ionic strength (with EDTA and N2 sparging) (n=3, 
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2.7.6 Effect of peptide cyclization on thiol-disulfide exchange 
The non-cyclic model peptides (T20, T21, T20-T20, T21-T21 and T20-T21) do not 
have any secondary structure, as confirmed by far-UV CD analysis. However, the CD 
spectrum for cT20-T21 shows internal hydrogen bonding, possibly due to the presence of 
a beta-turn-like structure (Figure 2.16). Initial studies carried out with T20 and cT20-T21 
with the same molar ratios as the heterodimer study (thiol: disulfide = 1.4:1) showed no 
reaction at 22, 40, or 60 oC. Thus, a higher thiol: disulfide ratio of 10:1 was used for kinetic 
studies using cT20-T21. We compared the rate of reaction of T20 with cT20-T21 at two 
different pH values and temperatures with that of T20-T21 under similar reaction 
conditions (Table 2.4) to determine the effect of peptide secondary structure on reaction 
kinetics. For scrambling reactions involving cT20-T21 and T20, rates were considerably 
slower than for the linear form (Figure 2.17). Even with a 10:1 molar ratio of thiol: disulfide, 
only a 26% decrease in disulfide content was observed after 6 hours at pH 9.0 and 22 oC, 
as compared to an 86% decrease for the linear T20-T21. Our results suggest that secondary 
structure has a marked effect on the reaction rate, and that secondary structural constraints 
may attenuate thiol-disulfide exchange in intact hGH relative to the intrinsic exchange rate 










Table 2.3: Activation parameters for thiol-disulfide exchange reactions and oxidation 






Table 2.4: The change in cT20-T21 and T20-T21 concentrations obtained after 6 hours for 
thiol-disulfide exchange reactions with T20 at different pH and temperature at thiol: 
disulfide of 10:1.  
 
 
Rate constant Ea (kJ/mol) A ΔH‡ (kJ/mol) ΔS‡ (J/mol.K) ΔG‡ 25 oC (kJ/mol)
k1 46±4 7.5*108 ±4.2a 43±6 -83±20 68±9
k2 41±2 2.0*108 ±2.6a 38±4 -96±15 66±6
k3 48±4 8.9*108 ±5.9a 50±6 -66±21 70±9
k4 48±4 2.3*109 ±4.4a 45±5 -75±16 67±7
k5 53±7 1.5*1012 ±16.0b 51±6 134±19 11±8
aunits in M-1s-1
bunits in M-3s-1















Figure 2.16: Far-UV CD spectra for A) T20-T21 and B) cT20-T21. The far-UV CD spectrum for 



























































Figure 2.17: Observed pseudo-first order rate constants for the loss of cT20-T21 and T20-
T21 at different concentration ratios and temperatures. Ratios in figure legend represents 
thiol:disulfide ratio (T20:T20-T21/cT20-T21). Initial concentrations of peptides were: 
[T20] = 450 µM; [T20-T21] = 45 µM for 10:1 studies and [T20] = 350 µM; [T20-T21] = 




The mechanism of thiol-disulfide exchange involves reaction of the thiolate anion 
(RS-) with a disulfide bond (R’SSR”) at neutral to alkaline pH [45, 46, 71]. The thiol group 
undergoes deprotonation to form the reactive nucleophile (RS-), this step is followed by 
the exchange of redox equivalents leading to oxidation of the attacking thiol and reduction 
of R'SSR" [45]. In our studies with model peptides derived from hGH, products consistent 
with this mechanism were detected, including T20-T20, T21, T21-T21 and rT20-T21. No 
additional oxidation products such as cysteine sulfenic acid, cysteine sulfinic acid, cysteine 
sulfonic acid or thiosulfinates were detected, either in the presence or absence of EDTA 
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studies.  Here we report thiol-disulfide exchange using model peptides (T20-T21, cT20-
T21, T20) representative of proteins containing an unpaired Cys and disulfide bonds. 
Although native hGH and most mAbs generally do not have unpaired Cys, these may be 
generated by β-elimination, incomplete folding or disulfide bond reduction during 
expression, folding, purification and/or fill-finish operations, and during storage in solution 
or solid formulations.  
The reaction between thiols and disulfides has been studied in detail by other groups 
[50, 119, 120]. Previously Luo et al. used a data modeling approach to determine oxidation 
reaction kinetics for the reaction of Cys-SH and H2O2 [140] and we have used a similar 
approach to study thiol-disulfide exchange. To our knowledge, however, this is the first 
report of a detailed kinetic model allowing the determination of both observed and 
microscopic rate constants for thiol-disulfide exchange in peptide model compounds.  In 
the kinetic model, reactions R1-R5 (Scheme 2.1) were sufficient to describe both thiol-
disulfide exchange and thiol oxidation in studies with oxidation suppressants. Thiol 
oxidation reactions R5 and R6 represent composite reactions that involve oxidation of T20 
or T21 via a RSOH intermediate [140]. RSOH is a reactive species that is completely 
consumed, was not detected analytically and as a result was excluded from the reaction 
scheme. Excellent fits of the model to our data suggest that the reactions represented by 
Scheme 2.1 effectively describe the mechanism for thiol-disulfide exchange between T20 
and T20-T21 and oxidation of free thiols (T20, T21) to form homodimers (T20-T20, T21-
T21) and heterodimer (T20-T21). In the reaction of T20 with T20-T21, omitting oxidation 
suppressants (EDTA and N2 sparging) resulted in an increase in the oxidation rate constant 
k5 by 366% and k6 to 8.9±2.6M-1s-1 from ~0, while the other rate constants remained 
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unchanged (Figure 2.8). The kobs value for the loss of T20 decreased by 130% in the 
presence of oxidation suppressants while kobs for the loss of T20-T21 remained unchanged. 
The results show that excluding oxidation suppressants accelerates the formation of 
scrambled disulfides (T20-T20 and T21-T21) via oxidative pathways. Hydroxyl ion 
mediated disulfide exchange and aggregation has been reported for atrial natriuretic peptide 
(ANP), a cyclic peptide with 25 amino acids and a disulfide bond (C4-C28) in the solid 
state [141]. However, alkaline hydrolysis of peptide bonds in T20-T21 and cT20-T21 was 
not observed up to pH 10.0. 
Rate constants obtained here for the reaction of T20 with T20-T21 are comparable 
to previous reports. For example, Holmgren et al. studied disulfide bond reduction in 
insulin with dithiothreitol (DTT) at neutral pH and determined a second-order rate constant 
for the reaction of 5 M-1s-1 [47]. In another study with DTT, Wiita et al. studied force-
dependent chemical kinetics of disulfide bond reduction [70]. In the absence of an external 
force and at pH 7.2, a second-order rate constant of 6.45 M-1s-1 was obtained. These values 
for thiol mediated disulfide exchange are similar to our model predictions for the reactions 
of both T20 and T21 with T20-T21 (Scheme 2.1, R3 and R4) at pH 7.0 (3-11 M-1s-1).  
Arrhenius activation energy values reported here (Table 2.3) are similar to those 
obtained by Fernandes et al., who reported Ea values for thiol-disulfide exchange in 
solution in the range 60-66 kJ/mol [148]. Wiita et al. assumed values for the Arrhenius 
parameter (A) of 105-1012 M-1s-1, and obtained activation energies between 30-65 kJ/mol 
for thiol-disulfide exchange [70]. Whitesides et al. determined activation parameters for 
the reaction of Ellman’s reagent and glutathione with three different thiols in water at 30 
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oC [71]; ∆G‡ = 44.4 – 65.7 kJ/mol, ∆H‡ = 37.7 – 66.9 kJ/mol and ∆S‡ = -19.7 – +13.4 
J/mol.K.  
The activation parameters reported here, with the exception of more negative values 
of ∆S‡, are similar to values cited above. Thiol-disulfide exchange proceeds via a linear 
SN2 mechanism [149, 150], with greater translational and vibrational constraint of the 
transition state than the reactants, resulting in a negative ∆S‡ and a positive ∆G‡. The values 
of the activation parameters reported here are consistent with expected values of -85 – -
125 J/mol.K for this mechanism [71] and suggest that translational and vibrational 
constraints play a more significant role for thiol-disulfide exchange reactions involving 
peptides than in small molecules.  Youngman et al. have shown that carbamidomethylation 
of all four Cys residues in hGH decreases stability by ~ 37.7 kJ/mol [151]. Protein 
destabilization by disulfide bond reduction increased the population of self-associated 
forms. This is similar to the activation energies reported here, suggesting that the activation 
energy for thiol-disulfide exchange in model peptides is of the same order as the decrease 
in stability that results from the reduction of disulfide bonds in native hGH.  
The results also show that the reaction is ten-fold slower in the cyclic peptide 
(cT20-T21) than in the linear form (T20-T21), suggesting that secondary structural 
constraints in hGH slow thiol-disulfide exchange.  Interestingly, this observation is 
contrary to previous reports. Rabenstein et al. determined observed rate constants for thiol-
disulfide exchange with Cys and Arg-vasopressin (AVP) at pH 7.0 and 25 oC [120]. AVP 
is a cyclic peptide with 9 amino acid residues. The reaction of AVP with Cys (CysSH) was 
100 times faster than the reaction between glutathione disulfide (GSSG) and CysSH. The 
authors attributed this to several factors including a more accessible disulfide bond formed 
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between two terminal Cys residues in AVP. The disulfide bond in cT20-T21 (C4-C11) is 
somewhat removed from the N- and C-termini, and may be less solvent exposed than in 
T20-T21, perhaps contributing to the reduction in rate observed here. Internal hydrogen 
bonding in the cT20-T21 peptide (CD spectrum, Figure 2.16) could impose a structural 
constraint which translates to reduced reactivity of the disulfide bond with T20. 
Additionally, in peptides with 1-3 residues between the Cys, cyclization is unfavorable due 
to geometric strain, while a stable disulfide bond is formed in peptides with 4-5 intervening 
amino acids [50]. The differences in structural effects between the studies reported here 
and previous reports indicate that the relationship between peptide secondary structure and 
reactivity in thiol-disulfide exchange is not completely understood, and that further studies 
are warranted, particularly given the relevance to therapeutic proteins such as hGH, 
monoclonal antibodies (mAbs) and human serum albumin. The results can be extended to 
therapeutic proteins and biosimilars to determine the influence of sequence, structure and 
processing conditions on reaction mechanisms and disulfide-mediated aggregation 




The studies reported here define the mechanistic details of thiol-disulfide exchange 
and oxidation in hGH model peptides in solution. Microscopic and apparent rate constants 
obtained from model predictions provide an insight into the effects of pH, temperature and 
secondary structure on thiol-disulfide exchange. Detailed kinetic analysis of degradation 
pathways like thiol-disulfide exchange is valuable for the development of protein drug 
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formulations, both in solution and in the solid state.  Further, the information can be used 
to improve our understanding of the contributions of thiol-disulfide exchange to 
aggregation in other therapeutic proteins with disulfide bonds and/or Cys residues. 
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CHAPTER 3. INVESTIGATING THE EFFECT OF LYOPHILIZATION AND 
SUBSEQUENT STORAGE IN THE SOLID STATE ON THIOL-
DISULFIDE EXCHANGE IN PEPTIDES DERIVED FROM HUMAN 
GROWTH HORMONE 
This work was published in the Journal of Pharmaceutical Sciences 






Lyophilization (freeze-drying) is frequently used to stabilize protein therapeutics. 
However, covalent modifications such as thiol-disulfide exchange and disulfide scrambling 
can occur even in the solid-state. The effects of lyophilization and storage of lyophilized 
powders on the mechanism and kinetics of thiol-disulfide exchange have not been 
elucidated and were investigated in the studies presented here. Reaction kinetics were 
monitored during different stages of lyophilization (freezing, primary drying and 
secondary drying) and during storage of the lyophilized powders at 22 oC and ambient RH. 
The concentrations of reactants and products were determined using RP-HPLC and product 
identity confirmed using LC-MS. Loss of native disulfide was observed for both linear and 
cyclic peptide during the primary drying step, however, the native disulfides were 
regenerated during secondary drying with no further change till the end of lyophilization. 
Deviations from Arrhenius parameters predicted from solution studies and the absence of 
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buffer effects during lyophilization suggest that factors such as temperature, initial peptide 
concentration, buffer type and concentration do not influence thiol-disulfide exchange 
during lyophilization. Results from a ‘cold finger’ method used to study peptide adsorption 
to ice indicate that there is no preferential peptide adsorption to the ice surface and the 
presence of an ice surface may not influence disulfide reactivity during primary drying. 
Overall, reaction rates and product distribution are different for the reaction of T20 with 
T20-T21 or cT20-T21 in the solid-state and aqueous solution while the mechanism of thiol-
disulfide remains unchanged. Increased reactivity of the cyclic peptide in the solid-state 
suggests that peptide cyclization does not offer protection against lyophilization and that 










Protein therapeutics continue to grow in commercial and therapeutic importance, 
providing new treatments for cancer, cardiovascular and autoimmune diseases. The 
biologics sector in the US grew by 18.2% between 2012-2013, with sales of $63.6 billion 
in 2012 [1]. Nevertheless, the development of therapeutic proteins can be compromised by 
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the inherent complexity and instability of these macromolecules [152, 153]. To improve 
stability and retain potency, protein pharmaceuticals are often lyophilized [154-156]. 
Lyophilization (freeze- drying) produces solid powders with high surface area and is used 
for storage of the protein following expression and for final marketed drug product [157]. 
Though lyophilization often reduces the rates of chemical and physical degradation, 
chemical and physical degradation can still occur during processing and subsequent storage 
in the solid state [132, 158, 159].  
Lyophilization cycles typically consist of freezing, primary drying and secondary 
drying steps [160]. The process can expose proteins to undesirable stresses such as cold 
denaturation, increased concentration of solutes and protein (“freeze concentration”), pH 
changes and dehydration, all of which can induce protein unfolding and/or structural 
perturbations [161, 162]. Costantino et al. observed secondary structure changes, a 
decrease in α-helicity and an increase in β-sheet and unordered structure, upon 
lyophilization of human growth hormone (hGH) [163]. Lyophilization induced structural 
changes have also been reported for recombinant human albumin (rHA) [95]. Such 
structural and/or conformational changes can further lead to aggregation during storage [14] 
and rehydration [164, 78]. Solid-phase aggregation of proteins can occur via different 
mechanisms in the presence of moisture; namely, thiol-disulfide exchange, disulfide 
scrambling, non-disulfide covalent aggregation and non-covalent aggregation [165].  
While there are reports of disulfide-mediated aggregation in the solid state for 
proteins that contain cysteines and/or disulfides [79, 166], the lack of a complete 
understanding of factors that influence reactivity reduces formulation to trial-and-error, 
informed by experience, in selecting composition and stabilizing excipients. Thus, an 
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improved mechanistic understanding of aggregation-inducing processes such as thiol-
disulfide exchange will be beneficial for the rational design of formulations that stabilize 
proteins during lyophilization and storage. 
Native disulfide bonds scramble via oxidative and hydrolytic pathways to form 
non-native bonds that can affect protein stability and activity. Two predominant pathways 
lead to disulfide-mediated covalent aggregation: (i) thiol-disulfide exchange (RSH + 
R1SSR2 ↔ R1SSR + R2SH) and (ii) disulfide scrambling (RSSR + R1SSR1 ↔ 2R1SSR) [2, 
3, 141]. In solution at neutral to alkaline pH, the thiolate anion (RS-) is the reactive species 
that initiates thiol-disulfide exchange. Nucleophilic attack of RS- on a native disulfide 
(R1SSR2) generates a non-native disulfide (R1SSR) and a new thiol (R2S-) in an SN2 
nucleophilic displacement reaction [45, 71]. Disulfide scrambling, a related reaction, is 
initiated by disulfide bond cleavage to generate a thiolate that then initiates thiol-disulfide 
or thiol-catalyzed exchange [165].  
Disulfide-mediated aggregation has been reported in lyophilized bovine serum 
albumin (BSA) [79] and β-galactosidase [166]. In rHA, lyophilization produced an 
increase in both β-sheet content and unordered structural elements resulting in partial 
protein unfolding, which further facilitated moisture-induced aggregation via thiol-
disulfide exchange upon storage [95]. Andya et al. observed disulfide linked dimers and 
trimers in recombinant humanized monoclonal antibody (rhuMAb) formulations following 
lyophilization and storage at 30 oC [167]. In the absence of excipients, reversible structural 
alterations during lyophilization promoted covalent aggregate formation upon storage. 
Degradation reactions can also occur in the solid state in the absence of process-induced 
structural changes. For example, in the absence of a stabilizing excipient, a rhuMAb (IgG) 
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aggregated in the solid state though native secondary structure was retained after spray 
drying [163]. Reports of disulfide-linked aggregates in lyophilized protein samples [79, 
166, 168] demonstrate the importance of designing processes and formulations that can 
inhibit disulfide bond degradation. 
Disulfide bonds can be cleaved under neutral to alkaline conditions via the attack 
of a hydroxyl ion. Alkaline hydrolysis of disulfide bonds can be classified into three 
pathways: i) direct attack-this results in the formation of sulfenic acid and a free thiol, ii) 
α-elimination- where the β proton of Cys is attacked to produce thiolate and thioaldehyde 
and iii) β-elimination- where the α proton of Cys is abstracted to produce dehydroalanine 
and persulfide.  
Human growth hormone (hGH) is a therapeutic protein used to treat growth 
hormone deficiency and other growth disorders. It has two disulfide bonds and no free 
thiols; with 191 amino acids the monomeric form has a molecular weight of 22 kDa. 
Structural perturbations in hGH have been reported in the solid state [101] and could 
further result in the formation of disulfide-linked aggregates during storage. A disulfide-
linked dimer of hGH (45 kDa) was found to have diminished receptor binding affinity and 
cell-proliferative activity [124]. Thus, given its relatively small size, therapeutic value and 
tendency to aggregate [135, 136], hGH was chosen as a suitable model to study thiol-
disulfide exchange kinetics in the solid state.  
The mechanistic information obtained from aqueous solution studies in Chapter 2 
provided a basis for understanding the effects of lyophilization process stresses and the 
solid environment on thiol-disulfide exchange. In this Chapter, studies pertaining to thiol-
disulfide exchange and disulfide scrambling in hGH-derived peptides during lyophilization 
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and subsequent room temperature storage of the lyophilized powders are reported. The 
hGH-derived peptides were lyophilized without excipients to determine process effects on 
disulfide exchange and scrambling kinetics. The results demonstrate that the rate of thiol-
disulfide exchange is accelerated during primary drying, and that peptide secondary 
structure does not influence reactivity during lyophilization. Factors such as temperature, 
initial peptide concentration, buffer type and concentration and peptide adsorption to ice 
did not influence thiol-disulfide exchange during primary drying. During storage in 
lyophilized solids, both the rates and the distribution of products differed for linear and 
cyclic disulfide-containing peptides when compared to those observed in aqueous solution. 
Peptide cyclization does not offer protection against thiol-disulfide exchange in the solid 
state, the observed rate constant (kobs) for the loss of cT20-T21 was 10-fold greater than 




Model peptides T20, T21, T20-T21, rT20-T21 and cT20-T21 (see Table 3.1 for 
structures) were purchased from GenScript (Piscataway, NJ) with >90% purity as a 
lyophilized powder. HPLC grade acetonitrile (ACN), NaCl and KCl were purchased from 
Fisher Scientific Co. (Pittsburgh, PA). K2HPO4, 5,5-dimethyl-1,3-cyclohexanedione 
(dimedone), ethylenediaminetetraacetic acid (EDTA) and sodium citrate tribasic dihydrate 
were purchased from Sigma Chemical Co. (St. Louis, MO). Trifluoroacetic acid (TFA) and 
formic acid (FA) were obtained from Thermo Scientific (Rockford, IL). Double-distilled 
water (DDI) used for buffer preparation and as HPLC mobile phase was deionized and 
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purified using a Milli-Q water system, (Millipore Ltd., Billerica, MA) and filtered with a 
0.2 µm filter. Glass vials (2 mL) and stoppers (13 mm gray butyl) for lyophilization were 
purchased from Wheaton (Millville, NJ). Methods 
 
3.4.1 Quantification of reactants and products by HPLC 
Samples were analyzed using reverse-phase high-performance liquid 
chromatography (RP-HPLC, Agilent 1200 series) with UV detection at 215 nm. Agilent 
Chemstation software was used for data acquisition and analysis. A ZORBAX Eclipse plus 
C18, 5 µm (4.6 X 250 mm) analytical column (Agilent Technologies, Santa Clara, CA) 
was used with gradient elution and the column temperature maintained at 25 oC. The 
gradient elution method and associated calibration plots were as described in our previous 
work [169]. Identification of reactants and products on LC-MS: Samples were analyzed 
using an ESI-LC/MS system (1200 series LC, 6520 qTOF; Agilent Technologies, Santa 
Clara, CA) with a ZORBAX 300SB-C18 column (1.0 X 50 mm, 3.5 µm) with gradient 
elution similar to that used in HPLC quantitation. Mobile phase A was 0.1% formic acid 
in water and mobile phase B was 0.1% formic acid in acetonitrile. A gradient run was 
initiated with 5% B, which was increased to 50% in 6.10 min, then held at 50% for 1 min 
followed by an increase to 100% in 0.6 min, decreased to 0% in 0.6 min, increased again 
to 100% in 0.6 min and finally returned to 5% in 0.6 min. The flow rate was maintained at 
50 µL/min and the column temperature was not controlled. Data were analyzed using 
MassHunter software. Reactants and products were identified using mass filters with 
peptide masses corresponding to the different reaction mechanisms for thiol-disulfide 
exchange and oxidation reactions.   
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3.4.2 Thiol-disulfide exchange reactions 
All peptides were used as provided by the manufacturer without further purification. 
Stock solutions were prepared in a 0.1% formic acid solution in DDI. Reaction kinetics 
were monitored during lyophilization and storage of lyophilized powders at 22 oC. For the 
reaction, 1500 µL of T20 (1125 µM), 1500 µL of T20-T21/cT20-T21 (112.5 µM) and 750 
µL of 50 mM phosphate buffer (PB) were added to a 15 mL BD falcon tube and mixed by 
pipetting. The final pH of the reaction mixture was adjusted using NaOH or HCl (exact 
volume to be added was determined from pilot studies) after a 100 µL aliquot was removed 
and quenched with 10 µL 20% formic acid in DDI (FA) to verify initial concentrations (t 
= 0 min before lyophilization). 200 µL aliquots of the reaction mixture were transferred 
into vials (on ice) and placed inside the freeze-dryer; shelves were pre-cooled to -40 oC. 
Frozen samples, collected during the freezing step, were thawed and quenched with 20 µL 
of 20% FA to prevent disulfide exchange prior to analysis. Lyophilization samples at the 
end of primary drying and during secondary drying were reconstituted with 200 µL of 0.1% 
FA; 150 µL of the reconstituted sample was quenched with 15 µL of 20% FA. For storage 
stability studies, reaction mixtures, solution and lyo samples were prepared as described 
above. At the end of the lyophilization cycle, vials were capped under a vacuum (not sealed) 
and stored at 22 oC. Samples were withdrawn in triplicate at each time point during 
lyophilization and storage. 30 µL and 10 µL of the quenched solution were then used for 
RP-HPLC and LC-MS analysis, respectively. Dilution factors from total reaction volume, 
addition of NaOH/HCl for pH adjustment and quench solution were accounted for in 
determining final peptide concentrations. No measurable changes in concentration were 
observed in quenched samples within the time scale of the experiment.  
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Buffer effect: T20 and T20-T21 were also lyophilized with 2.5 mM potassium 
phosphate and 10 mM sodium citrate buffer at pH 7.0 to investigate the effect of buffer 
type and concentration on thiol-disulfide exchange. Initial peptide concentrations and total 
reaction volume were as described above. For 2.5 mM PB, 750 µL of 10 mM buffer stock 
was used and for 10 mM sodium citrate, 750 µL of 50 mM buffer stock was used. Samples 
were withdrawn in triplicate, quenched and analyzed as described above.  
 
  92 
 
 
Table 3.1: Abbreviations and amino acid sequences of peptides detected in solid-state 
studies with hGH-derived peptides.  
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3.4.3 Lyophilization of peptide samples  
Solid samples were prepared by lyophilization in a programmable benchtop VirTris 
freeze-dryer (SP scientific, Gardiner, NY), using methods routine in our labs [129] (Table 
3.2). Briefly, the lyophilization cycle consisted of the following steps; freezing at -40 oC, 
then drying at -35 oC under vacuum (70 mTorr) for 2 h, -5 oC for 8 h, 5 oC for 8 h, 15 oC 
for 6 h (100 mTorr) and 25 oC for 10 h (100 mTorr). The same lyophilization cycle was 
used for all solid-state studies to eliminate processing conditions as a variable and was not 
optimized. The instrument was operated in manual mode to monitor disulfide exchange 
during lyophilization so that samples could be removed at the end of each step. Lyophilized 
samples at the end of the cycle appeared as dried powders and did not form elegant cakes 
due to the absence of any bulking agents. The glass transition temperature (Tg) of the 
lyophilized samples was measured using a DSC Q2000 (TA instruments, New Castle, DE) 
and moisture content was measured using TGA Q5000 (TA instruments, New Castle, DE) 
and SGA-100 (VTI Corporation, Hialeah, FL).   
 




Temperature (oC) -40 -35 -5 5 15 25
Duration (h) 2 2 8 8 6 10
Total time (h) 2 4 12 20 26 36
Vacuum (mTorr) N/A 70 70 70 100 100
       N/A, not applicable
      Step 1: Freezing, Step 2: primary drying and Steps 3-6: secondary drying 
6Step 1 2 3 4 5
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3.4.4 Peptide adsorption to ice 
The rates of thiol-disulfide exchange in hGH model peptides were affected by 
lyophilization. The role of adsorption to ice in these effects was assessed using a cold finger. 
A cold finger condenser (24/40 inner joints from Fisher Scientific) was connected with 
insulated tubing to a circulating water bath (Thermo Scientific) containing an ethylene 
glycol/water (1:1) mixture and the temperature set to -10 oC. This method was used 
previously by Kuiper et. al for purification of antifreeze proteins by adsorption to ice [170]. 
The cold finger was first placed in DDI seeded with ice crystals for 10 minutes to form an 
ice surface (Figure 3.1). Ice surface area and ice crystal morphology on the cold finger 
were not controlled using this method. The cold finger was then placed in a solution of 
peptides inside a Styrofoam box and the ice surface allowed to grow for 1 hour. A peptide 
solution was prepared by adding 32 mL of T20 (1250 µM), 32 mL of T20-T21 (125 µM) 
and 16 mL PB buffer (10 mM, pH 7.0, 0.08 M ionic strength, 0.5 mM EDTA and N2 
sparged). After adsorption for 1 hour, the cold finger was removed from the solution and 
placed inside an empty beaker (Figure 3.1). The coolant temperature was maintained at -
10 oC for another 6 hours. 100 µL of the solution remaining in the beaker (not frozen) and 
thawed ice surface on the cold finger were quenched with 10 µL of 20% FA and 30 µL of 
the quenched samples were injected onto the RP-HPLC column and analyzed for free thiols, 
native and scrambled disulfides using the method described above.  
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Figure 3.1: Picture of an ice surface formed on the cold finger after 10 mins (left). Picture 
of cold finger after adsorption of the peptide solution to the ice surface for one hour (right).  
 
3.4.5 Method for detecting reaction intermediates 
Sulfenic acid determination (reaction with dimedone): Dimedone was used as a 
trapping reagent to detect the presence of sulfenic acids, potential intermediates in 
oxidation-mediated thiol-disulfide exchange [52]. To detect sulfenic acids in lyophilized 
samples, dimedone was co-lyophilized with model peptides. To 10 mM PB (0.08 M ionic 
strength, 0.5 mM EDTA), 1.72 g of dimedone was added (total buffer volume = 200 mL) 
and the buffer sparged with N2. 1500 µL of T20-T21 (625 µM) was then added to 1500 µL 
of 0.1% formic acid in DDI and 750 µL of buffer with dimedone. The pH of the reaction 
mixture was adjusted to 8.0 using NaOH/HCl and the final concentration of dimedone 
before lyophilization was 12.5 mM (dimedone: T20-T21 = 50:1). 200 µL aliquots of the 
reaction mixture were transferred into glass vials and the samples were lyophilized using 
the cycle shown in Table 3.2. To compare with solution samples, 200 µL aliquots of the 
same reaction mixture were transferred to glass vials, capped and stored at 22 oC. At 
different time points during storage, samples were reconstituted with 200 µL 0.1% FA and 
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analyzed using RP-HPLC and LC-MS. Dehydroalanine detection: To detect 
dehydroalanine, an intermediate in the degradation of disulfide bonds via β-elimination [3], 
LC-MS spectra were scanned for a characteristic mass loss of 34 Da as reported previously 
[171].  
 
3.4.6 Data analysis 
For the reaction of T20 with linear T20-T21 in the solid state during storage, the 
data were consistent with a reaction scheme involving: (i) equilibrium ionization of T20 
and T21, (ii) irreversible thiol-disulfide exchange reaction of the ionized thiolate form of 
T20 (T20-S-) with T20-T21 and (iii) oxidation of the ionized thiolate forms of T20 and T21 
(Scheme 3.1). The scheme is similar to that reported earlier for the reaction in solution 
[169], but with an irreversible thiol-disulfide exchange reaction rather than a reversible one. 
The following equations were used to estimate microscopic rate constants: 
 
T20S- = T20 / {1 + (10-7)/ (10-pKa)}                   Eq.3.1 
 
T21S- = T21 / {1 + (10-7)/ (10-pKa)}                                             Eq.3.2 
 
d[T20-T21]/dt = -k1′ [T20S-][T20-T21] + k2′ [T20S-][T21S-]                                    Eq.3.3                 
 
d[T20-T20]/dt = k1′ [T20S-][T20-T21]                                                                       Eq.3.4                      
 
d[T20S-]/dt = -k1′ [T20S-][T20-T21] - k2′ [T20S-][T21S-]                                          Eq.3.5                         
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d[T21S-]/dt =  k1′ [T20S-][T20-T21] - k2′ [T20S-][T21S-]                                          Eq.3.6            
 
In the kinetic model, time is the independent variable, reactant and product 
concentrations are dependent variables, and the rate constants (k1′ and k2′) are treated as 
parameters to be determined by non-linear regression. The model returned a value of 8.3 
for thiol pKa when it was defined as a parameter to be determined by regression of pH 7.0 
data. Thus, the pKa values for the ionization of T20 and T21 (Ka20, Ka21) were fixed at 8.3, 
consistent with previous reports for cysteine [143, 144] and with our previous model for 
the solution-state reaction [169]. Rate constants k1′ and k2′ are second-order rate constants 
for thiol-disulfide exchange and thiol oxidation, respectively (Scheme 3.1). Kinetic data 
were fitted to the model (eqns. 4.1-4.6) using non-linear regression (SCIENTIST®, 
Micromath Research, St. Louis, MO). Pertinent models in SCIENTIST® were selected 
based on reported Model Selection Criterion (MSC) values; a greater MSC value represents 
a better model. MSC is independent of the scaling of data points and is similar to the Akaike 
Information Criterion (AIC), which is considered to be a better measure of model validity 
than R2 values for non-linear regression [145]. For the reaction of T20 with T20-T21 or 
cT20-T21 in lyophilized powders during storage at 22 oC, the data were fitted to an 
equation (Eq.3.7) for first-order irreversible reaction to determine the observed rate 
constant (kobs) 
 
A/A0 = exp (-kobs t)            Eq.3.7 
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Here, A = [T20-T21] or [cT20-T21], A0 is the initial concentration of the respective 




The mechanisms of thiol-disulfide exchange reactions between T20 and T20-T21 
or cT20-T21 have been elucidated in aqueous solution [169] and provide a basis for the 
quantitative analysis of thiol-disulfide exchange in the solid state. Here, thiol-disulfide 
exchange reactions were investigated in tryptic peptides derived from hGH during 
lyophilization and storage of lyophilized powders.  Native disulfides are T20-T21 and 
cT20-T21 and scrambled disulfides formed as products of thiol-disulfide exchange are 
T20-T20, T21-T21, SMDs and DMD (amino acid sequence of all peptides are shown in 
Table 3.1).  
 
3.5.1 Effect of lyophilization on thiol-disulfide exchange 
For the reaction of T20 with T20-T21 (thiol: disulfide = 1.4: 1(molar ratio)), 
primary drying resulted in a 33% loss of native disulfide (Figure 3.2a). The subsequent 
increase in T20-T21 levels during secondary drying (Figure 3.2a) can be attributed in part 
to the reversibility of the thiol-disulfide exchange reaction.  Despite this increase, a net 9% 
loss remained at the end of secondary drying (Figure 3.2a). At a greater initial thiol: 
disulfide ratio of 10:1 (molar ratio), a 24% decrease in T20-T21 was observed after primary 
drying (Figure 3.2b). During secondary drying, T20-T21 was regenerated from the 
monomers and scrambled disulfides, resulting in an overall decrease in native disulfide of 
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10% at the end of the lyophilization cycle (Figure 3.2b). Black dotted lines in Figures 3.2a 
and 3.2b are the predicted concentrations of T20-T21 based on solution-state model 
predictions, adjusted for the changing temperature profile during lyophilization using 
Arrhenius parameters (see below). The solution-state model provides reasonable 
predictions during freezing and primary drying, but does not describe concentrations 
during secondary drying. A mass balance from RP-HPLC and LC-MS data shows that 
products other than T20-T20 and T21 were not generated in detectable quantities and that 
≥ 96 % of the initial peptide mass was accounted for at all time points during lyophilization. 
The distribution of free thiols (T20 and T21), native disulfide (T20-T21) and scrambled 
disulfide (T20-T20) for the reaction of T20 with T20-T21 at 10:1 is shown in Figure 3.3.  
For the cyclic peptide, a 29% decrease in native disulfide was observed after 
primary drying (Figure 3.2b). Like the linear peptide, cT20-T21 was partially regenerated 
during secondary drying, resulting in a 17% decrease overall in native disulfide content at 
the end of lyophilization (Figure 3.2b). The distribution of free thiols (T20 and rT20-T21), 
native disulfide (cT20-T21) and scrambled disulfide (T20-T20) is shown in Figure 3.3. In 
addition to these species, small amounts of single mixed disulfides (SMD1, SMD2 ) and 
double mixed disulfide (DMD) (structures in Table 3.1) were also detected on LC-MS and 
RP-HPLC (data not shown), though these could not be analyzed quantitatively due to the 
lack of synthetic standards. Mass balance from RP-HPLC data obtained during freezing, 
primary and secondary drying accounts for ≥ 90% of the initial mass of cT20-T21 
(determined from concentrations of cT20-T21 and rT20-T21). The distribution of free 
thiols (T20 and rT20-T21), native disulfide (cT20-T21) and scrambled disulfide (T20-T20) 
for the reaction of T20 with cT20-T21 at 10:1 is shown in Figure 3.4. The factors that may 
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influence thiol-disulfide exchange during freeze-drying and the results of studies designed 




























Figure 3.2: Change in native disulfide content during lyophilization (n=3, +/- SD) at pH 
7.0 (10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged); I-freezing, II-
primary drying and III-secondary drying. Reaction of T20 with a) T20-T21 (thiol: disulfide 
= 1.4:1), b) T20-T21 (♦) and cT20-T21 (■) at thiol: disulfide = 10:1. Black dashed lines 
indicate the end of each stage during lyophilization and the black dotted lines represent 















































Figure 3.3: Change in concentrations of reactants and products during lyophilization (n=3, 
+/- SD) for the reaction of T20 with T20-T21 (thiol: disulfide = 10:1, pH 7.0, 10 mM PB, 
0.08 M ionic strength, 0.5 mM EDTA and N2 sparged); I-freezing, II-primary drying and 
III-secondary drying. Symbols represent actual data points: T20 (■), T21 (●), T20-T20 (□), 
T21-T21 (○) and T20-T21 (♦). Initial concentrations of reactants in solution (before 
lyophilization): [T20] = 450 µM; [T20-T21] = 45 µM. On the plot, t=0 (min) represents 
solution concentrations before lyophilization.  
 
 
Figure 3.4: Change in concentrations of reactants and products during lyophilization (n=3, 
+/- SD) for the reaction of T20 with cT20-T21 (thiol: disulfide = 10:1, pH 7.0, 10 mM PB, 
0.08 M ionic strength, 0.5 mM EDTA and N2 sparged); I-freezing, II-primary drying and 
III-secondary drying. Symbols represent actual data points: T20 (■), T20-T20 (□), cT20-
T21 (♦) and rT20-T21 (◊). Initial concentrations of reactants in solution (before 
lyophilization): [T20] = 450 µM; [T20-T21] = 45 µM. On the plot, t=0 (min) represents 
solution concentrations before lyophilization.  
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3.5.2 Disulfide bond stability during lyophilization 
Lyophilization of hGH derived peptides showed a difference in the distribution of 
scrambled disulfides when compared to solution studies.  Native disulfides (T20-T21 and 
cT20-T21) were regenerated during secondary drying. For the cyclic peptide, non-native 
disulfides (SMDs and DMD, Table 3.1) were detected in the solid state in addition to T20-
T20. While previous studies have shown that lyophilization alters thiol-disulfide product 
distribution [129], the factors contributing to these differences were not identified. Here, 
we investigated the effects of temperature, peptide concentration, buffer and peptide 
adsorption to ice on disulfide bond stability during lyophilization.   
Effect of temperature and concentration: Arrhenius parameters determined from 
thermal stress studies in aqueous solution (thiol: disulfide = 1.4:1) were used to predict 
reaction kinetics at reactant concentrations and temperatures used in lyophilization (black 
dotted line in Figures 3.2a and 3.2b). At a higher thiol: disulfide ratio (Figure 3.2b), 
Arrhenius predictions agree well with data obtained during freezing and primary drying. 
However, the solution-state model overestimates the extent of thiol-disulfide exchange 
during secondary drying and does not account for the increase in native disulfide during 
the transition from primary drying to secondary drying. Deviations from Arrhenius 
behavior suggest that factors other than temperature and initial peptide concentrations (e.g., 
phase change, peptide adsorption to ice, peptide structural changes, changes in reaction 
mechanism and/or freeze concentration) influence thiol-disulfide exchange during the 
freeze-drying process, since the model predictions are based on both the concentrations of 
the reactants and temperature.   
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Effect of buffer type and buffer concentration: T20 was lyophilized with T20-T21 
at pH 7.0 and 4-fold lower buffer concentration (2.5 mM PB, 0.04 M ionic strength, 0.5 
mM EDTA and N2 sparged). The rate of loss of T20-T21 was similar to that observed 
during lyophilization with 10 mM PB (Figure 3.5). Similarly, when T20 was co-lyophilized 
with T20-T21 in sodium citrate buffer (10 mM, 0.5 mM EDTA and N2 sparged), the native 
disulfide concentration decreased during primary drying and then increased during 
secondary drying (Figure 3.5). While there are some differences in T20-T21 concentration 
during primary drying, particularly at a low buffer concentration (2.5 mM PB), the T20-
T21 concentration is similar at the end of primary drying and after two hours of secondary 
drying (-5 oC, 70 mTorr) in all three buffers (Figure 3.5). These results suggest that buffer 
concentration and type (phosphate vs. citrate) do not contribute to the observed loss of 
native disulfide during primary drying.  
Lyophilization induced damage to disulfide bonds: To investigate the effect of 
peptide adsorption to an ice surface on thiol-disulfide exchange, a “cold finger” was used 
(see methods, Figure 3.1). The ice surface on the cold finger and the solution after 
adsorption were analyzed using RP-HPLC (data not shown). Peptide concentrations on the 
ice after adsorption for 1 hr were; [T20] = 326 µM and [cT20-T21] = 33 µM. The results 
showed that the ratio of T20 to cT20-T21 on the ice (10:1) after adsorption for 1 hr is 
similar to the molar ratio (10:1) in the initial reaction mixture before adsorption. Although 
cT20-T21 does not adsorb preferentially to the ice surface, thiol-disulfide exchange 
between T20 and cT20-T21 still occurs on ice (6 hr sample thawed and analyzed on the 
HPLC, data not shown).  




Figure 3.5: Effect of buffer type and buffer concentration on thiol-disulfide exchange 
during lyophilization; freezing (I), primary drying (II) and secondary drying (III). Plot 
shows change in T20-T21 concentration (n=3, +/- SD), co-lyophilized with T20. All 
buffers contain 0.5 mM EDTA and were sparged with N2, pH of reaction mixture was 
adjusted to 7.0 before lyophilization. Initial concentrations of reactants in solution (before 
lyophilization): [T20] = 450 µM; [T20-T21] = 45 µM. On the plot, t=0 (min) represents 
solution concentrations before lyophilization. 
 
Primary drying duration: The duration of the primary drying step (-35 oC, 70 
mTorr) was increased from 2 to 6 hours to determine the effect of drying time on thiol-
disulfide exchange (Figure 3.6). The concentration of native disulfide decreases in the 
initial 2 hours of primary drying. After this initial loss, the native disulfide is regenerated 
with continued drying for another 2 hours. Between 4 and 6 hours, there is no further 
change in T20-T21. While a longer primary drying step can preserve the native disulfide 
to some extent, lyophilization induced damage to the disulfide bond still occurs and may 
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Figure 3.6: Change in concentration of T20-T21 lyophilized with T20 ( thiol: disulfide = 
6:1, pH 7.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged) during 
freezing and primary drying (n=3) (♦). Primary drying time was increased from 2 to 6 hours. 
On the plot, t=0 (min) represents solution concentrations before lyophilization.  
 
3.5.3 Thiol-disulfide exchange in lyophilized powders during storage 
The thiol-disulfide exchange reaction between T20 and T20-T21 or cT20-T21 at 
pH 7.0 (pre-lyophilization) in lyophilized powders stored at 22 oC was monitored over 0-7 
and 0-12 days for T20-T21 and cT20-T21, respectively. Storage stability studies were 
truncated after 7 days for T20-T21, since oxidative pathways began to dominate (Figure 
3.7).  Tg measured for the lyophilized powder at the end of secondary drying was 20.6 oC, 
and the moisture content at the end of secondary drying and after storage for 14 days at 22 
oC was 1-1.5%.  
Reaction of T20 with T20-T21: The change in the concentration of T20-T21 during 
storage is shown in Figure 3.8. Rate constants for the exchange (k1′) and oxidation reaction 
(k2′) were estimated by fitting the data to the model of Scheme 3.1. Excellent model fits to 
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The rate constants for the reaction of T20 with T20-T21 in the solid state are shown in 
(Table 3.3). Mass balance from RP-HPLC data at the end of 7 days accounts for 95% of 
initial mass of peptides. The observed pseudo-first order rate constant (kobs) for the loss of 
T20-T21 during storage in aqueous solution is of the same order as kobs in the solid state, 
indicating that the reaction is not slowed appreciably in the lyophilized form.  
 
 
Figure 3.7: Concentration of scrambled and native disulfides formed via oxidative 
pathways during storage of lyophilized powders (n=3, +/- SD). Inset zooms in to show 
change in concentrations of T20-T21 and T21-T21. T20-T21 was co-lyophilized with T20 
(thiol: disulfide = 10:1, pH 7.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 
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Figure 3.8: Reaction of T20 with T20-T21 in lyophilized powders stored at 22 oC (n=3, 
+/- SD). Initial concentrations of reactants in solution (before lyophilization): [T20] = 450 
µM; [T20-T21] = 45 µM. Buffer conditions: pH 7.0 , 10 mM phosphate buffer, 0.08 M 
ionic strength, 0.5 mM EDTA and N2 sparged.  
 
Thiol ionization
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Thiol oxidation 
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Figure 3.9: Reaction of T20 with T20-T21 in lyophilized powders stored at 22 oC (n=3, 
+/- SD). Initial concentrations of reactants in solution (before lyophilization): [T20] = 450 
µM; [T20-T21] = 45 µM. Buffer conditions: pH 7.0 , 10 mM phosphate buffer, 0.08 M 
ionic strength, 0.5 mM EDTA and N2 sparged. Plot shows concentrations of T20 (■), T21 
(●), T20-T20 (□), T21-T21 (○) and T20-T21 (♦). Solid lines are non-linear regressions 
based on the model in Scheme 3.1. Initial time point (t = 0 days) corresponds to a sample 
reconstituted immediately after lyophilization. 
 
 
Table 3.3: Microscopic and observed rate constants for thiol-disulfide exchange between 
T20 and T20-T21 in lyophilized solids and aqueous solution.  
 
 
























Parameter  Aqueous solution (22 oC), pH 7.0 Lyophilized solids (22 oC), pH 7.0
k1' (T20-T21) n/a 0.45±0.04 M-1s-1
k2' (T20-T21) n/a 9.57±1.00 M-1s-1
kobs (T20-T21) 1.00*10-4±4.00*10-6 s-1 a 1.78*10-4±1.84*10-5 s-1
kobs (cT20-T21) 1.15*10-5±1.00*10-6 s-1 a 1.56*10-4±1.14*10-5 s-1
n/a -not applicable, different model was used to determine k1' and k2'
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Reaction of T20 with cT20-T21: During storage of the cyclic peptide cT20-T21 in 
lyophilized powders containing T20, the loss of the disulfide bond was faster in the solid 
state than in aqueous solutions stored at the same conditions (Figure 3.10). The 
concentration of cT20-T21 in solution increases over time due to oxidation as rT20-T21 is 
oxidized to cT20-T21, behavior similar to that observed for cT20-T21 in aqueous solution 
studies [169]. Mixed disulfides (SMDs and DMD; structures in Table 3.1) were detected 
on both RP-HPLC (Figure 3.11) and LC-MS (data not shown), consistent with the reaction 
mechanism in Scheme 3.3b. No other oxidation products such as sulfenic, sulfinic or 
sulfonic acid were detected. A mass balance from RP-HPLC data at the end of 12 days 
accounts for 80% of all peptides present in the storage samples. This suggests that the 
remaining 20% of the initial mass is present as SMDs or DMD, which are not quantitated 
but detected on LC-MS and RP-HPLC, or as other undetected species. Figure 3.12 shows 
a concentration vs. time plot for T20, rT20-T21, native (cT20-T21) and scrambled disulfide 
(T20-T20) obtained during storage of cyclic peptide. Unlike T20-T21, the concentration of 
cT20-T21 does not increase during storage after 7 days (Figure 3.10). This suggests that 
lyophilization induced stresses favor thiol-disulfide exchange between T20 and cT20-T21, 
as temperature and pH did not influence reactivity to as great an extent in solution [169]. 
Observed rate constants (kobs) for the loss of cT20-T21 during storage in lyophilized 
powders are shown in Table 3.3. At a pH 7.0, the kobs value for cT20-T21 in the solid state 
is ~10-fold greater than its kobs value in aqueous solution, and is comparable to kobs for T20-
T21 in lyophilized solids at pH 7.0. This suggests that structural constraints imposed by 
cyclization slow the thiol-disulfide exchange reaction in solution but not in lyophilized 
solids.    




Figure 3.10: Change in concentration of cT20-T21 lyophilized with T20 ( thiol: disulfide 
= 10:1, pH 7.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged) during 
storage (n=3, +/- SD) at 22 oC (■), and in solution (♦) (thiol: disulfide = 10:1, pH 7.0, 10 
mM PB, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged). Both solid and solution 
samples were stored at 22 oC in lyo vials, n = 3. Open symbols show the initial 
concentration of cT20-T21 in solution before lyophilization (□) and before storage as 
solution at 22 oC (◊). Initial data points (t = 0 days, filled symbols) represent solution 

























Figure 3.11: HPLC chromatograms (215 nm) obtained at various times during storage of 
lyophilized T20 and cT20-T21 at 22 oC (pH before lyophilization was 7.0). Solution sample 
before lyophilization (A), solid sample immediately after lyophilization (B) and solid 
sample after 3 days (C). Peak labels: 1) T20; 2) T20-T20; 3) DMD; 4) SMD 1&2; 5) cT20-
T21 and 6) rT20-T21.  




Figure 3.12: The concentration of reactants and products for a kinetic study with T20 and 
cT20-T21 during storage at 22 oC. Buffer conditions before lyophilization: pH 7.0, 10mM 
phosphate buffer with 0.5 mM EDTA and N2 sparging. Initial concentrations of peptides 
were: [T20] = 450 µM (Δ); [cT20-T21] = 45 µM (). The symbols represent actual data 
points obtained from samples at different times (n=3, +/- SD): T20 (■), cT20-T21 (♦), T20-
T20 (□) and rT20-T21 (◊). 
 
To determine disulfide bond stability without a free thiol in the solid state, T20-
T21/cT20-T21 was lyophilized without T20. When T20-T21 was lyophilized without T20 
at pH 7.0, only the two homodimers; T20-T20 and T21-T21 were detected as products of 
disulfide bond scission on RP-HPLC. While cT20-T21 lyophilized without T20 at pH 7.0 
was very stable even after a few weeks at 22 oC. To further elucidate the mechanism of 
disulfide bond degradation in the solid state, T20-T21/cT20-T21 was co-lyophilized with 
dimedone at pH 8.0 (see methods). Change in T20-T21 and cT20-T21 concentrations with 
time at pH 8.0 (pH in solution before lyophilization) are shown in Figures 3.13 and 3.14.  
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T20 sulfenic acid (T20-SOH) and dimedone adduct (m/z = 378.7059) was detected 
in solid samples stored at 22 oC for 2 weeks using LC-MS after reconstitution and in 
solution samples stored at the same conditions (Figure 3.15). In addition, T20-SO2H (T20 
sulfinic acid) was detected in solution samples; this is formed by further reaction of T20-
SOH with a hydroxyl ion [172, 173]. These products of alkaline hydrolysis are consistent 
with a direct attack of OH- on the disulfide bond in T20-T21 (Scheme 3.2). Damage to the 
disulfide bond in the cyclic peptide at pH 8.0 by alkaline hydrolysis was lower than that of 
the linear form. No dimedone adducts were detected on the LC-MS. However, small 
amounts of cysteine dehydroalanine (Scheme 3.2) were observed. This is consistent with 
disulfide bond degradation via β-elimination mechanism.  
 
             
Figure 3.13: Change in T20-T21 (pH 8.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM 
EDTA and N2 sparged) concentration during storage (n=3, +/- SD) without T20, as a 
lyophilized powder (♦) and in solution (■). T = 0 (day) on plot represents solution sample 
analyzed at the same time as samples reconstituted immediately after lyophilization. Initial 

























Figure 3.14: Change in cT20-T21 (pH 8.0, 10 mM PB, 0.08 M ionic strength, 0.5 mM 
EDTA and N2 sparged) concentration during storage (n=3, +/- SD) without T20, as a 
lyophilized powder (♦) and in solution (■). T = 0 (day) on plot represents solution sample 
analyzed at the same time as samples reconstituted immediately after lyophilization. Initial 




Figure 3.15: Mass spectrum (extracted ion chromatogram) showing the T20-S-dimedone 
adduct. Lyophilized T20-T21 (initial concentration = 250 µM, PB pH 8.0, 0.5 mM EDTA, 
0.08 M ionic strength and N2 sparged) was analyzed on the LC-MS upon reconstitution 
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The mechanism of thiol-disulfide exchange is well established in aqueous solution. 
In neutral to basic solution, the thiolate anion is the reactive nucleophile, attacking a 
disulfide bond via an SN2 mechanism [45, 71]. Thiol-disulfide exchange is known to occur 
in the solid state as well [14, 79, 95], though the reaction mechanisms have not been fully 
elucidated. In the studies reported here, hGH-derived model peptides were lyophilized 
without excipients to investigate the effect of lyophilization on thiol-disulfide exchange 
kinetics and mechanisms. The amino acid sequences of the model and their masses are 
shown in Table 3.1. In studies of the solution-state reaction of the linear peptide (T20-T21) 
with T20, the T20-T20 homodimer and T21 were detected as the initial products, as we 
  117 
 
 
have reported previously [169].  At longer time points, the T21-T21 homodimer was also 
observed. These products are consistent with two thiol-disulfide exchange reactions, in 
which: (i) T20-T21 initially reacts with T20 to produce the T20-T20 homodimer and T21, 
and (ii) T20-T21 reacts with T21 produced in the first reaction to produce the T21-T21 
homodimer and regenerate T20 (Scheme 3.3a). Solution-state reaction kinetics were not 
adequately described by a kinetic scheme based only on these two reactions, however, and 
oxidative pathways were included. This suggests that even in the presence of oxidation 
suppressants (EDTA and N2 sparging), T20 and T21 also undergo oxidation to form T20-
T20, T21-T21 and T20-T21 via a sulfenic acid intermediate. Kinetic models including both 
thiol-disulfide exchange and oxidation steps provided excellent fits to data, both in the 
presence and in the absence of oxidation suppressants [169].  
When the reaction of T20-T21 with T20 was monitored during lyophilization and 
storage in the solid state, T20-T20 and T21 were again detected as initial products, 
consistent with reaction 1 in Scheme 3.3a. Reaction 2 in scheme 3.3a was not observed in 
the solid state during storage (in the timeframe that the reaction was monitored) based on 
model fits to the data in SCIENTIST®. As in solution [169], kinetic profiles suggested that 
T20 and T21 were oxidized to T20-T20, T21-T21 and T20-T21 on extended storage in the 
solid state (> 7days at 22 oC; Figure 3.7). Oxidation products such as cysteine sulfenic, 
sulfinic and sulfonic acid and thiosulfinates were not detected for samples containing T20-
T21 co-lyophilized with T20. However, when T20-T21 was lyophilized without T20 (see 
methods), sulfenic acid and a dimedone adduct were detected (Figure 3.15). The presence 
of sulfenic acid as an intermediate suggests that disulfide linked peptides can undergo 
alkaline hydrolysis when a free thiol (T20) is not present, as reported previously [172, 174]. 
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Kinetic analysis further suggests that, during lyophilization, T20-T20 and T21 are 
generated (k1 > k-1) during primary drying and then partly consumed (k1 < k-1) during the 
first step of secondary drying (Table 3.2), after which there is no appreciable change in 
product distribution. During storage in the lyophilized solid, the product distribution is 
altered and kinetic analysis suggests that thiol-disulfide exchange is essentially irreversible. 
Possible physicochemical contributions to these kinetic effects are discussed below.   
In solution-state reactions of the cyclic peptide (cT20-T21) with T20, only T20-
T20 and rT20-T21 were detected as products [169]. Mixed disulfides (SMDs and DMD; 
Table 3.1) were not observed under any conditions in aqueous solution. After 6 hours, 
oxidation of rT20-T21 to cT20-T21 was the dominant pathway even under oxidation-
suppressed conditions.  In contrast, SMDs, DMD, rT20-T21 and T20-T20 were identified 
as products of the reaction of cT20-T21 with T20 in the solid state. Oxidation of rT20-T21 
to cT20-T21 was not the dominant reaction even after 12 days of storage in lyophilized 
solids at 22 0C, and the concentration of cT20-T21 did not increase with time (Figures 3.10 
and 3.12). As with the linear peptide, oxidation products such as cysteine sulfenic, sulfinic 
and sulfonic acid and thiosulfinates were not detected. While sulfenic acid and dimedone 
adducts were not detected for cT20-T21 lyophilized without T20, trace amounts of cysteine 
dehydroalanine were detected (data not shown), again suggestive of alkaline hydrolysis in 
the absence of a free thiol.   
In the reaction of the cyclic peptide cT20-T21 with T20 in the solid state, mixed 
disulfides (SMDs and DMD) were detected in addition to T20-T20 and rT20-T21 during 
lyophilization and storage (Figure 3.11, Scheme 3.3b). Mixed disulfides were not detected 
in solution studies [169], suggesting that rates of loss from this pool (k-3, k4) are rapid 
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relative to rates of formation (k3, k-4) so that these species do not accumulate in solution 
(Scheme 3.3b). The absence of the double mixed disulfide (DMD) in solution can be 
attributed to the decreased reactivity of cT20-T21 and hence lower concentrations of T20-
T20, which in solution did not accumulate to levels sufficient to drive the reaction towards 
DMD. In contrast, both SMDs and DMD were detected during the primary drying stage of 
lyophilization, and the native disulfide was regenerated during secondary drying (Table 
3.2).  
The observed mechanism of thiol-disulfide exchange between T20 and cT20-T21 
is similar to that reported previously for tocinoic acid (TA (ox)) and glutathione (GSH) 
during lyophilization, where both SMDs and the DMD were detected [129]. TA (ox) is a 
cyclic peptide with 6 amino acids and terminal Cys residues linked by a disulfide bond 
(Scheme 3.3b, Table 3.4). Though the mechanism remains unchanged here, the relative 
rates of some thiol-disulfide exchange reactions (scheme 3.3b) are different for cT20-T21 
and TA (ox). TA (ox) was consumed in an irreversible thiol-disulfide exchange reaction at 
the end of lyophilization [129], while for cT20-T21 most of the native disulfide was 
regenerated at the end of step 3 (Table 3.2). The results suggest that although the type of 
disulfide and thiol containing peptides may play a role in reaction kinetics during 
lyophilization, the overall mechanism for thiol-disulfide exchange in cyclic peptides can 
be represented by Scheme 3.3b.   
The loss of native disulfide for both T20-T21 and cT20-T21 during the freezing 
step may be initiated by freeze-concentration, leading to high local concentrations of the 
peptide reactants (T20 and T20-T21 or cT20-T21). The loss of disulfide bonds during 
freezing is consistent with previous studies of tumor growth factor-β1, in which increased 
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intra- and intermolecular disulfide bond exchange was observed during freezing and long-
term storage at -70 oC [175]. Here, deviations from solution Arrhenius parameters (Figure 
3.2) and the absence of a buffer effect (Figure 3.5) suggest that factors such as temperature, 
peptide concentration, buffer type and concentration have no effect on thiol-disulfide 
exchange observed during primary drying. Further, the absence of preferential peptide 
adsorption to ice using the ‘cold finger’ method suggests that the ice surface itself does not 
play a role in thiol-disulfide exchange. Instead, loss of the disulfide bond during primary 
drying may be due to a reduced activation barrier for thiol-disulfide exchange as the 
environment becomes less polar, as observed at the active site of ribonucleotide reductase 
[148].  
In the simple peptides studied here, most of the native disulfide in T20-T21 and 
cT20-T21 is regenerated during secondary drying (Figure 3.2). In larger proteins with 
multiple disulfide bonds, such reverse reactions may not regenerate the original disulfide 
bond, but may instead result in intramolecular disulfide scrambling and/or covalent 
aggregation, depending on the proximity of the groups involved. The role of thiol group 
proximity to a disulfide bond was investigated previously for small heat shock protein and 
glutathione [67]. The distance between thiols and disulfides, and their relative mobility, 
can be affected by freeze-drying induced unfolding, particularly for hGH, which is known 
to undergo structural perturbations during lyophilization [101]. The formation of 
intermolecular disulfide bonds can further lead to aggregation during storage and/or 
rehydration. Here, the reactivity of the native disulfide bonds in T20-T21 and cT20-T21 
appears to decrease as drying proceeds (Figure 3.2 and Steps 4, 5 and 6, Table 3.2), perhaps 
the result of reduced mobility of the reactive species in the solid state. 
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The results suggest that, at neutral to slightly alkaline pH, proteins with free thiols 
and disulfides can undergo thiol-disulfide exchange during lyophilization and storage in 
the solid state, which can further lead to the formation of disulfide-linked aggregates. 
Though peptide cyclization retards disulfide exchange in solution, in the solid state the 
observed disulfide bond degradation for cT20-T21 is greater than in solution and similar 
to that of the linear peptide, T20-T21. Thus, increased stability of a disulfide bond 
conferred by secondary structure in solution may not necessarily translate to increased 
stability in the solid state. Further, structural constraints may not influence disulfide 
degradation kinetics during lyophilization and storage in the solid state, especially when 
free thiols are present on the surface of proteins and are in close proximity to a disulfide 
bond. Thus, the use of lyophilization alone as a stabilizing strategy may not be sufficient 
to retard thiol-disulfide exchange and offer protection against chemical degradation during 
storage. Reasonable formulation strategies include restricting free thiol content before 
lyophilization, using suitable excipients to stabilize protein structure when free thiols are 
not present on the surface, excluding O2 from formulations (if products of oxidative 
pathways are detected) and formulating proteins at low pH followed by reconstitution at 
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R1S- + R2SSR3                                 R1SSR2 + R3S- (1)





linear peptide, aqueous solution + (fast) + (fast) + (fast) + (fast)
linear peptide, lyophilization + (slow) + (slow) nd nd
linear peptide, storage in the solid-state + (slow) nd nd nd
+ : reaction observed


























cyclic peptide, aqueous solution + (fast) + (fast) + (fast) + (fast) nd nd
cyclic peptide, lyophilization + (slow) + (slow) + (slow) + (slow) + (slow) + (slow)
cyclic peptide, storage in the solid-state + (slow) + (very slow) + (slow) + (very slow) + (slow) + (very slow)
+: reaction observed
nd- not detected, based on products observed
Reaction scheme
Rate constant (M-1s-1)
k3 k-3 k4 k-4 k5 k-5
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Table 3.4: Abbreviations and amino acid sequences of tocinoic acid, glutathione and their 

































































The studies reported here detail the effects of lyophilization and storage of 
lyophilized powders on the mechanisms and rates of thiol-disulfide exchange. Peptide 
secondary structure does not influence disulfide (T20-T21 or cT20-T21) reactivity in the 
solid state when co-lyophilized with a free thiol (T20). Further, lyophilization does not 
retard thiol-disulfide exchange during storage in the solid state. The results obtained 
provide an insight into the effect of process stresses on disulfide exchange and are valuable 
to the design of robust lyophilization processes for the development of stable peptide and 





CHAPTER 4. THIOL-DISULFIDE EXCHANGE IN HUMAN GROWTH 
HORMONE 




Protein therapeutics such as hormones and monoclonal antibodies contain thiols 
and/or disulfides that can participate in thiol-disulfide exchange reactions at neutral to 
alkaline pH. This can result in the formation of mixed/scrambled disulfides that affect 
protein therapeutic efficacy and elicit undesirable immunogenic responses upon 
administration.  Thiol-disulfide exchange reactions were monitored in recombinant human 
growth hormone (rhGH) and model tryptic peptides derived from hGH (cT20-T21 and 
T20-T21pep) to investigate higher-order structure effects on reaction kinetics. Different free 
thiol-containing peptides (varying length and amino acid sequence) were used to initiate 
thiol-disulfide exchange in intact hGH and in model peptides at pH 7.0 and 37 oC. Protein 
samples were digested with trypsin and analyzed for native disulfides, scrambled disulfides 
and free thiols on the LC-MS.  For peptide-level studies, concentration of disulfide-linked 
peptides were determined using RP-HPLC and product identity was confirmed on the LC-
MS. Loss of native disulfide in cT20-T21 and T20-T21pep within 60 min of reaction was 




effects. Of all the peptides tested, GSH was the most reactive, forming the highest 
percentage of mixed disulfides in intact hGH and in the model peptides. At longer time-
points (>240 min) during the reaction, native disulfides in both hGH and cT20-T21 were 
regenerated and the fastest rates of regeneration were observed for cysteine  and the 
dipeptide CR. Tripeptides, RCR and QCR, had lower reactivity towards native disulfides 









In the biopharmaceutical industry, formation of correct disulfide links in 
recombinant proteins is central to the development of safe and efficacious protein 
therapeutics. While perturbation of native disulfide bonds is advantageous for regulating 
the biological activity of enzymes such as thioredoxin reductase, disulfide bond disruption 
is undesirable in protein drugs; mismatched disulfides can result in misfolding, aggregation, 
loss of biological activity and stability [54]. To ensure drug quality and product 
homogeneity, particularly with an increase in the development of biosimilars globally, the 
presence of these scrambled disulfides and the extent of scrambling need to be determined 




thiol-disulfide exchange is expected to reduce attrition rates during drug development and 
decrease the time to market protein drug products.  
Formation of protein mixed disulfides (P-S-S-R) is not uncommon and occurs in 
all biological environments, typically by two mechanisms; a) thiol-disulfide exchange; P-
S-S-P + R-SH ↔ P-S-S-R + P-SH and b) via sulfenic acid formation; P-SOH + R-SH → 
P-S-S-R + H2O [61], where R-SH is any low-molecular weight thiol (reduced), P-S-S-P is 
the native disulfide bond in a protein, P-SH is the protein with a free thiol, P-SOH is protein 
sulfenic acid and P-S-S-R is the mixed disulfide. Thiol-disulfide exchange reactions are 
favored at neutral to alkaline pH and the reaction proceeds via an SN2 nucleophilic 
displacement. The oxidized form of low-molecular weight thiols (R-S-S-R) are used to 
form protein disulfide bonds via oxidation while the reduced forms (R-SH) are used to 
rearrange scrambled disulfide bonds in vivo. The leaving group typically has a lower pKa 
compared to the central sulfur atom that is attacked by a thiolate anion [61]. For example, 
small molecule catalysts that facilitate folding of proteins contain thiol groups with a low 
pKa [176], which enhances the leaving group ability of the corresponding thiolate anion 
(RS-) and increases the redox potential.  
Intrinsic factors other than thiol pKa are also known to affect thiol-disulfide 
exchange; these include ionic strength of the medium [63], geometric strain imposed on 
the disulfide bond by higher-order structure [66] and stability of the native disulfide bond 
relative to a non-native bond [65].  
Proteins can form mixed/scrambled disulfides with other thiols, that are either 
present as an impurity or in the protein as a free Cys [177,178]. The sulfur group that has 




exchange reactions in comparison to more buried residues, even if it exists as a free Cys 
[179]. These protein mixed disulfides can then initiate other thiol-disulfide exchange 
reactions resulting in the formation of disulfide-linked aggregates. Disulfide bond 
degradation in therapeutic proteins can also occur via β-elimination [3] and thiol-catalyzed 
exchange [78] during processing and storage or after administration in vivo in the presence 
of low-molecular weight thiols in serum [49]. In some proteins like monoclonal antibodies, 
incomplete disulfide bond formation also results in free Cys [123] that can then initiate 
disulfide-mediated degradation events.  
Rearrangement of native disulfide bonds to form mixed disulfides via thiol-
disulfide exchange has been reported in a number of therapeutic proteins [14, 72, 78].  
Disulfide-linked isomers of interleukin-2 (IL-2) were observed in the presence of a 
chaotrope under alkaline conditions. IL-2 has one free Cys and one disulfide bond in its 
native form, alkaline and denaturing conditions deprotonate the free thiol thus mediating 
thiol-disulfide exchange reactions that generate less active disulfide-linked isomers [90]. 
Thiol-disulfide exchange reactions have also been observed in monoclonal antibodies, the 
CH1 domain of IgG2 contains a free Cys that is involved in the formation of disulfide-
linked oligomers (intermolecular disulfides) upon agitation stress [178]. While thiol-
disulfide exchange is known to occur in proteins and peptides, the effects of protein higher-
order structure and peptide primary structure on reaction kinetics are not as well understood 
and are the focus of studies reported here.  
Human growth hormone is a therapeutic protein that is used for the treatment of a 




syndrome, chronic kidney insufficiency and hGH deficiencies. In 2012, hGH was one of 
the top 200 pharmaceutical products by retail sales in the US [180]. Amino acid sequences 
of the two native disulfide-containing tryptic peptides are shown in Table 4.1. There are no 
free Cys residues in hGH, however, a free thiol group maybe generated via β-elimination 
[3, 141] and can facilitate disulfide exchange and lead to loss of therapeutic efficacy. With 
access to cDNA for hGH expression in-house, relatively small size of the protein and 
results obtained previously for model tryptic peptides derived from hGH, hGH was the 
model protein of choice for investigating thiol-disulfide exchange.  
In our previous studies (Chapters 2 and 3), we investigated the mechanism and 
kinetics of thiol-disulfide exchange in tryptic peptides derived from human growth 
hormone in aqueous solution and in the solid state at a thiol: disulfide = 10: 1 (molar ratio) 
[69, 181]. Results showed that peptide secondary structure (peptide cyclized by a disulfide 
bond) offers protection against thiol-disulfide exchange in solution [69]. However, in the 
solid state, no protection was observed and reaction kinetics were similar for both linear 
and cyclic peptides while the mechanism remained unchanged [181]. Here, we report 
experimental data for the effect of higher order structure and peptide primary structure on 
thiol-disulfide exchange using model peptides and recombinant human growth hormone 
(rhGH). Thiol-disulfide exchange reactions were monitored at a thiol: disulfide molar ratio 
of 100: 1 at pH 7.0 and 37 oC. Results show that loss of native disulfide via thiol-disulfide 
exchange in cT20-T21 and T20-T21pep (peptides mimicking native C-terminal disulfide in 
hGH) is greater than loss of native disulfide in hGH in the presence of T20a, GSH, RCR, 
CR and C, indicating the role of higher-order structure. GSH was the most reactive of all 




and 57.7% loss of native disulfide in cT20-T21 and hGH respectively. Tripeptides, RCR 
and QCR had lower reactivites towards the native disulfide when compared to GSH but 
favored faster (>GSH) regeneration of native disulfides in hGH. In the presence of RCR, 
native disulfide was faster than with QCR. Loss of native disulfide was the lowest and 




HPLC grade acetonitrile (ACN), NaCl and KCl were purchased from Fisher 
Scientific Co. (Pittsburgh, PA). H2O2 and Na2CO3 (anhydrous granules) were obtained 
from Mallinckrodt Baker Inc. (Phillipsburg, NJ). K2HPO4, ethylenediaminetetraacetic acid 
(EDTA), Trizma® hydrochloride (Tris.HCl), urea, sucrose, glutathione (oxidized-GSSG), 
glutathione (reduced-GSH), L-Cysteine (Cys/C) and glycerol were purchased from Sigma 
Chemical Co. (St. Louis, MO). Trifluoroacetic acid (TFA) and formic acid (FA) were 
obtained from Thermo Scientific (Rockford, IL). Double-distilled water (DDI) used for 
buffer preparation and as HPLC mobile phase was deionized and purified using a Milli-Q 
water system, Millipore Ltd (Billerica, MA) and filtered with a 0.2 µm filter. Flash digest 
kit (trypsin) for protein digestion was obtained from Perfinity Biosciences (West Lafayette, 
IN).  Human growth hormone (1 mg/mL) was purchased as a lyophilized powder (0.34 mg 
phosphate buffer and 8 mg mannitol) from ProSpec-Tany TechnoGene Ltd., Ness Ziona, 







4.5.1 hGH expression and purification 
The plasmid containing the recombinant human growth hormone (r-hGH) 
expression gene was obtained from Dr. J. Laurence (Kansas University). This plasmid 
codes for hGH with an additional 28 amino acids at the N-terminus with a molecular weight 
of 25 kDa (Figure 4.1). The plasmid was transformed into the BL21 (DE3) E.coli cells for 
protein expression, using the protocol provided by New England BioLabs. Cells carrying 
the plasmid for hGH were grown in terrific broth media containing 100 µg/ mL ampicillin 
in an incubator shaker at 37° C. The cells were induced at OD600 = 0.8 with 1 mM IPTG. 
Post-induction was carried out in incubator shaker at 20° C for 16 hours. Expression of r-
hGH in the induced cells was checked with 12% SDS-PAGE and was found to be over-
expressed as inclusion bodies (Figure 4.2a). 
Purification of rhGH: rhGH was purified using the method as described previously 
[182]. Induced E.coli cells were harvested by centrifugation at 6500 rpm for 15 min. The 
cell pellet was resuspended in 50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA at pH 8.0 
and sonicated to lyse the cells. r-hGH inclusion bodies were separated from the soluble cell 
lysate by centrifugation at 13, 000 rpm for 30 mins. The pellet with cell debris was 
resuspended in buffer, 50 mM Tris-HCl, 5 mM EDTA, 1% deoxycholate (DOC) at pH 8.0, 
sonicated and centrifuged to further clarify the inclusion bodies. The pellet was washed 
with buffer, 50 mM Tris-HCl at pH 8.0 and centrifuged to remove any DOC from the 
previous step. Pure inclusion bodies were solubilized in buffer containing 100 mM Tris-




containing, 50 mM Tris-HCl, 2 M Urea, 0.5 mM EDTA, 3 mM GSH, 0.6 mM GSSG, 10% 
Glycerol and 2% sucrose at pH 8.0. Refolding of r-hGH was carried out by the step-wise 
dialysis of the protein solution against buffer 50 mM Tris-HCl, 0.5 mM EDTA, 10% 
Glycerol, 2% sucrose at pH 8.0 by descending the concentration of urea from 2-0 M at each 
step (1.5, 0.5 and 0 M). The refolded r-hGH was filtered and purified further using a HiPrep 
26/60 Sephacryl S-100 high resolution column (Amersham Biosciences) equilibrated with 
50 mM Tris-HCl, 2% sucrose at pH 8.0 and the fraction containing the monomeric r-hGH 
were checked with 12% SDS-PAGE for the purity (Figure 4.2b). Concentration of purified 
hGH was determined using a UV-Vis spectrophotometer (Agilent Technologies, Santa 
Clara, CA). MS analysis of the purified protein confirms the presence of two native 
disulfide bonds as found in the commercially available recombinant hGH (Figure 4.3 and 
Table 4.1). Near-UV CD analysis with a J-815 CD spectrometer (JASCO, Easton, MD) 
was used to assess protein tertiary structure. 
 
Figure 4.1: Amino acid sequence of hGH expressed and purified in our lab (MW = 25 
kDa). Sequence highlighted in blue shows the additional 28 amino acids at the N-terminus. 
Highlighted in yellow are the four Cys residues and the native disulfide bonds are 






















Figure 4.2: Expression and purification of rhGH: (A) Expression of r-hGH in uninduced (lane 
1) and induced (lane 2) culture was checked with 12% SDS-PAGE. (B) Purification of refolded 
r-hGH in HiPrep 26/60 Sephacryl S-100 high resolution column (Amersham Biosciences, 
Piscataway, NJ). Gel filtration chromatogram showing the resolved monomeric r-hGH. Inset, 




Figure 4.3: Total ion chromatogram for the tryptic digest of r-hGH. The two native disulfide 
bonds are in peptides T6-T16 and T20-T21 with retention times 26.1 and 12.17 min respectively. 





4.5.2 Thiol-disulfide exchange in model peptides 
RP-HPLC analysis: peptide samples were analyzed using an Agilent 1200 series 
HPLC system equipped with a UV-detector operated at 215 nm. Analytical column and 
gradient elution were the same as described previously [69]. Calibration plots were linear 
in the following concentration ranges; 5-500 µM (T20-T21pep), 20-200 µM (T20), 20-200 
µM  (T21), 5-500 µM (cT20-T21), and 5-500 µM (rT20-T21).  
Sample preparation: Peptides T20a (GIVQCR), T20 (IVQCR), CR, RCR, QCR, 
cT20-T21, T20-T21pep and rT20-T21 (Table 4.2) were obtained from GenScript 
(Piscataway, NJ) with >90% purity as lyophilized powders. Stock solutions were made in 
0.1% formic acid in DDI (pH ~ 2.5) to minimize oxidation of free thiols. Peptide T20a was 
synthesized to study thiol-disulfide exchange in intact hGH and draw comparisons to 
previous studies with model peptides, where T20 was used as the reactive thiol [69, 181]. 
Using T20 to initiate disulfide exchange in hGH would make differentiation of scrambled 
and native disulfides difficult, for example, T20-T21 could be the native disulfide, product 
of disulfide exchange with T20 or an intermolecular disulfide (between two protein 
molecules). T20a is similar in sequence to T20 with the addition of a Gly at the N-terminal, 
this difference allows easy identification of scrambled disulfides with T20a. To determine 
reactivity of T20a and to investigate buffer effect, reaction of T20a with T20-T21 peptide 
(thiol: disulfide = 10: 1) was monitored kinetically in 10 mM phosphate buffer (PB) and 
50 mM Tris.Hcl with 2% sucrose at 22 oC. Final pH of the reaction mixture was 7.0, 
samples were analyzed as described previously [69].  kobs (Pseudo-first order) for the loss 












Figure 4.4: Change in concentration of T20-T21 (♦) for the reaction with A) T20a (10 mM 
PB, pH 7.0, 0.08 M ionic strength, 0.5 mM EDTA and N2 sparged) and with B) T20a (50 
mM Tris.HCl and 2% sucrose, pH 7.0) at 22 oC (n=3, +/- SD). Initial concentration of 












































Investigating the effect of amino acid sequence and peptide length on thiol-
disulfide exchange: reaction kinetics were monitored at pH 7.0 and 37 oC in aqueous 
solution. For the reaction, 1500 µL of T20a/T20/GSH/RCR/QCR/CR/C (12500 µM), 1500 
µL of T20-T21pep/cT20-T21 (125 µM) and 750 µL of 50 mM phosphate buffer (0.08 M 
ionic strength and 0.5 mM EDTA) were added to a 15 mL BD falcon tube and mixed by 
pipetting. The final pH of the reaction mixture was adjusted to 7.0 using NaOH or HCl 
(exact volume to be added was determined from pilot studies) after a 100 µL aliquot was 
removed and quenched with 10 µL 20% formic acid in DDI (FA) to verify initial 
concentrations (t=0 min). Samples were withdrawn in triplicate at different time points, 
quenched with 20% FA, analyzed and quantitated using RP-HPLC as described in Chapters 
2 and 3.  
 
4.5.3 Enzymatic digestion using the Perfinity flash digest protocol 
hGH samples were added to the Perfinity flash digest kit tubes with digestion buffer 
(ratio of sample to buffer was 1:2.4). Digestion was performed at 60 oC and 1400 rpm using 
a ThermoMixer C (Eppendorf, Hauppauge, NY) for 15-17 mins. Digested samples were 
then transferred to microcentrifuge tubes and centrifuged at 14000 rpm for 2 mins. After 
centrifugation, the supernatant was removed, quenched with 10 µL of 20% FA in DDI and 
analyzed on the LC-MS (~20 µL).  
 
4.5.4 Removal of unreacted peptides using a desalting column 
To minimize scrambling during digestion, ZebaTM spin desalting columns with 7K 




peptides from the reaction mixture with hGH. The spin columns were first placed in an 
empty collection tube (1.5-2 mL) and centrifuged at 4700 rpm using an Eppendorf 
centrifuge (Eppendorf, Hauppauge, NY) equipped with a F45-11-12 rotor for 1 min to 
remove the storage buffer. Reacted samples (80-85 µL) were then added carefully to the 
center of the resin bed. After the sample had adsorbed onto the resin bed, the spin columns 
were then placed inside new collection tubes and centrifuged at 4700 rpm for 2 mins. 
Desalted sample was collected and digested using the Perfinity flash digest kit as described 
above and analyzed on the LC-MS.  
 
4.5.5 LC-MS analysis and disulfide bond identification using MassHunter software 
Mass analyses were carried out on an LC-MS system (1200 series LC, 6520 qTOF, 
Agilent Technologies, Santa Clara, CA). Peptides in the digested samples were separated 
prior to MS analysis using a Zorbax 300SB-C18 column from Agilent Technologies. 
Solvent A was 0.1% FA in water and solvent B was 0.1% FA in ACN. A gradient run was 
initiated with 5% B then held at 5% for 5 min and increased to 20% in 8 min, in the next 
step gradient was increased to 25% in 10 min and to 60% in 5 min. followed by an increase 
to 100% in 0.6 min, decreased to 0% in 0.6 min and finally returned to 5% in 2.4 min. The 
flow rate was maintained at 50 µL/min and the column temperature was not controlled. To 
determine native and scrambled disulfide species, a library of all peptides containing a 
disulfide bond and/or free Cys was generated. Briefly, amino acid sequence of hGH was 
entered into the software and after selecting the digestion enzyme and missed cleavages, 
an in silico digest was performed. We used trypsin as the enzyme and the number of missed 




process was then repeated by switching out native disulfides to scrambled disulfides and 
free thiols. From these lists, all peptides with disulfide bonds and/or free cysteines were 
selected and combined to create a mass filter list. Mass spectra of all digested hGH samples 
were then scanned against the mass filter list to determine the presence of scrambled 
disulfides and the extent of disulfide scrambling. Loss of native disulfide (T20-T21) was 
monitored at different reaction times using peak areas from extracted ion chromatograms 
(XIC); concentration was calculated using the calibration plot (Figure 4.5) constructed with 
a peptide standard from GenScript (Piscataway, NJ). Similar calibration plots were 
constructed for T20 and T21 using peptide standards.  
 
4.5.6 Thiol-disulfide exchange in hGH 
For the reaction of hGH with thiol-containing peptides (T20a, GSH  RCR or CR) 
and C, 280 µL of hGH purified in-house (0.56 mg/mL or 22.4 µM) in 50 mM Tris.HCl 
buffer and 2% sucrose (pH 8.0) was mixed with 70 µL T20a/GSH/RCR/CR/C (8950 µM 
in 0.1% FA in DDI). The pH of the final reaction mixture was 7.0 and the final molar ratio 
of peptide to protein was 100:1 (1790 µM: 17.9 µM). 90 µL aliquots of the reaction mixture 
were then transferred to microfuge tubes (n=3 for each time point) and placed in an 
incubator at 37 oC. Samples were withdrawn in triplicate at various times, desalted, 
digested and analyzed using LC/MS as described above. Control samples (hGH alone or 
model disulfide peptides alone) were diluted, desalted and digested as for the reaction 
samples at other time points.  To determine contributions from the additional 28 amino 
acids in the modified hGH expressed in-house, the reaction of Prospec hGH with GSH was 




Tris.HCl and 2% sucrose before reaction with GSH. Sample dilution and analysis were 
carried out as above.  
 
 
Figure 4.5: Calibration plot for T20-T21 (synthetic standard from GenScript); constructed 
using peak areas (n=3, +/- SD) from XIC at different peptide concentrations.  
 
     
  










































T6 Monomer, free thiol group NH2- YSFLQNPQTSLCFSESIPTPSNR-OH 2615.233 2615.2284
T16 Monomer, free thiol group NH2- NYGLLYCFR-OH 1147.549 1147.5412
T20 Monomer, free thiol group NH2- IVQCR-OH 617.3319 617.33









4.5.7 Near-UV CD measurement 
Near-UV CD spectroscopy was used to assess the effects of disulfide reduction on 
the tertiary structure of hGH. Samples with and without 5 mM β-mercaptoethanol were 
diluted to 2 μM final hGH concentration. Molar ellipticity was measured on a JASCO J-
815 spectrometer (JASCO Analytical Instruments, Easton, MD) in a 10 mm path length 










rT20-T21 Monomer, free thiol group NH2- IVQCRSVEGSCGF-OH
T20a Monomer, free thiol group NH2- GIVQCR-OH
T20 Monomer, free thiol group NH2- IVQCR-OH
GSH Monomer, free thiol group NH2- ECG-OH
RCR Monomer, free thiol group NH2- RCR-OH
QCR Monomer, free thiol group NH2- QCR-OH
CR
Monomer, free 





quartz cuvette. Spectra were acquired for wavelengths of 250 nm to 350 nm at a scanning 
speed of 50 nm/min. 
 
4.5.8 Amide hydrogen-deuterium exchange mass spectrometry (HDX-MS)  
HDX-MS was conducted to determine the solvent accessibility of hGH under native 
and reduced conditions. A 2 mg/mL solution of hGH was prepared in buffer containing 10 
mM sodium phosphate, 1.6 % mannitol, pH 7.0 (buffer A). To obtain reduced hGH, a 2 
mg/mL solution was prepared in buffer containing 10 mM sodium phosphate, 1.6 % 
mannitol, 10 mM DTT, pH 7.0 (buffer B) and incubated on ice for 1 h. HDX was initiated 
by mixing 3 μL of the sample with 27 μL of deuterated buffer A and buffer B for native 
and reduced hGH, respectively. Exchange was carried out at 23 ˚C for 10 s to 10 min. 
Reactions were quenched by adding 30 μL of ice cold buffer containing 0.2 M sodium 
phosphate, 0.5 M Tris(2-carboxyethyl)phosphine hydrochloride, 6 M guanidine 
hydrochloride to a final pH of 2.5. Deuterium uptake was measured using a the LC/MS 
system described above and equipped with a custom-built column refrigeration unit (0 ˚C) 
to minimize back exchange. Approximately 50 pmol of protein was injected onto to an 
immobilized pepsin column. The digests were desalted and trapped in a peptide microtrap 
(Michrom Bioresources, Auburn, CA) with 10% ACN, 90% water, and 0.1% for 4 min. 
Peptides were eluted onto a reverse phase analytical column (Zorbax 300SB-C18; Agilent 
Technologies, Santa Clara, CA) for 4.3 min using a gradient to 60% ACN, 40% water, and 
0.1% FA. Mass spectra were acquired in the m/z range 200-1700. Peptic digests of 
undeuterated hGH were analyzed and their mass identified using the MassHunter software 




deuterated samples using HDExaminer software (Sierra Analytics, Modesto, CA) to 
determine the level of deuterium uptake. The analysis times for all HDX samples were very 
similar, so that the observed deuterium uptake values were not subjected to back-exchange 
corrections. Data from 5 min HDX were mapped onto the crystal structure of hGH (PDB 
ID: 1 HGU) using PyMOL software (PyMOL Molecular Graphics System, Version 1.3, 




4.6.1 Thiol-disulfide exchange in hGH:  product identification 
Thiol-disulfide exchange in hGH was investigated using T20a, GSH, cysteine (C) 
and several small Cys-containing peptides such as CR and RCR (Table 4.2), to explore the 
effects of different thiol containing molecules on reaction kinetics. Control samples 
containing hGH alone incubated at 37 oC and analyzed after 60 mins and 1 day did not 
show scrambled species (data not shown), indicating that disulfide exchange does not occur 
under the conditions investigated here in the absence of a free thiol group. LC/MS analysis 
of intact protein samples during the reaction of hGH with T20a showed peaks 
corresponding to protein mixed disulfides with T20a (data not shown), confirming that 
thiol-disulfide exchange does not occur during digestion. The list of scrambled species 
observed for hGH in reaction with various thiol-containing peptides, the amino acid 
sequences of the scrambled products, their molecular weights and their chromatographic 




For the reaction of hGH with T20a (at thiol: disulfide = 100:1), four scrambled 
disulfides; T20a-T20, T20a-T21, T20a-T6 and T20a-T16 (Table 4.3) and free thiols; T6, 
T16, T20 and T21 (Table 4.1) were identified. No inter- or intra-molecular disulfides were 
detected at any time point during the reaction. GSH is commonly used in protein refolding 
and is also known to form mixed disulfides with proteins [61, 67]. In the reaction of hGH 
with GSH, the loss of both native disulfides (T20-T21, T6-T16) was observed within a few 
minutes resulting in the detection of mixed disulfides (Table 4.3) and free thiols (Table 
4.1). The data are consistent with a reaction mechanism identical to that proposed for T20a 
(Scheme 4.1), since no other degradation products were detected.  
Interestingly, for the reaction with CR, the mixed disulfide (T20-CR) and free thiols 
(T6, T16 and T21) were not detected in any of the samples. All the other mixed disulfides, 
T21-CR, T6-CR and T16-CR and T20 were detected (Table 4.4). Mixed disulfides (T6-
RCR, T16-RCR and T21-RCR) and free thiols (T20 and T6) were detected for the reaction 
of hGH with RCR (Table 4.5). With C as the thiol reagent, the loss of the native disulfide 
was slower than for T20a, GSH or CR. Only T21-C and T20 were detected (Table 4.5); 
mixed disulfides (T20-C, T6-C and T16-C) and free thiols (T6, T16 and T21) were not 
detected. The detection of scrambled disulfides at all four Cys residues in hGH suggests 
that both native disulfides are prone to attack by a reactive thiolate anion in aqueous 
solution at pH 7.0. It is interesting that in the presence of C, scrambling was detected only 
at the C-terminal disulfide bond. This may be due to rapid regeneration of the native 






Table 4.3: Amino acid sequence of mixed disulfide-linked peptides from hGH: for the 
reaction of hGH with T20a.  
 
 
Table 4.4: Amino acid sequence of mixed disulfide-linked peptides from hGH: for the 






Table 4.5: Amino acid sequence of mixed disulfide-linked peptides from hGH: for the 




4.6.2 Thiol-disulfide exchange in hGH: product quantitation 
Thiol-disulfide exchange in hGH was quantified for the C-terminal disulfide bond, 
which links the tryptic peptides T20 and T21. Quantitative analysis of disulfide scrambling 
in T6-T16 was not performed due to the lack of peptide standards (i.e., for T6-T16, T6 and 
T16) and the low aqueous solubility of T6.  At the C-terminal disulfide bond (T20-T21), 
the concentrations of T20-T21, T20 and T21 were determined using XIC peak areas and 




protein-thiol mixed disulfides were determined from mass balance: [Mixed disulfides] = 
[T20-T21]total – ([T20-T21]t + ([T20] + [T21])/2). Intra- and intermolecular disulfides and 
products of thiol oxidation such as sulfenic, sulfinic and sulfonic acid were not detected. 
Thus, it was assumed that disulfide bond cleavage of 1 mol of T20-T21 releases 1 mol of 
T20 and 1 mol of T21 that are present either in their free thiol form or in mixed disulfides. 
The percent loss of native disulfide at different times during the reaction was determined 
from [T20-T21] in the control sample (i.e., at t = 0) and [T20-T21] at time, t.  
The distributions of mixed disulfides, free thiols and the native disulfide (T20-T21) 
over time for the reaction of hGH with different thiols are shown in Figures 4.6 and 4.7. 
Loss of native disulfide (%) in the presence of free thiol-containing peptides and C is 
reported in Table 4.6.  After 60 min, T20-T21 showed the greatest loss with with GSH and 
the least with C. After 1 day, the native disulfide was regenerated to a greater extent with 
C followed by CR and RCR (Table 4.6). The presence of an Arg residue adjacent to Cys 
was found to favor regeneration of the native disulfide over GSH. A similar product profile 
was obtained for Prospec hGH (22kDa) for the reaction with GSH (Figure 4.8), suggesting 
that the leader sequence at the N-terminus in the hGH expressed in-house (25 kDa) does 














Figure 4.6: Concentrations of T20-T21 (♦), T20 (■), T21 (●) and T20a-T20+T20a-T21 or 
T20-S-S-G+T21-S-S-G (▲) for the reaction of hGH with T20a (A) and GSH (B) at pH 7.0 
(40 mM Tris.HCl and 1.6% sucrose) and 37 oC (n=3, +/- SD). Initial molar ratio of thiol: 
hGH was 100:1. Concentration of hGH alone before reaction with T20a is represented by 


























Figure 4.7: Concentrations of T20-T21 (), T20 (), T21 (●) and mixed disulfides (▲) 
for the reaction of hGH with (A) RCR, (B) CR and (C) C at pH 7.0 (40 mM Tris.HCl and 
1.6% sucrose) and 37 oC (n=3, +/- SD). Initial molar ratio of thiol: hGH was 100:1. Control 
sample represents hGH alone before reaction with CR. Lines on plot are to improve 


































































Figure 4.8: Concentrations of T20-T21 (), T20 (), T21 (●) and T20-S-S-G+T21-S-S-
G (▲) for the reaction of Prospec hGH with GSH at pH 7.0 (40 mM Tris.HCl and 1.6% 
sucrose) and 37 oC (n=3, +/- SD). Initial molar ratio of thiol: hGH was 100:1. T=0 min 
sample represents hGH alone before reaction with GSH. Lines on plot are to improve 
readability and do not represent regression analysis. 
 
4.6.3 Effect of higher order structure on thiol-disulfide exchange 
To investigate the effects of higher order structure on thiol-disulfide exchange and 
to show that close proximity of a free thiol group to a disulfide bond is a prerequisite for 
regeneration of native disulfide bonds, model disulfide-linked peptides were used. Thiol-
disulfide exchange was monitored in cT20-T21 and T20-T21pep at pH 7.0 and 37 oC. For 
cT20-T21, the concentrations of the single mixed disulfides (SMDs) and the double mixed 
disulfide (DMD) (Scheme 4.1) were determined from mass balance; [SMDs + DMD] = 
[cT20-T21]o –([cT20-T21]t + [rT20-T21]t)  as synthetic peptide standards for SMDs and 
























was used for quantitation. In the presence of GSH (Table 4.2), SMDs and DMD and rT20-
T21 were formed via thiol-disulfide exchange of the native bond in cT20-T21 (Scheme 4.1; 
Figure 4.9a). Though similar products (SMDs, DMD and rT20-T21) were observed for the 
reaction of cT20-T21 with all free thiols (Figure 4.10), the time courses of product 
distribution differed. As in hGH, the native disulfide was regenerated in cT20-T21 after 1 
day (Table 4.6).  
Thiol-disulfide exchange in T20-T21pep: Disulfide bond cleavage in T20-T21pep via 
thiol-disulfide exchange resulted in the formation of mixed disulfides with GSH (T20-S-
S-G & T21-S-S-G), free thiols (T20 & T21) and trace amounts of homodimers (T20-T20 
& T21-T21) (Figure 4.9b). At the end of 2 days, T20-T21pep was consumed completely, 
unlike thiol-disulfide exchange studies with cT20-T21 and hGH in which the native 
disulfides were regenerated. These results obtained with disulfide-linked peptides suggest 
that the higher order structure influences reactivity, making the native disulfides less 
accessible to attack by a thiolate anion in hGH (determined by % loss of native disulfide 
shown in Table 4.6) but does not inhibit the reaction completely. Thus, proximity of thiol 
groups to a disulfide bond (dictated by peptide/protein structure) determines the type of 
disulfide bond (intra vs. inter) that can be re-formed. The presence of an Arg residue 













Figure 4.9: Concentrations of species for the reaction of cT20-T21/T20-T21pep with GSH 
at pH 7.0 (10 mM phosphate buffer) and 37 oC (n=3, +/- SD), initial molar ratio of GSH: 
cT20-T21/T20-T21pep was 100:1. A) Concentrations of cT20-T21 (♦), rT20-T21 (■) and 
SMDs + DMD (▲). B) Concentrations of T20-T21pep (♦), T20 (■), T21 (●) and mixed 
disulfides (▲). T=0 min represents concentration of native disulfide (cT20-T21/T20-
T21pep) before initiation of reaction by adjusting the pH to 7.0.  Lines on plot are to improve 












































Figure 4.10: Distribution of cT20-T21 (♦), rT20-T21 (■) and SMDs+DMD (▲) for the 
reaction of cT20-21 with A) T20a, B) CR, C) RCR, D) QCR and E) C and F) T20 at pH 
7.0 and 37 oC in 10 mM PB (0.08 M ionic strength, 0.5 mM EDTA and N2 sparged). T=0 
min represents sample collected before reaction was initiated by adjusting pH to 7.0, thiol: 








Table 4.6: The change in native disulfide concentration in peptides and hGH obtained after 1 hour 
and 1 day for thiol-disulfide exchange reactions with different free thiols at pH 7.0 and 37 oC.  
 
 
4.6.4 Effect of hGH structure on regeneration of native disulfide 
To measure the extent of loss of hGH native structure upon disulfide bond cleavage 
breakage, and to correlate the regeneration of native disulfides following thiol-disulfide 
exchange, near-UV CD spectroscopy and amide HDX-MS were conducted for hGH in both 
oxidized and reduced states. Near-UV CD showed no appreciable differences in tertiary 
structure between the native and reduced forms (Figure 4.11).  
HDX-MS has been widely used to study protein structure and conformation at 
peptide level resolution [183]. Here, a total of 31 peptic peptides covering 100% of hGH 
sequence were identified and analyzed. Comparison of the level of deuterium uptake 
between the native and reduced state showed no appreciable differences (Figure 4.12), 
suggesting that hGH retains its native structure after disulfide bond cleavage. The C-
terminal peptide fragment, 182-191 containing the two cysteine residues (C182 and C189) 
are involved in disulfide formation is ~ 50% deuterated in both the native and reduced 
Disulfide Thiol pH Temp (oC)
% decrease of native 
disulfide after 60 mins
% decrease of native 
disulfide after 1 day
GIVQCR (T20a) 61.9±4.8 53.7±1.7





















states. Similarly, peptide fragment 47-53 containing C53 and fragment 160-172 containing 
C165 showed 53% and 38% deuterium uptake, respectively. Subtractive analysis of peptide 
fragments 160-172 and 166-175 shows that residues 160-165 are more than 60% deuterated. 
Overall, the near-UV CD and HDX-MS results suggest that the disulfide containing regions 
in hGH are highly solvent accessible and that the structure of fully reduced hGH is close 
to the native state. This suggests that the regeneration of native disulfide bonds following 
disulfide exchange may be favored by the orientations of the native Cys partners in close 
proximity to one another. 
 
 



























Figure 4.12: Crystal structure of hGH (PDB ID: 1 HGU) representing the percent 
deuterium uptake in native (A) and reduced (B) state following 5 min of HDX. Data from 









Scheme 4.1: Thiol-disulfide exchange at the C-terminal disulfide bond (T20-T21) in 
hGH/disulfide bond in cT20-T21; R-S- is the thiolate form of the free thiol-containing 
peptide (Table 4.2) and R-S-S-R is the oxidized form. The blue dashed lines represent a 

















Figure 4.13: Concentration vs time plot for the loss of cT20-T21 (n=3, +/- SD) during the 
reaction with GSH, CR, RCR, QCR and C at pH 7.0 and 37 oC in 10 mM PB (0.08 M ionic 
strength, 0.5 mM EDTA and N2 sparged). Initial thiol: disulfide was 100:1 (molar ratio). 












In the studies reported here, thiol-disulfide exchange reactions between intact 
hGH/cT20-T21/T20-T21pep and free thiol-containing peptides (Table 4.2) were 
investigated in aqueous solution at pH 7.0 and 37 oC. The amino acid sequences of native, 
scrambled and free thiol containing peptides and their masses are shown in Tables 4.1, 4.2, 
4.3, 4.4, 4.5 and C.2. From our previous studies with hGH-derived peptides [69, 181] and 
other reports [45, 71], it is well known that thiol-disulfide exchange is favored at neutral to 
alkaline conditions. Although thiol-disulfide exchange was observed at both the native 
disulfides in hGH (T20-T21 and T6-T16), quantitative analysis of disulfide scrambling was 
performed only for the C-terminal disulfide.  
After purification, hGH was digested using the Perfinity flash digest kit and 
analyzed using LC/MS for the presence of native, scrambled disulfides and free thiols. 
Perfinity digestion was compared with overnight digestion with trypsin in solution and 
with digestion with trypsin immobilized on magnetic and agarose beads to determine 
digestion efficiency (Table C.1, Appendix C). For all digestion protocols except the flash 
digest kit, scrambled disulfides were detected and digestion was incomplete after 60 min 
(Table C.1). In contrast, digestion with the flash digest kit was complete in 17 min and no 
scrambled disulfides were detected.  
For the reaction of hGH with different thiol-containing peptides, products generally 
conforming to Scheme 4.1 were detected (except intermolecular disulfides), and the 
distribution of these species varied with reaction time. Mixed disulfides were detected at 




disulfides (Table 4.1) were also observed. The reactivity of the C-terminal native disulfide 
(T20-T21) in hGH decreased in the order GSH>T20a>RCR>CR≈C and regeneration of 
native disulfides was favored over the formation of mixed disulfides in the order 
C≈CR>RCR>GSH>T20a (Table 4.6). Though most of the native disulfides were 
regenerated in the presence of GSH (75-80%), RCR (85-90%), CR (92-95%) and C (94-
99%), the presence of even low levels of mixed disulfides may be detrimental to the 
therapeutic efficacy and stability of hGH, given the functional roles of the two native 
disulfide bonds. The C-terminal disulfide bond (T20-T21) is required for binding to the 
growth hormone receptor and to maintain normal stability, while the disulfide bond in T6-
T16 is necessary for biological activity [91].  
The concentration of hGH can also influence thiol-disulfide exchange and/or 
disulfide scrambling, though these effects were not investigated here.  For example, in 
studies of porcine somatotropin (porcine hGH), disulfide exchange led to the formation of 
irreversible thixotropic gels (disulfide-linked aggregates) at concentrations > 25 mg/mL 
during storage at 39 oC for 14 days [184]. Initial concentrations used in our studies range 
from 0.3 to 0.45 mg/mL, concentrations  ~ 100-fold lower than those used by Buckwalter 
et al. High hGH concentrations within the secretory granules (50-100 mg/mL) also favor 
intermolecular exchange and result in the formation of disulfide-linked dimers and 
oligomers [137, 185]. Due to the low yield of hGH purified in-house (<0.6 mg/mL) and 
the cost of commercially available hGH, studies at higher concentrations were not practical 
here, and the absence of any intermolecular disulfides (Table C.2 in Appendix C) may 





SMDs, DMD and rT20-T21 were identified as products of the reaction of cT20-
T21 with all the free thiol-containing peptides (Table 4.2). Oxidation products such as 
cysteine sulfenic, sulfinic and sulfonic acid and thiosulfinates were not detected, and 
Scheme 4.1 effectively describes the products observed. Overall, the loss of native disulfide 
in cT20-T21 after 60 min decreases in the order GSH>T20>CR>T20a>QCR>C>RCR and 
regeneration of native disulfide is favored after 1 day in the order 
CR>C>RCR>QCR>T20a>T20>GSH. The amino acid length of all peptides used here 
ranges from 1-5. The results suggest that thiol size in this range has no effect on reactivity. 
In contrast primary sequence, particularly the presence of Arg adjacent to a Cys, promotes 
the reformation of the native disulfide. The loss of native disulfide (% loss in 60 min) in 
cT20-T21 is greater than the loss of native disulfide (T20-T21) in hGH with GSH, T20a, 
RCR, CR and C (Table 4.6).  
Native disulfides in hGH were re-formed in the presence of GSH, RCR, CR, C and 
to a lesser extent with T20a. Rabenstein et al. made a similar observation with somatostatin 
and GSH. At concentrations of GSH less than 4 mM, Rabenstein et al observed that the 
rate of thiol-disulfide exchange to re-form the native disulfide was faster than the rate of 
thiol-disulfide exchange to form the fully reduced form [119]. The authors also concluded 
that the conformational properties of the mixed disulfides may place the mixed disulfide in 
close proximity to the thiol group that then regenerates the native disulfide. Similar results 
have been reported for the reaction of small heat shock protein 25 (Hsp25) with GSH, 
where the formation of an intersubunit protein disulfide (native disulfide) is preferred over 
the mixed disulfides [67]. Here, near-UV CD and HDX-MS of both reduced (with BME) 




structure, thus favoring regeneration of native disulfides. Youngman et al. have shown that 
folding of hGH is similar in the presence and absence of disulfide bonds [151], further 
suggesting that disulfide bond reduction does not affect protein structure.  
Regeneration of native disulfides was fastest in the presence of RCR, CR and C. 
For the reaction of hGH with C, formation of mixed disulfides was minimal and most of 
the native disulfide remained intact (no thiol-disulfide exchange at T6-T16) after 60 mins 
and 1 day. Previously, Raman et al. have shown that the Cysteine/Cystine redox system is 
more efficient in the oxidative folding of high concentrations (0.05 mg/mL) of lysozyme 
when compared to GSH/GSSG [186]. Though only Cysteine was added to the studies here, 
oxidation of Cys over time can result in the formation of Cystine thus providing a 
Cystine/Cystine redox system. This observation with lysozyme and our results suggest that 
Cys favors the formation of native disulfides over mixed disulfides such that the rate of 
formation of mixed disulfides << the rate of regeneration of native disulfides, attributing 
to the detection of only one of the mixed disulfides (T21-C). Also, the thiol group in Cys 
itself has a low pKa (8.3) that would make it a better leaving group.  
With RCR and CR, the presence of a positively charged group adjacent to the Cys 
would be expected to increase reactivity of the thiol group by lowering thiol pKa. A thiol 
group with low pKa makes a better leaving group [61] as the charge stabilizes the thiolate 
form over the mixed disulfide [62] thus favoring reformation of native disulfides in both 
cT20-21 and hGH. The presence of an Arg adjacent to Cys182 in growth hormone is highly 
conserved among different species; the positively charged residue lowers pKa of the thiol 
group making it the most reactive of the four Cys residues [137].  Having two Arg residues 




reactivities of CR and RCR were observed for cT20-T21 (Figure 4.13). However, with 
QCR, the regeneration is not as fast as it is with RCR and CR (Figure 4.13). In agreement 
with the results obtained here, Okumura et al. observed that with a glutathione derivative, 
RCG (oxidized and reduced), prouroguanylin folded into its native conformation more 
efficiently than with GSH [187]. The increase in folding efficiency was attributed to the 
presence of a positive charge (from Arg) adjacent to the Cys residue. T20a is similar in 
sequence to the tryptic fragment, T20, in hGH and this could explain why the native 
disulfide in cT20-T21 and hGH (Table 4.6) is not regenerated faster than with GSH as 
observed for other peptides with a neighboring Arg.  
The unified software package DiANNA was used to determine the Cys state in all 
the free thiol-containing peptides to gain a better understanding of the observed differences 
in reactivities. The algorithm predicts the susceptibility of Cys residues to either participate 
in a disulfide bond or to be in the reduced state with 76-81 % accuracy [188]. Scores 
obtained for the different peptides used to initiate thiol-disulfide exchange are shown in 
Table 4.7. A higher score corresponds to an increased susceptibility to be in that state. The 
lowest scores for half Cys were obtained for C and CR, suggesting that in the presence of 
these thiols, regeneration of the native disulfide will be favored over mixed disulfides, in 
accordance with the results obtained here (Figure 4.13). However, similar half Cys scores 
were obtained for RCR, QCR and GSH and no correlations could be made to the results 
reported here. rT20-T21, reduced form of cT20-T21 had the highest half Cys score, 
suggesting that the disulfide bond in cT20-T21 would be favored over its reduced form or 
a mixed disulfide with another free thiol-containing peptide. The differences in peptide 




addition to the influence of primary structure on thiol pKa, higher order structure also plays 
a role and can determine the type of disulfide bond that can be regenerated.  
 





The studies reported in this chapter using intact hGH, disulfide-linked and free 
thiol-containing peptides as model compounds, demonstrate that higher-order structure, 
proximity of thiols to a disulfide and primary structure influence thiol-disulfide exchange. 
Higher-order structure was found to protect the native disulfides to some extent, however, 
thiol-disulfide exchange still occurs at both the native disulfides in intact hGH. Loss of the 
native disulfides in hGH did not result in structural changes as observed using CD and 
HDX. Regeneration of the native disulfide was favored in the presence of peptides that 
contain an Arg residue adjacent to the reactive Cys for both hGH and a cyclic peptide 













(cT20-T21). These results provide an improved understanding of thiol-disulfide exchange 
reactions in hGH and are valuable to the development of protein drugs that contain 




CHAPTER 5. CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
In order to improve stability of therapeutic proteins during the manufacturing 
process and storage, it is important to understand the mechanisms of degradation pathways 
both in aqueous solution and in the solid state. These deleterious degradation reactions can 
significantly affect the therapeutic value of proteins. The studies reported in this 
dissertation have elucidated the mechanism of one such pathway, thiol-disulfide exchange, 
in human growth hormone. Model tryptic peptides derived from hGH were used to 
investigate reaction mechanisms and kinetics in Chapters 2 and 3, providing mechanistic 
details on the reaction in the absence of higher order structure and other degradation 
pathways. Chapter 4 provided insight into the effects of higher-order structure on thiol-
disulfide exchange using intact hGH as a model protein. 
 
5.1 Thiol-disulfide exchange in aqueous solution (Chapter 2) 
 
The results presented in chapter 2 demonstrated that in aqueous solution, 
microscopic rate constants for thiol-disulfide exchange are pH independent while the 
observed rate constants for the loss of native disulfide are pH dependent. Further, thiol-
disulfide exchange follows Arrhenius behavior and the calculated activation parameters 
are similar to previous reports in the literature for low-molecular weight thiols and proteins 




(R3 and R4, Scheme 2.1) were similar suggesting that they are all essentially the same 
reaction. The negative entropy of activation values that were obtained (Table 2.3) for thiol-
disulfide exchange reactions (R3 and R4, Scheme 2.1) are representative of SN2 
nucleophilic displacement reactions. Though the presence of oxidation suppressants 
(EDTA and N2 sparging) did not completely inhibit oxidation reactions (R5 and R6, 
Scheme 2.1), the oxidation reactions did not affect the intrinsic rates of thiol-disulfide 
exchange. Finally, peptide secondary structure was shown to influence reactivity of the 
disulfide bond; loss of native disulfide in the linear peptide was ~10-fold greater than in 
the cyclic peptide.  
 
5.2 Thiol-disulfide exchange during lyophilization and storage in the solid state 
(Chapter 3) 
 
These studies explored the effects of a process stress (lyophilization) and 
subsequent storage in the solid state on thiol-disulfide exchange in hGH-derived peptides. 
The results from Chapter 3 demonstrate that the mechanism of thiol-disulfide exchange is 
similar in aqueous solution and in the solid state. However, differences in reaction rates 
and distribution of products were observed. Further, peptide cyclization offered little or no 
protection from thiol-disulfide exchange during lyophilization and storage. Increased 
reactivity of the cyclic peptide in the solid state shows that lyophilization may not always 
be a suitable approach to improve the stability of peptide and protein formulations. This 
information is valuable to the pharmaceutical industry, especially when protein 




more stable during storage in the solid state. The ‘cold finger’ was used to study adsorption 
of peptides and proteins to ice surfaces and evaluate the role of surfactants in protein 
formulations where ice-induced degradation is suspected. A general reaction scheme for 
the reaction of linear or cyclic peptides that contain disulfide bonds with a free thiol 
(Scheme 3.3, Chapter 3) was also proposed. This reaction scheme can be used as a guide 
to identify scrambled species when the reactive thiol group and disulfide-containing moiety 
(linear or cyclic) are known. The relative rates of these reactions may vary between solution 
and the solid state and will be influenced by the type of thiol/disulfide, pH and temperature.  
 
5.3 Thiol-disulfide exchange in human growth hormone (Chapter 4) 
 
The results presented in Chapter 4 show that thiol-disulfide exchange also occurs 
in intact hGH in the presence of reactive thiolate anions. By using the Perfinity flash digest 
protocol, scrambled disulfides were not produced during digestion, allowing analysis of 
hGH samples. However, scrambling may occur during digestion for proteins that have a 
free Cys in their native form (not tested here) and suitable alkylating agents need to be 
evaluated for their ability to minimize disulfide exchange in parallel with their effect on 
digestion efficiency and digestion times.  
For the protein concentrations tested here, no intermolecular or intramolecular 
disulfides were detected. Protein mixed-disulfides were detected with GSH, free thiol-
containing peptides and cysteine. However, most of the native disulfide was regenerated at 
the end of one day. A similar trend was observed with the cyclic peptide, suggesting that 




disulfide.  Overall, loss of native disulfide in cT20-T21 and T20-T21pep was greater than 
loss of native disulfide in hGH. Further, the presence of an Arg residue neighboring the 
reactive Cys was found to favor regeneration of the native disulfide over GSH. Together, 
the results suggest that protein higher order structure and peptide secondary structure 
influence thiol-disulfide exchange. 
  
5.4 Recommendations for future work 
 
The stabilizing effects of excipients on thiol-disulfide exchange are not well known; 
this is an area for future investigation.  A previous report of thiol-disulfide exchange 
examined the effect of sucrose on the reaction during lyophilization [129]. Though some 
protection was observed during the freezing and primary drying steps, loss of native 
disulfide during secondary drying in the presence of sucrose was similar to vials 
lyophilized without sucrose [129]. It would also be interesting to study thiol-disulfide 
exchange in intact hGH in the solid state both in the presence and absence of excipients, 
since hGH is known to undergo structural changes upon lyophilization. Though an 
excipient may have a stabilizing effect on thiol/disulfide mediated degradation, it may 
facilitate degradation via a different mechanism. Thus, the compatibilities of excipients 
with different proteins and potential degradation pathways (both physical and chemical) 
have to be carefully assessed in aqueous solution and in solid-state formulations.  
The effects of glass transition temperature (Tg) and moisture content on thiol-
disulfide exchange were not investigated here. Incorporation of some excipients in 




negative effect (e.g., low Tg, change in pH and/or loss of structure). The moisture content 
of lyophilized peptide samples in Chapter 2 was 1-1.5% immediately after lyophilization 
and after storage for 14 days.  Even with such low moisture content, the cyclic peptide 
degraded more rapidly in the solid state than in solution samples. It is possible that as the 
moisture content increases, sample dilution with water molecules protects the native 
disulfide bond from thiol-disulfide exchange as reported previously for recombinant 
human albumin [95]. Thus, studies relating the kinetics of thiol-disulfide exchange and the 
kinetics of water sorption are needed, in order to identify the particular moisture content 
that can lead to protein instability.  
The results obtained in Chapter 4 with intact hGH showed that no structural changes 
were observed upon disulfide bond cleavage thus favoring regeneration of the native 
disulfide over inter-/intramolecular scrambled disulfides. Even though lyophilization is 
known to induce structural changes in hGH [101], denaturants (e.g., GdnHCl, urea), 
mechanical force and agitation may have different effects on higher-order structure that 
can result in an altered distribution of scrambled disulfides in the presence of reactive thiols. 
It would be interesting to monitor thiol-disulfide exchange in hGH with different 
denaturing agents/stresses and to identify conditions in which disulfide degradation is 
favored.   
The results reported in this dissertation can also be extended to understand the 
effects of primary structure and length of the attacking thiol groups on thiol-disulfide 
exchange. Though steric effects related to the size of the reactive nucleophile are known to 
influence reaction kinetics to a greater extent than the size of disulfide-containing moiety 




been for deamidation in peptides and proteins [189, 190]. For example, the effects of amino 
acids flanking the Cys residue are not well understood except for the presence of an 
arginine, which was shown to favor regeneration of the native disulfides, as reported here 
and by Okumura et al [187]. Other positively charged amino acids such as His and Lys 
may have similar effects and are yet to be investigated. Another area for future work is to 
use the information presented here to study therapeutic proteins with similar and distinct 
higher order structures, e.g., using model peptides from a protein that is rich in β-sheets 
instead of α-helices.   
Finally, since serum is known to contain low molecular weight thiols such as Cys 
and GSH [72], the mechanistic details of thiol-disulfide exchange reported here can be 
extended to understand the reaction in therapeutic proteins in vivo after administration. 
Jiang et al. have used a continuous flow dialysis system to evaluate protein disulfide 
conversion [191]; a similar system can be used for other therapeutic proteins to evaluate 
the potential for loss of native protein disulfides. This can provide an insight into the 
formation of modified forms of the protein drug that may have altered properties. It is 
already known that monoclonal antibodies of the IgG4 class undergo Fab-arm exchange, a 
disulfide rearrangement phenomena, in serum and these modified molecules have been 
shown to have therapeutic effects that differ from those of the native protein. 
 
5.5 Implications for protein formulation 
 
The results obtained in Chapter 3 with both the linear and cyclic peptides suggest 




approach to inhibiting thiol-disulfide exchange and β-elimination is to formulate proteins 
and peptides that contain thiols and disulfides at low pH prior to lyophilization, followed 
by reconstitution in near neutral buffer before administration. Low pH prior to 
lyophilization has been shown to arrest β-elimination in insulin during storage in the solid 
state [79]. This approach may work well for some proteins when compared to others 
depending on inherent protein stability at low pH. Thermal stability of proteins varies with 
pH [192] and may further facilitate disulfide-mediated degradation events during and after 
lyophilization. Overall, the effect of pH on the conformational stability of a protein and 
excipients must be well understood before this approach can be employed.  
Another stabilization strategy is to use excipients in peptide and protein 
formulations before lyophilization. In the absence of excipients, proteins can undergo 
structural changes during processing that may favor thiol and/or disulfide-mediated 
degradation. For example, upon structural changes, a buried Cys residue may be exposed 
to oxidative agents or be brought in close proximity to a native disulfide bond resulting in 
the formation of intermolecular bonds, high molecular weight aggregated and/or non-
native intramolecular disulfides. Increasing the buffer concentration is another strategy that 
can be used to control thiol-disulfide exchange. The buffer concentrations tested in the 
studies reported here (10 – 40 mM) did not have a significant effect on thiol-disulfide 
exchange in the linear peptide (Chapter 2). However, in a study with bovine serum albumin, 
disulfide-mediated aggregation was reduced when 1 M sodium phosphate was added to the 
initiating buffer (5 mM phosphate, 150 mM NaCl, pH = 7.3). A possible explanation for 
the observed reduction is that phosphate anions prevent the attack of thiolate anions on the 




For proteins that contain free thiols such as human serum albumin, protein tyrosine 
phosphatases and recombinant human α1-antitrypsin, thiol derivatizing agents and protein 
engineering approaches can be employed to retain biological activity and improve stability 
[3].  These approaches are discussed in detail in Chapter 1 and can be used when the free 
Cys residues are known to have no functional role. Thiol derivatization, however, is not a 
suitable strategy for proteins where the role of Cys is unknown. Derivatization restricts free 
thiol content and will minimize thiol-catalyzed and thiol-disulfide exchange reactions 
during lyophilization and storage. Protein concentration may also influence the formation 
of disulfide-linked aggregates. For example, at high concentrations of porcine 
somatotropin (>25 mg/mL), disulfide-linked aggregates were detected at 39 oC after 14 
days during storage [184]. Optimizing protein concentrations to a range that delivers an 
effective dose and provides stability during storage is essential to developing safe and 
effective protein therapeutics.  
The presence of oxygen, metal ions (CuII and FeIII) and reactive oxygen species 
(ROS) such as peroxides, superoxide and hydroxyl radical can result in the formation of 
sulfenic, sulfinic and sulfonic acids and thiolsulfinate or a new non-native disulfide bond 
[140, 193, 194]. Although oxidative pathways were found to have no effect on the intrinsic 
rates of thiol-disulfide exchange (Chapter 2), these products of oxidative pathways can 
diminish the therapeutic efficacy of protein and peptide drugs that contain free thiols. 
Nitrogen sparging and storage of protein formulations in a nitrogen atmosphere will inhibit 
O2-mediated oxidative pathways. Some common excipients like polyvinyl pyrrolidone and 
polyethylene glycol contain peroxides as impurities. These excipients should be excluded 




peroxides are detected. If metal-catalyzed thiol oxidation is suspected, EDTA can be used 
as a metal ion chelator to stabilize thiol containing peptides and proteins. In some cases 
however, the presence of transition metal cations (Cu2+) can be beneficial when used as an 
oxidizing agent to minimize free thiol groups prior to lyophilization [78].  The addition of 
divalent metal ions (Cu2+) catalyzed thiol oxidation at a rapid rate relative to thiol-disulfide 
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Appendix A: Data modeling with SCIENTIST® 







T20T20' = K1*T20S*T20T21-K2*T20T20*T21S+K5*T20S*T20S*T20S*T21S 
T21T21' = K3*T21S*T20T21-K4*T21T21*T20S 









K1 = 0.0004 
K2 = 0.0006 
K3 = 0.0002 
K4 = 0.0006 
pKa = 8.3 
pKb = 8.3 
 
// Initial conditions: 
T = 0.0 
T20 = 350.00 
T20T21 = 250.00 
T21 = 0.0 
T20T20 = 0.0 
T21T21 = 0.0 
T20S = T20/(1+((10^(-7))/(10^(-pKa)))) 









Appendix B: SGA and DSC measurements for lyophilized samples 
 
Figure B.1: VTI data for lyo sample (T20 and cT20-T21, pH 7.0, 10 mM PB, 0.08 M ionic 
strength and 0.5 mM EDTA) collected on SGA-100 (VTI Corporation, Hialeah, FL). Data 
was measured at 0% RH and at 25 oC at the end of secondary drying. 
 
  
Figure B.2: DSC data for lyo sample (T20 and cT20-T21, pH 7.0, 10 mM PB, 0.08 M 



















Appendix C: Purification and digestion optmization of hGH 
rhGH was purified from E.coli after cell harvesting using the protocol shown in the flow 
chart below.  
 
Figure C.1: Flow chart showing purification steps for hGH from the cell pellet. Buffers 
used for each step are shown in boxes and amount of each buffer added are in green next 















50 mM Tris.HCl 5% sucrose 
2 M Urea                       3 mM GSH
0.5 mM EDTA               0.6 mM GSSG
































Add 10 or 5 mL
Add 40 or 45 mL
Add 50 mL
2.5 L for dialysis




















Digestion protocol Disulfide scrambling
Digestion complete 




on magnetic beads Y N
Trypsin immobilized 
on agarose beads Y N





Table C.2: Amino acid sequence of all possible scrambled intra-and intermolecular 
disulfide-linked peptides from hGH. 
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